Programme Book
05–08 June 2019

Glasgow · Scotland
Scottish Event Campus (SEC)

www.espghancongress.org
@ESPGHAN Society · #ESPGHAN19
Table of Contents

**ESPGHAN Annual Meeting**
- Make it YOUR meeting! 2
- Venue Map Scottish Event Campus (SEC) 4
- Welcome Letter 6

**ESPGHAN Society**
- ESPGHAN Council & Committees 8
- Society Meetings 9
- ESPGHAN Annual General Meeting 10
- For Members Only 12
- ESPGHAN Society & Membership 14
- Young ESPGHAN 16
- Awards & Grants 18

**Scientific Programme**
- **Wednesday, 05 June 2019**
  - Programme Overview 20
  - Chronological Programme 22
  - Young ESPGHAN Session 33
- **Thursday, 06 June 2019**
  - Programme Overview 34
  - Chronological Programme 36
- **Friday, 07 June 2019**
  - Programme Overview 46
  - Chronological Programme 48

**Poster Exhibition**
- Abstract Submission & Reviewing 76
- ePoster Presentations 78
- Posters selected for Poster Walk 88
- Posters 96
- Abstract Reviewers 138

**Industry & General Information**
- Education Partner Programme 144
- Congress Sponsors 146
- Endoscopy Learning Zone 148
- Satellite Symposia 154
- Sponsors & Exhibitors List 164
- Exhibition Plan 166
- Exhibitor Directory Listing 169
- Disclosure of Sponsorships 206
- General Information 207
- Glasgow Map · Public Transport 214

**Q&A**
- Join the discussions via the Congress APP
- Submit your questions during the session
- Chairs will choose interesting questions during discussion time

**Voting**
- Voting via the Congress APP
- Participate in interactive sessions
- Choose the session, start the voting feature and share your vote

**Session Recording**
- Available for all invited sessions*
- Slides and audio available
- Online 2 hours after the end of the session
- Access via Congress Talks & Speakers

*Kindly note that the publication is based on agreement of the speakers. Abstract sessions will not be recorded.

**Congress Talks & Speakers**
- Session recordings, eposters, speaker CV’s and abstracts
- Annual Meetings 2016 – 2019
- Access through www.espghancongress.org
- Create your own personal login

**Congress APP**
- Venue information
- Scientific programme
- Abstracts
- ePosters
- Faculty
- Sponsors and exhibitors
- General information
- Interactive modules: Q&A, voting, networking

**Make it YOUR meeting!**
Congress APP – Q&A – Voting – Session Recording

Date of printing: 2 May 2019 – subject to change –
www.espghancongress.org
Dear Colleagues and Friends,

On behalf of ESPGHAN we are delighted to welcome you to the ESPGHAN 52nd Annual Meeting taking place in Glasgow, Scotland from 05 – 08 June 2019.

Each year the ESPGHAN Annual Meeting attracts key opinion leaders in the fields of Paediatric Gastroenterology, Hepatology and Nutrition from around the world to share knowledge and insights on the latest developments, findings and trends. With an attendance of over 4,600 from 100 countries in 2018, it is the largest conference of its kind in the world.

This year over 1,000 abstracts were accepted. The authors will present their latest research results and the meeting will allow for an abundance of opportunities to meet colleagues in your related fields from across the globe. The scientific programme will once again include a wide range of sessions, symposia, a clinical track, postgraduate courses as well as the ever-popular hands-on Endoscopy Learning Zone as well as for the first time at ESPGHAN a live endoscopy session.

Scotland as well as Glasgow, is a popular destination for education and culture alike attracting tourists and businesspersons. Rich in history and tradition a friendly welcome is guaranteed wherever you go with some of the world's oldest universities, with research including medical and life sciences. The city and country therefore is an ideal setting for ESPGHAN's journey and provides an inspiring atmosphere for the ESPGHAN 52nd Annual Meeting.

We thank you very much for your participation and wish you a rewarding and enjoyable experience!

Prof. Raanan Shamir
ESPGHAN President

Prof. Richard Russell
Chair Local Organizing Committee
ESPGHAN Council & Committees

**ESPGHAN Council**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Raanan Shamir</td>
<td>Israel</td>
</tr>
<tr>
<td>President Elect</td>
<td>Sanja Kolaček</td>
<td>Croatia</td>
</tr>
<tr>
<td>General Secretary</td>
<td>Jorge Amil Dias</td>
<td>Portugal</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Annamaria Staiano</td>
<td>Italy</td>
</tr>
<tr>
<td>Education Secretary</td>
<td>Iva Hojsak</td>
<td>Croatia</td>
</tr>
<tr>
<td>Internat. Affairs Representative</td>
<td>Almuthe Christina Hauer</td>
<td>Austria</td>
</tr>
<tr>
<td>Scientific Secretary</td>
<td>Matthias Zilbauer</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Gastroenterology Committee</td>
<td>Nikhil Thapar</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Hepatology Committee</td>
<td>Henkjan Verkade</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Nutrition Committee</td>
<td>Magnus Domellöf</td>
<td>Sweden</td>
</tr>
<tr>
<td>Allied Health Professionals</td>
<td>Jackie Falconer</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>YOUNG ESPGHAN Committee</td>
<td>Nathalie Rock</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Chair of LOC</td>
<td>Richard Russell</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

**Scientific Programme Committee**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Raanan Shamir</td>
<td>Israel</td>
</tr>
<tr>
<td>Scientific Secretary</td>
<td>Matthias Zilbauer</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair of LOC</td>
<td>Richard Russell</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Nikhil Thapar</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Hepatology</td>
<td>Henkjan Verkade</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Magnus Domellöf</td>
<td>Sweden</td>
</tr>
<tr>
<td>Allied Health Professionals</td>
<td>Jackie Falconer</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

**Local Organising Committee UK**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Richard Russell</td>
</tr>
<tr>
<td>Further members</td>
<td>Andrew Barclay</td>
</tr>
<tr>
<td></td>
<td>Elaine Buchanan</td>
</tr>
<tr>
<td></td>
<td>Victoria Garrick</td>
</tr>
<tr>
<td></td>
<td>Richard Hansen</td>
</tr>
<tr>
<td></td>
<td>Deirdre Kelly</td>
</tr>
<tr>
<td></td>
<td>David Wilson</td>
</tr>
</tbody>
</table>

**Society Meetings**

**Wednesday, 05 June 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td>ESPGHAN Research Committee Meeting</td>
<td>ESPGHAN Meeting Room 1</td>
<td>Invite Only</td>
</tr>
</tbody>
</table>

**Thursday, 06 June 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 14:15</td>
<td>ESPGHAN Nutrition Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>ESPGHAN Ethics Committee Meeting</td>
<td>ESPGHAN Meeting Room 1</td>
<td>Invite Only</td>
</tr>
<tr>
<td>13:30 – 15:00</td>
<td>ESPGHAN Public Affairs Committee Meeting</td>
<td>ESPGHAN Meeting Room 1</td>
<td>Invite Only</td>
</tr>
<tr>
<td>16:30 – 17:30</td>
<td>ESPGHAN Publication Committee Meeting</td>
<td>ESPGHAN Meeting Room 1</td>
<td>Invite Only</td>
</tr>
</tbody>
</table>

**Friday, 07 June 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:45</td>
<td>ESPGHAN Gastroenterology Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>ESPGHAN Hepatology Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>10:30 – 13:00</td>
<td>ESPGHAN AHP Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>15:00 – 17:00</td>
<td>Young ESPGHAN Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>17:30 – 19:45</td>
<td>ESPGHAN Annual General Meeting</td>
<td>Lomond Hall</td>
<td>Open to ESPGHAN Members</td>
</tr>
</tbody>
</table>

**Saturday, 08 June 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:30</td>
<td>ESPGHAN National Societies Meeting</td>
<td>ESPGHAN Meeting Room 1</td>
<td>Invite Only</td>
</tr>
<tr>
<td>09:30 – 10:30</td>
<td>ESPGHAN Finance Committee Meeting</td>
<td>ESPGHAN Meeting Room 2</td>
<td>Invite Only</td>
</tr>
<tr>
<td>Time</td>
<td>No.</td>
<td>Topic</td>
<td>Presenter</td>
</tr>
<tr>
<td>--------</td>
<td>-----</td>
<td>------------------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>17:30</td>
<td>1.</td>
<td>President’s Welcome</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>17:30</td>
<td>2.</td>
<td>Apologies for absence</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>17:30</td>
<td>3.</td>
<td>Notification of other business</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>17:30</td>
<td>4.</td>
<td>Approval of AGM Minutes – Geneva 2018</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>17:40</td>
<td>5.</td>
<td>President’s Report</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>18:10</td>
<td>6.</td>
<td>Finances</td>
<td></td>
</tr>
<tr>
<td>18:10</td>
<td>6.1</td>
<td>Financial Report 2018</td>
<td>Annamaria Staiano</td>
</tr>
<tr>
<td>18:30</td>
<td>7.</td>
<td>Proposed Changes to Constitution</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>7.1</td>
<td>Updates to Constitution 2019</td>
<td>Jorge Amil Dias</td>
</tr>
<tr>
<td>18:30</td>
<td>7.2</td>
<td>Ongoing updates to Rules and Regulations</td>
<td>Jorge Amil Dias</td>
</tr>
<tr>
<td>18:55</td>
<td>8.</td>
<td>New Members and Elections</td>
<td></td>
</tr>
<tr>
<td>18:55</td>
<td>8.1</td>
<td>2019_01 – New Members</td>
<td>Jorge Amil Dias</td>
</tr>
<tr>
<td>18:55</td>
<td>8.2</td>
<td>New Council Members</td>
<td>Jorge Amil Dias</td>
</tr>
<tr>
<td>19:05</td>
<td>9.</td>
<td>Future Meetings</td>
<td></td>
</tr>
<tr>
<td>19:05</td>
<td>9.1</td>
<td>ESPGHAN 2020 – Copenhagen</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>19:05</td>
<td>9.2</td>
<td>ESPGHAN 2021 – Vienna</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>19:05</td>
<td>9.3</td>
<td>ESPGHAN 2022 – Milan</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>19:05</td>
<td>9.4</td>
<td>Voting on 2023 Destination</td>
<td>AGM</td>
</tr>
<tr>
<td>19:15</td>
<td>10.</td>
<td>Questions from the Members on Committee and Activity Reports</td>
<td>Chairs &amp; Representatives</td>
</tr>
<tr>
<td>19:15</td>
<td>10.1</td>
<td>Gastroenterology</td>
<td>Nikhil Thapar</td>
</tr>
<tr>
<td>19:15</td>
<td>10.2</td>
<td>Hepatology</td>
<td>Henkjan Verkade</td>
</tr>
<tr>
<td>19:15</td>
<td>10.3</td>
<td>Nutrition</td>
<td>Magnus Domellöf</td>
</tr>
<tr>
<td>19:15</td>
<td>10.4</td>
<td>Young ESPGHAN</td>
<td>Natalie Rock</td>
</tr>
<tr>
<td>19:15</td>
<td>10.5</td>
<td>Allied Health Professionals</td>
<td>Jackie Falconer</td>
</tr>
<tr>
<td>19:15</td>
<td>10.6</td>
<td>Public Affairs</td>
<td>Deirdre Kelly</td>
</tr>
<tr>
<td>19:15</td>
<td>10.7</td>
<td>Publication</td>
<td>Bert Koletzko</td>
</tr>
<tr>
<td>19:15</td>
<td>10.8</td>
<td>International Affairs</td>
<td>Almuthe Christina Hauer</td>
</tr>
<tr>
<td>19:15</td>
<td>10.9</td>
<td>Ethics</td>
<td>Martin Burdelski</td>
</tr>
<tr>
<td>19:15</td>
<td>10.10</td>
<td>JPGN</td>
<td>Hania Szajewska</td>
</tr>
<tr>
<td>19:15</td>
<td>10.11</td>
<td>Education</td>
<td>Iva Hojsak</td>
</tr>
<tr>
<td>19:30</td>
<td>11.</td>
<td>Any other Business</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>19:40</td>
<td>12.</td>
<td>Thanks to Outgoing Council Members</td>
<td>Raanan Shamir</td>
</tr>
<tr>
<td>19:45</td>
<td>13.</td>
<td>Close of Meeting</td>
<td></td>
</tr>
</tbody>
</table>

**Next Meeting**

**AGM 2020**

05 June 2020 · 17:30 – 19:45

Copenhagen, Denmark
For Members Only

**ESPHAN Members & Young ESPGHAN Lounge**

**Location**  Exhibition Hall (Hall 4)
**Date**  Open all day from Thursday, 06 June through Saturday, 09 June 2019 (14:15)

Join our comfortable area for members in the exhibition hall next to the ESPGHAN booth.
The Members and Young ESPGHAN Lounge is combined to enhance communication between all members.
Meet your friends and colleagues in a relaxed and comfortable atmosphere and enjoy some snacks and drinks throughout the day. Come in and start networking!

**Special activities at the Young ESPGHAN Lounge**

Members of the Young ESPGHAN Committee will attend the lounge and are there to meet you and answer your questions about ongoing activities and voluntary involvement.

**Thursday, 06 June 2019**
12:45 – 13:45 (Lunch Break)
**Meet the President and the ESPGHAN Council:** take the chance to interact with the President and board members of ESPGHAN, talk about your needs, concerns or just enjoy the informal friendly meeting.
10:00 – 10:45 and 16:30 – 17:15 (Coffee Breaks)
**Meet the Young ESPGHAN:** get to know the Young ESPGHAN Committee and let them know how they can help you. Discover the events dedicated to Young ESPGHAN all year long: Educational events, Mentorship Programme, Image of the Month, Young investigator forum, Young ESPGHAN session

**Friday, 07 June 2019**
10:30 – 11:15 (Coffee Break)
**Meet the ESPGHAN Awardees:** come and meet the young people who have been awarded an ESPGHAN prize and learn from their experience why and how you should apply.

All ESPGHAN Members have access to the lounges – please present your badge at the entrance.

**ESPHAN Mentorship Reunion**

Young ESPGHAN would like to invite all mentors and mentees participating in the ESPGHAN Mentorship Programme, from all the three previous editions to a Reunion Meeting on **Wednesday, 05 June from 18:00 – 19:00** at the Mezzanine area of the SEC.

Here you can meet up with each other to catch up and make new plans while having a drink and a bite!
All participants already active in the programme have received an invitation via the ESPGHAN office.
All persons interested in becoming a mentor and/or mentee can contact YE committee during this reunion or by email.

**Members Evening**

**Location**  Argyle Street Arches (253 Argyle Street, Glasgow G2 8DL)
**Date**  Friday, 07 June 2019, 20:15
**Costs**  50 € per person
**Transfer**  20:00 from SEC (after the end of the ESPGHAN AGM)
Return transfer from 22:30 onwards
**Dress Code**  Casual

A bustling downtown event location welcomes all ESPGHAN Members to a Scottish night full of local experiences. Come and join your colleagues and friends for some delicious Scottish food and drinks and don’t miss the famous Ceilidh dance!

Don’t forget to bring your ticket!
Please note that this event needs to be registered in advance and is for members only.
All members who pre-registered for a free ticket in combination with the attendance of the Annual General Meeting, will receive a bracelet at the AGM.

**ESPHAN Annual General Meeting**

**Location**  Lomond Hall
**Date**  Friday, 07 June 2019, 17:30 – 19:45
Registration and pre-session reception: from 17:00 onwards
Society & Membership

Key Activities

ESPGHAN has three standing committees focusing on Gastroenterology, Hepatology and Nutrition. All aim to promote child health and increase understanding and treatment of disease states. ESPGHAN members are further involved in various working groups that concentrate on particular aspects of child care and/or disease states. The Allied Health Professional Committee aims to enhance the multidisciplinary approach in Gastroenterology, Hepatology & Nutrition in Europe, while the Young ESPGHAN Committee promotes and supports specialist training and guides trainees towards full membership of ESPGHAN. ESPGHAN also promotes scientific exchange amongst research groups in Europe and amongst trainees, young doctors and scientists through Young Investigator Forums, Monothematic Meetings, International Schools and Eastern European Schools.

ESPGHAN Booth

For any queries about ESPGHAN, membership or any other society related matters, please contact a member of the ESPGHAN Office at the society booth.

You can find us in the Exhibition Hall 4 next to the Members Lounge.

ESPGHAN Office

European Society for Paediatric Gastroenterology, Hepatology and Nutrition

office@espghan.org

www.espghan.org

Become a Member

By becoming a member of ESPGHAN, you will experience and gain access to a range of benefits including an international network of specialists who promote and encourage collaboration and exchange of information within GI-, Hepatology-, Nutrition Committees, working groups and their outcomes.

Subscription to JPGN, the Journal of Pediatric Gastroenterology and Nutrition, receipt of ESPGHAN newsletters, accesses to the member’s area of the ESPGHAN website and discounted registration fees for the ESPGHAN Annual Meeting are among the benefits of ESPGHAN members. According to your professional status you can choose between full, corresponding, trainee, allied-health professional and emeritus membership.

Members must have an active interest in paediatric gastroenterology and/or hepatology or nutrition (PGHN).

To promote the health of children
Young ESPGHAN at 52nd Annual Meeting, Glasgow

The YOUNG ESPGHAN Committee is organizing several events dedicated to trainee ESPGHAN members. More details in the section for members only.

- Meet the President and the ESPGHAN Council
- Meet the Young ESPGHAN Committee
- Meet the ESPGHAN Awardees
- Mentorship reunion
- Young ESPGHAN session (both members and non-members can attend this session)

Join ESPGHAN, become a Young ESPGHAN Member!

The Young ESPGHAN membership addresses people less than 10 years active in the field of Paediatric Gastroenterology, Hepatology and Nutrition (PGHN).

Being a member gives you opportunities such as:
- Access to the biggest network in PGHN in Europe
- Reduction in congress fees
- Eligibility for grants & research prizes
- Participation in 2 educational events/year: summer schools, masterclasses, young investigator forum
- Becoming a Mentee in the Mentorship program
- Attending the special events dedicated to Young ESPGHAN members during each Annual Meeting

Membership application is open twice a year! Please upload your application on the ESPGHAN website before 30 September or 31 March.

Contact
For more information about Young ESPGHAN membership and activities kindly contact us at young@espghan.org, or visit our website:
www.espghan.org/home/join-us
www.espghan.org/about-espghan/committees/young-espghan

Follow us on
Twitter – @Young_ESPGHAN and
LinkedIn – Young ESPGHAN
to be the first to find out about Young ESPGHAN events and news.

2018 in retrospective

Young ESPGHAN has developed a relationship with UEG Young Talent group, having 2 meetings, first at UEG Week 2018 and the second at ECYG 2018 and is aiming to strengthen it. Young ESPGHAN was represented by 4 Young ESPGHAN members at the 1st European Conference of Young Gastroentrologists which took place in Zagreb, in December 2018. Also, Young ESPGHAN Committee is working on establishing a connection with other international societies of interest and young representatives of national societies among European countries.

In 2018 the Image of the Month contest has been launched on the ESPGHAN website. Its aim is to present a monthly clinical image (radiology, endoscopy or pathology) and case on the website of the ESPGHAN and on the social media. The best image/case will win a prize.

In 2017 the Young ESPGHAN Mentorship programme was launched aiming at creating a platform of interaction between junior and senior ESPGHAN members. Senior members can help junior members by giving insight in the functioning of the society and opportunities within ESPGHAN as well as helping them to develop their career path. Participants in this programme, both mentors and mentees, receive a professional mentorship training. There have been three very successful trainings in July 2017 in Glasgow, March 2018 in Brussels and March 2019 in Porto.

The Young ESPGHAN Committee has updated its mission and rules statement as well as the ESPGHAN training syllabus. Communication between the Young ESPGHAN Committee and the trainees/young investigators is assured by newsletters, social media and via the ESPGHAN website. The Young ESPGHAN Committee has sent around surveys on PGHAN training and research opportunities during training and has assisted the transition to full members.

Young ESPGHAN – consisting of trainees and young investigators – is the fastest growing members-group within ESPGHAN. The Young ESPGHAN Committee represents their interests, shortlists trainees or young investigators for scientific committees and encourages them to participate in specific working groups.

Young ESPGHAN Committee
Nathalie Rock
Switzerland, Chair
Line Modin
Denmark, Secretary
Andrea Nita
Romania, Committee Member
Fiona Cameron
United Kingdom, Committee Member
Dimitrios Tapsas
Greece, Committee Member

Young ESPGHAN – consisting of trainees and young investigators – is the fastest growing members-group within ESPGHAN. The Young ESPGHAN Committee represents their interests, shortlists trainees or young investigators for scientific committees and encourages them to participate in specific working groups.
Awards & Grants

ESPGHAN provides a number of awards and grants to members and non-members alike. These awards are wide ranging and are both project based and travel awards and grants.

- **Research Grant Initiative** .......................... up to 100,000 €
- **Research and Networking Grants** ........................... 50,000 €
- **Charlotte Anderson Travel Award** (next awarded 2019) ........ 5,000 €
- **ESPGHAN International Exchange Award** ........................... 3,000 €
- **Young Investigator Awards (YIA)** ............................. up to 1,000 €
- **ESPGHAN Conference Prizes** ........................... 2,500 €
- **ESPGHAN / NASPGHAN Travel Award** .......................... 5,000 $/€
- **UEG Week YIA** .................................................. up to 1,000 €
- **WCPGHAN Young Investigator Award** ............................. up to 1,000 €

The Research and Networking Grants are available for ESPGHAN members to apply for funding for research and networking projects that involve cross border partnerships. The deadline for applications is 31 July 2019.

**Conference Prizes**
The below prizes will be awarded with 2,500 € during the Closing Session for the best abstract presentations in Gastroenterology, Hepatology and Nutrition.

- **The Annual John Harries Prize**  
  For the best presentation on Gastroenterology

- **The Annual Alex Mowat Prize**  
  For the best presentation on Hepatology

- **The Annual Jean Rey Prize**  
  For the best presentation on Nutrition

**Young Investigator Awards**
The purpose of the Young Investigator Awards is to support travel expenses of up to 1,000 € for Young Investigators who have had their abstract accepted for presentation at the ESPGHAN Annual Meeting. The candidate must be the first author and/or presenter of the work being presented.

For further information on the Awards and Grants please visit: [www.espghan.org](http://www.espghan.org)
## Programme Overview

**Wednesday, 05 June 2019**

### Alsh I + II
- **AHP Course**
- **Course in PGHaN**
- **IBD Course**

### Lomond Hall
- **Working Groups**

### Hall 1
- **Session 1: Nutrition**
  - (combined session)

### Boisdale I
- **Coffee Break**

### Carron I
- **PreventCD Meeting**
  - (Invite Only)
- **Esophageal Atresia WG**

### Carron II
- **Helicobacter Pylori WG**
  - (Invite Only)

### Dochart I
- **Network for Intestinal Rehabilitation and Transplantation in Europe (NITE)**
- **European Reference Network RARE LIVER**

### Dochart II
- **Endoscopy SIG**
- **Coffee Break**

### Etive
- **Coffee Break**

### Fyne
- **Educational Task Force (Invite Only)**

### Alsh I + II
- **AHP Open Meeting**

### Lomond Hall
- **Lunch Break**

### Hall 1
- **SIG-CD Steering Committee**
  - (Invite Only)
- **Cystic Fibrosis and Pancreas WG**

### Boisdale I
- **Neonatal Nutrition SIG**
- **Coffee Break**

### Carron I
- **Special Interest Group on Gut Microbiota & Modification**
  - (Invite Only)
- **Eosinophilic Gastrointestinal Diseases (EGID)**
  - (Invite Only)

### Carron II
- **Special Interest Group on Coeliac Disease**
  - (Invite Only)
- **Neurogastro, Motility and Functional GI Disorders SIG/WG**
- **Eosinophilic Gastrointestinal Diseases (EGID)**
  - (Invite Only)

### Dochart I
- **Outcomes in Nutrition Trials WG**
  - (Invite Only)
- **International Registry of Congenital Porto-systemic shunts (IRCPSS)**

### Dochart II
- **Outcomes in Nutrition Trials WG**

### Etive
- **Polyposis WG**

### Fyne
- **Basic and Translational Research and Epigenetics in PGHN SIG**

---

**18:30 Welcome Reception** - Exhibition Hall

---

**as of 2 May 2019 - subject to change**

---

**www.esphangcongress.org**
**Wednesday, 05 June 2019**

### AHP Course

08:00 – 09:30 Lomond Hall

**Session 1: Nutrition** *(combined session with Course in PGHaN)*

**Chairs** Jackie Falconer, United Kingdom · Heather Grant, United Kingdom

- **08:00** Blended diet and enteral feeding; the perceived benefits, controversies and suggestions for clinical practice  
  Sarah Durnan, United Kingdom

- **08:30** Eosinophilic eosaphagitis – medical and dietary treatment options  
  Diana Flynn, United Kingdom · Tracey Cardigan, United Kingdom

- **09:00** Old and new dietary treatments in Crohn’s disease  
  Rotem Sigall-Boneh, Israel

| 09:30 – 10:00 | Coffee Break |

**Session 2: Gastroenterology**

**Chairs** Rut Anne Thomassen, Norway · Sarah MacDonald, United Kingdom

- **10:00** Motility – medical diagnosis, investigations and management  
  Michiel P. van Wijk, The Netherlands

- **10:30** Nursing management of rectal irrigation  
  Jenna Tarr, United Kingdom

- **10:50** Ethical considerations in feeding the neurological child with intestinal failure  
  Susan Protheroe, United Kingdom

- **11:10** Feeding the child with dysmotility  
  Tracey Johnson, United Kingdom

- **11:30** Update of the new ESPGHAN PN guidelines  
  Magnus Domellöf, Sweden

| 10:00 – 11:50 | Alsh I + II |

**11:50 – 12:30** Alsh I + II

**AHP Open Meeting**

**Chair** Jackie Falconer, United Kingdom

- **12:30 – 13:30** Lunch Break

**13:30 – 14:30** Alsh I + II

**Session 3: Abstracts and innovative practice**

**Chairs** Paula Crespo-Escobar, Spain · Kathleen Ross, United Kingdom

- **13:30** N-O-001 What impact does gastro-intestinal surgery have on the growth of very low birth weight preterm infants?  
  Hannah Duggan, United Kingdom

- **13:40** G-O-001 Long-term follow-up of gut-directed hypnotherapy self-exercises at home using CD versus individual therapy by qualified therapists in children with irritable bowel syndrome or functional abdominal pain syndrome  
  Robyn Rexwinkel, The Netherlands

- **13:50** N-O-002 Characteristics of polymeric formula and route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in children with Crohn’s disease  
  Sara Sila, Croatia

- **14:00** G-O-002 Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease  
  Rotem Sigall-Boneh, Israel

- **14:10** The Scottish transition model in IBD  
  Victoria Garrick, United Kingdom

| 14:30 – 15:00 | Coffee Break |
**Session 4: Joint Hepatology/GI session**

**Chairs** Sara Mancell, United Kingdom · Tena Niseteo, Croatia

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Nutritional management in Pancreatitis – latest guidelines (NICE and ESPGHAN)</td>
<td>Keith Lindley, United Kingdom</td>
</tr>
<tr>
<td>15:20</td>
<td>PN use pre liver transplant</td>
<td>Jonathan Hind, United Kingdom</td>
</tr>
<tr>
<td>15:40</td>
<td>Transplant aquired food allergy</td>
<td>Ruth De Bruyne, Belgium</td>
</tr>
<tr>
<td>16:00</td>
<td>Panel – difficult case – short gut syndrome</td>
<td>Paul Henderson, United Kingdom · Jonathan Hind, United Kingdom · Elaine Buchanan, United Kingdom · David Hoole, United Kingdom · Catherine Paxton, United Kingdom</td>
</tr>
</tbody>
</table>

**The best papers this year in JPGN**

**Chairs** Hania Szajewska, Poland · Mel Heyman, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td>Welcome and opening remarks</td>
<td>Hania Szajewska, Poland</td>
</tr>
<tr>
<td>17:02</td>
<td>The best gastroenterology papers</td>
<td>Johanna Escher, The Netherlands</td>
</tr>
<tr>
<td>17:10</td>
<td>The best nutrition papers</td>
<td>Hans van Goudoever, The Netherlands</td>
</tr>
<tr>
<td>17:18</td>
<td>The best hepatology papers</td>
<td>Piotr Socha, Poland</td>
</tr>
<tr>
<td>17:26</td>
<td>The best pancreatology papers</td>
<td>Michael Wilschanski, Israel</td>
</tr>
<tr>
<td>17:34</td>
<td>ESPGHAN guidelines in JPGN. Novelties</td>
<td>Lorenzo D'Antiga, Italy</td>
</tr>
<tr>
<td>17:42</td>
<td>My first JPGN paper accepted</td>
<td>Fiona Cameron, United Kingdom</td>
</tr>
<tr>
<td>17:50</td>
<td>JPGN 2014-2019: Where are we now? Where are we going?</td>
<td>Hania Szajewska, Poland</td>
</tr>
<tr>
<td>17:55</td>
<td>Informal discussion with the audience</td>
<td>All JPGN Editors</td>
</tr>
</tbody>
</table>
Wednesday, 05 June 2019

**Session 3: Gastroenterology I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Biologics and biosimilars: what should I choose and when?</td>
<td>Amit Assa, Israel</td>
</tr>
<tr>
<td>13:30</td>
<td>Basic and advanced care of patients with coeliac disease in 2019</td>
<td>Peter Gillett, United Kingdom</td>
</tr>
<tr>
<td>14:00</td>
<td>Investigation of common and rare cause of chronic diarrhea in children using case studies</td>
<td>Simon Murch, United Kingdom</td>
</tr>
</tbody>
</table>

**Session 4: Gastroenterology II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Everything you need to know about aerodigestive disorders in children</td>
<td>Paraic McGrogan, Qatar</td>
</tr>
<tr>
<td>15:30</td>
<td>Polyposis syndromes in children – recognition, management and prognosis</td>
<td>Shlomi Cohen, Israel</td>
</tr>
<tr>
<td>16:00</td>
<td>Recognising common and obscure diagnoses at endoscopy – an interactive quiz</td>
<td>Paolo Lionetti, Italy</td>
</tr>
</tbody>
</table>

**Young ESPGHAN Session**

> Details on page 33

**IBD Course**

**Session 1: The basics**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Chairs’ introduction</td>
<td>Dan Turner, Israel · Christos Tzivinikos, United Arab Emirates</td>
</tr>
<tr>
<td>08:05</td>
<td>The clinical relevance of PIBD classification</td>
<td>Sibylle Koletzko, Germany</td>
</tr>
<tr>
<td>08:30</td>
<td>So many genes in VEOIBD – how to bring to practice?</td>
<td>Aleixo Muise, Canada</td>
</tr>
<tr>
<td>09:00</td>
<td>From bench to our patients’ mouth: nutritional therapy in Crohn’s disease</td>
<td>Konstantinos Gerasimidis, United Kingdom</td>
</tr>
</tbody>
</table>

**Session 2: Treatment**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Does the evidence support proactive monitoring of anti-TNF levels?</td>
<td>Anne Griffiths, Canada</td>
</tr>
<tr>
<td>10:30</td>
<td>Unusual solutions for usual challenges in PIBD</td>
<td>Arie Levine, Israel</td>
</tr>
<tr>
<td>11:00</td>
<td>Who to choose for biologics at disease onset?</td>
<td>Frank Ruemmele, France</td>
</tr>
<tr>
<td>11:30</td>
<td>Practicalities in prescribing vedolizumab, ustekinumab and tofacitineb in children</td>
<td>Lissy de Ridder, The Netherlands</td>
</tr>
</tbody>
</table>

13:00 – 14:30 Lomond Hall

15:00 – 16:30 Lomond Hall

09:30 – 10:00 Coffee Break

12:00 – 13:00 Lunch Break
### Session 3: IBD Specialist topics

**Chairs** Annamaria Staiano, Italy · Jorge Amil Dias, Portugal

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>A clinical approach to pancreatic disorders in IBD</td>
<td>Michael Wilschanski, Israel</td>
</tr>
<tr>
<td>13:30</td>
<td>A tandem talk: stenotic Crohn's disease – when primary medical or surgical is appropriate?</td>
<td>Gregor Walker, United Kingdom · David Wilson, United Kingdom</td>
</tr>
<tr>
<td>14:00</td>
<td>Management of perianal Crohn's disease</td>
<td>Paolo Lionetti, Italy</td>
</tr>
<tr>
<td>14:30–15:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 4: Difficult cases

**Chairs** Anne Griffiths, Canada · Gregor Walker, United Kingdom · Dan Turner, Israel · David Wilson, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Relapsing and refractory UC</td>
<td>Iain Chalmers, United Kingdom</td>
</tr>
<tr>
<td>15:45</td>
<td>Managing the high risk Crohn's patient</td>
<td>Marina Aloi, Italy</td>
</tr>
<tr>
<td>15:00–16:30</td>
<td>Hall 1</td>
<td></td>
</tr>
</tbody>
</table>

### Working Groups (Members Only)

- **Endoscopy SIG**
  - Chair: Mike Thomson, United Kingdom
  - **PreventCD meeting (Invite Only)**
    - Chair: Luisa Mearin, The Netherlands
  - **Esophageal Atresia WG**
    - Chair: Frédéric Gottrand, France
  - **Helicobacter Pylori (Invite Only)**
    - Chair: Patrick Bontems, Belgium
  - **Network for Intestinal Rehabilitation and Transplantation in Europe (NITE)**
    - Chair: Jutta Koeglmeier, United Kingdom
  - **European Reference Network RARE LIVER**
    - Chair: Ekkehard Sturm, Germany
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>Carron II</td>
<td><strong>Helicobacter Pylori</strong></td>
<td>Patrick Bontems, Belgium</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>Fyne</td>
<td><strong>Educational Task Force (Invite Only)</strong></td>
<td>Iva Hojsak, Croatia</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>Dochart I</td>
<td><strong>Neonatal Nutrition SIG</strong></td>
<td>Hans van Goudoever, The Netherlands</td>
</tr>
<tr>
<td>12:00 – 15:00</td>
<td>Etive</td>
<td><strong>Graft Injury Group (GIG) (Invite Only)</strong></td>
<td>Deirdre Kelly, United Kingdom</td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>Boisdale I</td>
<td><strong>GENIUS WG</strong></td>
<td>Frank Ruemmele, France</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Carron I</td>
<td><strong>Special Interest Group on Coeliac Disease Steering Committee (Invite Only)</strong></td>
<td>Carmen Ribes Koninckx, Spain</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>Carron II</td>
<td><strong>Cystic Fibrosis and Pancreas WG</strong></td>
<td>Frank Bowedes, The Netherlands</td>
</tr>
<tr>
<td>13:00 – 15:00</td>
<td>Dochart I</td>
<td><strong>Special Interest Group on Gut Microbiota &amp; Modification</strong></td>
<td>Hania Szajewska, Poland - Zvi Weizman, Israel</td>
</tr>
<tr>
<td>13:00 – 15:00</td>
<td>Dochart II</td>
<td><strong>Eosinophilic Gastrointestinal Diseases (EGID) (Invite Only)</strong></td>
<td>Alexandra Papadopoulou, Greece</td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>Carron I</td>
<td><strong>Special Interest Group on Coeliac Disease (Invite Only)</strong></td>
<td>Carmen Ribes Koninckx, Spain</td>
</tr>
<tr>
<td>15:00 – 16:00</td>
<td>Dochart I</td>
<td><strong>Neurogastro, Motility and Functional GI Disorders SIG/WG</strong></td>
<td>Silvia Salvatore, Italy</td>
</tr>
<tr>
<td>15:00 – 16:00</td>
<td>Dochart II</td>
<td><strong>Eosinophilic Gastrointestinal Diseases (EGID)</strong></td>
<td>Alexandra Papadopoulou, Greece</td>
</tr>
<tr>
<td>15:00 – 16:30</td>
<td>Etive</td>
<td><strong>Outcomes in Nutrition Trials WG (Invite Only)</strong></td>
<td>Merit Tabbers, The Netherlands</td>
</tr>
<tr>
<td>15:00 – 16:30</td>
<td>Fyne</td>
<td><strong>International Registry of Congenital Porto-systemic shunts (IRCPSS)</strong></td>
<td>Valérie McLin, Switzerland</td>
</tr>
</tbody>
</table>
Wednesday, 05 June 2019

16:00 – 18:00 Carron I
Special Interest Group on Coeliac Disease (SIG-CD)
Chair Carmen Ribes Koninckx, Spain

16:00 – 16:30 Etive
Outcomes in Nutrition Trials WG
Chair Merit Tabbers, The Netherlands

16:30 – 18:00 Boisdale I
Porto IBD SIG
Chair Dan Turner, Israel

16:30 – 18:00 Carron II
Clinical Malnutrition WG
Chair Konstantinos Gerasimidis, United Kingdom

16:30 – 18:30 Dochart II
Polyposis WG
Chairs Shlomi Cohen, Israel · Warren Hyer, United Kingdom

16:30 – 18:00 Fyne
Basic and Translational Research and Epigenetics in Paediatric Gastroenterology, Hepatology and Nutrition SIG
Chair Andreas Jenke, Germany

17:30 – 18:00 Dochart I
Hepatology Interest Group
Chair Henkjan Verkade, The Netherlands

Wednesday, 05 June 2019 · 17:00 – 18:00 · Lomond Hall
Young ESPGHAN Session
Everything we know about writing and publishing, work and life, success and failure – a different Young ESPGHAN conversational session with contributions from her, me and you.

The presenter:

Helen Mcclory, PhD
Author
Helen has a PhD in literature and creative writing from the University of Glasgow.
Helen Mcclory lives in Edinburgh and grew up between there and the isle of Skye. Her first collection, On the Edges of Vision, was published by Queen’s Ferry Press in August 2015 and won the Saltire First Book of the Year 2015. Her second collection, Mayhem & Death, was written for the lonely and published in March 2018.
Mayhem & Death is the matured, darker companion to On the Edges of Vision and shows Mcclory’s ever expanding ability to envelop and entrance her readers with lyrical language of lore, stunning settings and curious characters. There is a moor and a cold sea in her heart.

Helen about herself:
‘Part islander, part denizen of the ‘city of Hume and Boswell’ (and Burke and Hare, and by spirit, Jekyll and Hyde), I’ve lived in Sydney (for graduate studies) and in New York City, though for the moment I’m back in Edinburgh working on my next project and daydreaming of more travels.’

The Content:
Come and join us for a unique session organised by the Young ESPGHAN Committee!
Over the past fifty years the study of literature has become a generally accepted aspect of medical education. Literature is highly suited to assist learners in questioning conventional thinking and assumptions about various dimensions of work, life, professionalism, identity, and health.
Therefore, the seemingly separate universes of an author and a young doctor are sewed together in a conversation between Helen Mcclory and Line Modin, MD, PhD. who will interview Helen on stage and invite you to ask questions along the way.
This interactive session will be a diverse mix of literary performances, non medical and medical perspectives on writing and publishing, work and life and all the stuff that lies in between.
We genuinely look forward to invite you into a different session.

What to expect:
• Discussions on work life balance in an unbalanced world. Perspectives from a Scottish author
• How to finish, how to publish – how to prevent the paper from staying in the drawer ?
• The process of successful writing
• How to fail (successfully) in writing
### Thursday, 06 June 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Clyde Hall</th>
<th>Lomond Hall</th>
<th>Hall 1</th>
<th>Hall 2</th>
<th>Hall 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15</td>
<td>Breakfast Symposium</td>
<td>see page 154</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
</tr>
<tr>
<td>08:15</td>
<td>Breakfast Symposium</td>
<td>see page 157</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
</tr>
<tr>
<td>08:30</td>
<td>Opening Session</td>
<td>see page 36</td>
<td>State of the Art</td>
<td>see page 36</td>
<td>State of the Art</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>10:45</td>
<td>Plenary Session</td>
<td>Highest Scoring Abstracts</td>
<td>see page 37</td>
<td>see page 37</td>
<td>see page 37</td>
</tr>
<tr>
<td>12:15</td>
<td>Keynote Lecture</td>
<td>Hepatology</td>
<td>see page 37</td>
<td>see page 37</td>
<td>see page 37</td>
</tr>
<tr>
<td>12:45</td>
<td>Lunchtime Symposium</td>
<td>see page 157</td>
<td>Lunchtime Symposium</td>
<td>see page 158</td>
<td>see page 158</td>
</tr>
<tr>
<td>14:00</td>
<td>Parallel Symposium</td>
<td>Monitoring in paediatric IBD</td>
<td>Parallel Symposium</td>
<td>Dysphagia</td>
<td>Parallel Symposium</td>
</tr>
<tr>
<td>14:30</td>
<td>see page 38</td>
<td>see page 39</td>
<td>see page 39</td>
<td>see page 40</td>
<td>see page 41</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>17:15</td>
<td>Parallel Session</td>
<td>Gastroenterology 1</td>
<td>Clinical Practice in Hepatology</td>
<td>Parallel Session</td>
<td>Gastroenterology 2</td>
</tr>
<tr>
<td>17:15</td>
<td>see page 42</td>
<td>see page 42</td>
<td>see page 42</td>
<td>see page 43</td>
<td>see page 44</td>
</tr>
<tr>
<td>18:15</td>
<td>Evening Symposium</td>
<td>see page 161</td>
<td>Evening Symposium</td>
<td>see page 160</td>
<td>Evening Symposium</td>
</tr>
<tr>
<td>18:30</td>
<td>see page 161</td>
<td>see page 160</td>
<td>see page 160</td>
<td>see page 160</td>
<td>see page 160</td>
</tr>
</tbody>
</table>
Thursday, 06 June 2019

07:15 – 08:15  Lomond Hall

**Breakfast Symposium**

Industry sponsored > Details on page 154

07:15 – 08:15  Hall 2

**Breakfast Symposium**

Industry sponsored > Details on page 157

07:15 – 08:15  Hall 3

**Breakfast Symposium**

Industry sponsored > Details on page 154

08:30 – 09:30  Clyde Hall

**Opening Session**

09:30 – 10:00  Clyde Hall

**State of the Art Lecture**

Chair  Raanan Shamir, Israel

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>Immune mediated inflammatory diseases: what would Lister do next?</td>
</tr>
<tr>
<td></td>
<td>Iain B. McInnes, United Kingdom</td>
</tr>
</tbody>
</table>

10:00 – 10:45  Coffee Break

10:45 – 12:15  Clyde Hall

**Plenary Session: Highest Scoring Abstracts**

Chairs  Richard Russell, United Kingdom · Matthias Zilbauer, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>G-O-003</td>
<td>Human RIPK1 deficiency - molecular insights from children with inflammatory bowel disease</td>
<td>Daniel Kotlarz, Germany</td>
</tr>
<tr>
<td>10:55</td>
<td>G-O-004</td>
<td>Contractile segment impedance (CSI) for the diagnosis of gastroesophageal reflux disease during high resolution esophageal manometry: a pediatric study</td>
<td>Taher Omari, Australia</td>
</tr>
<tr>
<td>11:05</td>
<td>H-O-001</td>
<td>First report of the international registry of congenital porto-systemic shunts</td>
<td>Valérie McLin, Switzerland</td>
</tr>
<tr>
<td>11:15</td>
<td>N-O-003</td>
<td>Gut microbiome and its metabolic activity in children with intestinal failure dependent on long-term parenteral nutrition</td>
<td>Esther Neelis, The Netherlands</td>
</tr>
<tr>
<td>11:25</td>
<td>G-O-005</td>
<td>Technical outcomes in pediatric ERCP: experience with the multicenter pediatric ERCP database initiative (PEDI)</td>
<td>David Troendle, USA</td>
</tr>
<tr>
<td>11:35</td>
<td>H-O-002</td>
<td>Renal function after liver transplantation at paediatric age: effects of long-term calcineurin inhibitor treatment</td>
<td>C. J. van der Vlist, The Netherlands</td>
</tr>
<tr>
<td>11:45</td>
<td>N-O-004</td>
<td>Neural pathways activated by formula consumption</td>
<td>Colin Prosser, New Zealand</td>
</tr>
<tr>
<td>11:55</td>
<td>G-O-006</td>
<td>Risk factors for anastomotic strictures in the first year after oesophageal atresia REPAIR: data from a prospective multicentric cohort</td>
<td>Madeleine Aumar, France</td>
</tr>
</tbody>
</table>

12:15 – 12:45  Clyde Hall

**Keynote Lecture: Hepatology**

Chair  Henkjan Verkade, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Reversing liver fibrosis</td>
</tr>
</tbody>
</table>
Thursday, 06 June 2019

13:00 – 14:00 Clyde Hall

**Lunchtime Symposium**

Industry sponsored > Details on page 157

13:00 – 14:00 Lomond Hall

**Lunchtime Symposium**

Industry sponsored > Details on page 158

13:00 – 14:00 Hall 2

**Lunchtime Symposium**

Industry sponsored > Details on page 158

12:30 – 14:30 Lunch Break

14:30 – 16:30 Clyde Hall

**Parallel Symposium: Monitoring in paediatric IBD**

Chairs: Patrick van Rheenen, The Netherlands · Sally Lawrence, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Tight monitoring of disease activity of PIBD in clinical practice</td>
<td>Marina Aloi, Italy</td>
</tr>
<tr>
<td>14:55</td>
<td>G-O-007 Pharmacogenetics of anti-TNF therapy in paediatric Crohn’s disease and ulcerative colitis. Comparison with adults</td>
<td>Sara Salvador-Martin, Spain</td>
</tr>
<tr>
<td>15:05</td>
<td>Capsule endoscopy or MRE for PIBD?</td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>15:25</td>
<td>The new Crohn’s small and large bowel Capsule - new horizons</td>
<td>Salvatore Oliva, Italy</td>
</tr>
<tr>
<td>15:45</td>
<td>G-O-008 Pan-enteric capsule endoscopy in paediatric Crohn’s Disease - the Ped-Pan study: preliminary results of a multicenter trial</td>
<td>Salvatore Oliva, Italy</td>
</tr>
<tr>
<td>15:55</td>
<td>G-O-009 A global prospective observational study in paediatric-onset IBD: the PIBD-SETQuality inception cohort</td>
<td>Martine A. Aardoom, The Netherlands</td>
</tr>
<tr>
<td>16:05</td>
<td>The clinical role of whole exome sequencing outside of VEOIBD setup</td>
<td>Aleixo Muise, Canada</td>
</tr>
</tbody>
</table>

13:00 – 14:00 Lomond Hall

**Parallel Symposium: Dysphagia**

Chairs: Annamaria Staiano, Italy · Marc Benninga, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Pharyngeal dysphagia</td>
<td>Nathalie Rommel, Belgium</td>
</tr>
<tr>
<td>14:50</td>
<td>Achalasia</td>
<td>Maartje Singendonk, The Netherlands</td>
</tr>
<tr>
<td>15:10</td>
<td>G-O-010 Heller myotomy is more efficient than endoscopic dilatation for treating oesophageal achalasia in children: a retrospective multicentre study</td>
<td>Frédéric Gottrand, France</td>
</tr>
<tr>
<td>15:20</td>
<td>Eosinophilic oesophagitis</td>
<td>Osvaldo Borrelli, United Kingdom</td>
</tr>
<tr>
<td>15:40</td>
<td>Oesophageal atresia</td>
<td>Frédéric Gottrand, France</td>
</tr>
<tr>
<td>16:00</td>
<td>G-O-011 Clinical presentation of rumination syndrome in a tertiary/quaternary referral centre: the role of oesophageal high-resolution impedance manometry (HRIM)</td>
<td>Teresa Di Chio, United Kingdom</td>
</tr>
<tr>
<td>16:10</td>
<td>GERD: dysphagia from complications and treatment</td>
<td>Michiel P. van Wijk, The Netherlands</td>
</tr>
</tbody>
</table>

13:00 – 14:00 Hall 1

**Parallel Symposium: The gut-liver axis**

Chairs: Girish Gupte, United Kingdom · Jörg Jahnel, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Signaling pathways between liver and gut</td>
<td>Frank Bodewes, The Netherlands</td>
</tr>
<tr>
<td>15:03</td>
<td>H-O-003 Long-term follow-up of liver disease in children and young people with cystic fibrosis (CF) in the UK</td>
<td>Line Modin, United Kingdom</td>
</tr>
<tr>
<td>15:13</td>
<td>Management options for sclerosing cholangitis</td>
<td>Etienne Sokal, Belgium</td>
</tr>
<tr>
<td>15:46</td>
<td>H-O-004 Evaluation of defensins as markers of gut microbiota disturbances in children with obesity and non-alcoholic fatty liver disease</td>
<td>Aldona Wierzbicka-Rucińska, Poland</td>
</tr>
<tr>
<td>15:56</td>
<td>Gut and hepatic encephalopathy</td>
<td>Debbie L. Shawcross, United Kingdom</td>
</tr>
</tbody>
</table>
Thursday, 06 June 2019

Parallel Symposium: Nutritional status – monitoring

Chairs Koen Huysentruyt, Belgium · Konstantinos Gerasimidis, United Kingdom

14:30 – 16:30 Hall 2

14:30 An update of nutritional screening tools for paediatric patients
Jessie Hulst, Canada

15:00 N-O-005 The interactive effect of prenatal iron deficiency and family economy education on children’s motor development in China
Jie Shao, China

15:10 N-O-006 Vitamin D in Brazilian paediatric population from North to South
Marcia Cavichio, Brazil

15:20 Pitfalls in nutritional assessment in sick or critically ill paediatric patients
Konstantinos Gerasimidis, United Kingdom

15:50 N-O-007 Comparison of Fenton intrauterine growth chart and INTERGROWTH-21 postnatal growth chart to assess growth restriction at birth and discharge in very low birth weight neonates
Susanta Kumar Badatya, India

16:00 Non-nutritional Factors in determining nutritional status in chronic illness
Jarod Wong, United Kingdom

Live Endoscopy

14:30 – 16:30 Hall 3

This is the first live endoscopy symposium in ESPGHAN history and something we hope will become a core component of future programmes.

Due to the nature of live endoscopy, we cannot give a precise programme with specific timings, however, we will be beaming live cases with commentary from two theatres in the International Academy for Paediatric Endoscopy Training, Sheffield Children’s Hospital across the course of the afternoon.

We expect to show cases including:

- Laparoscopically-assisted endoscopic jejunostomy
- Endoscopic division of congenital duodenal congenital web
- Multiple polyectomy from PTEN hamartoma tumour syndrome
- Single stage percutaneous endoscopic gastrostomy button
- Argon plasma coagulation for anastomotic ulceration
- Over-the-scope clips and Hemospray for gastrointestinal bleeding
  (if case availability allows)

This will help to showcase some of the GI-surgical interface and also the approaches that prevent the need for formal surgical intervention.

An interactive debate on approaches with audience participation and an ongoing dialogue with the team performing the procedures is expected. We hope it will be instructive as well as stimulating and will be well attended, serving as a spring board for future years.

We advise interested delegates to attend early for this session, which we anticipate being busy.

16:30 – 17:15 Coffee Break
Thursday, 06 June 2019

17:15 – 18:15 Clyde Hall

Parallel Session: Gastroenterology 1

Chairs: Christos Tzivinikos, United Arab Emirates · Jochen Kammermeier, United Kingdom

17:15 G-O-012
Accurate classification of paediatric colonic IBD subtype using random forest machine learning classifier
Jasbir Dhaliwal, Canada

17:25 G-O-013
Delineating the phenotype of paediatric PSC-IBD using longitudinal data analysis
Amanda Ricciuto, Canada

17:35 G-O-014
Nationwide incidence and prevalence of paediatric inflammatory bowel disease in Scotland 2015-2017 demonstrates the highest paediatric prevalence rate recorded worldwide
Christopher J. Burgess, United Kingdom

17:45 G-O-015
The evolving role of biologic therapy in paediatric very early onset inflammatory bowel disease (VEO-IBD)
Eileen Crowley, Canada

17:55 G-O-016
Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study
Marina Aloi, Italy

18:05 G-O-017
Clock gene disruption may be a causative event in inflammatory bowel disease flares and a target for treatment
Yael Weintraub, Israel

17:15 – 18:15 Lomond Hall

Clinical Practice in Hepatology

Chairs: Nedim Hadzic, United Kingdom · Karen Murray, USA

17:15
Abnormalities in liver ultrasound: 1. what the radiologist sees
Stéphanie Franchi-Abella, France

17:30
Abnormalities in liver ultrasound: 2. OK… and now what?
Piotr Czubkowski, Poland

17:45
Infections of the liver: a practical approach
Giuseppe Indolfi, Italy

17:15 – 18:15 Hall 1

Parallel Session: Gastroenterology 2

Chairs: Osvaldo Borrelli, United Kingdom · Alexandra Papadopoulou, Greece

17:15 G-O-018
Automated stool consistency scoring for non-toilet trained children by machine learning algorithms
Thomas Ludwig, Singapore

17:25 G-O-019
Plasma dosage of ghrelin and leptin related to gastric emptying time and esophageal pH-impedance parameters in obese children and adolescents
Letizia Zenzeri, Italy

17:35 G-O-020
Protocol adherence and behavior-related artefacts in paediatric high resolution manometry
Marin L. Leijdekkers, The Netherlands

17:45 G-O-021
Evaluation of probiotic Lactobacillus reuteri (DSM17938) for treatment of gastro-oesophageal reflux in preterm neonates: a prospective observational study
Girish Deshpande, Australia

17:55 G-O-022
Fibrostenotic phenotype in patients with eosinophilic esophagitis, is not exclusive of adults
Diana Marcela Montoya Villa, Spain

18:05 G-O-023
The prevalence of lymphocytic oesophagitis and of eosinophilic oesophagitis in children: a 5-year observational study in a tertiary care pediatric center
Aneta Szalacha-Szczerz, Poland
Thursday, 06 June 2019

Parallel Session: Nutrition 1

Chairs: Alexandre Lapillonne, France · Nicholas Embleton, United Kingdom

17:15 – 18:15 Hall 2

17:15 N-O-008 Human milk oligosaccharide 2'-fucosyllactose more efficiently modulates immunogenicity during maturation of human dendritic cells in the presence of scGOS/lcFOS prebiotics
Saskia Overbeek, The Netherlands

17:25 N-O-009 Modulation of 3'SL level in pre-weaning milk impacts attention, learning and memory in the adult offspring
Jonas Hauser, Switzerland

17:35 N-O-010 Maternal secretor status is associated with reduced incidence of respiratory infections in infants in the microbiota and health cohort
Olga Sakwinska, Switzerland

17:45 N-O-011 Combination of specific pre- and postbiotics in infant formula induces gut barrier maturation closer to mother’s milk and supports gut functionality in mice
Mona Mischke, The Netherlands

17:55 N-O-012 Term infant formula supplemented with bovine milk-derived oligosaccharides shifts stool microbiota closer to that of breastfed infants
Jian Yan, Switzerland

18:05 N-O-013 Growth in infants with cow’s milk protein allergy fed an amino acid-based formula
Yvan Vandenplas, Belgium

Parallel Symposium: Specialised Endoscopy

Chairs: Prithviraj Rao, United Kingdom · Ilse Broekaert, Germany

17:15 - 18:15 Hall 3

17:15 POEM
Luigi Dall’Oglio, Italy

17:35 G-O-025 Polyp progression in paediatric patients with familial adenomatous polyposis syndrome – is annual surveillance required – a single center experience
Anele Chukwuemeka, United Kingdom

17:45 The place of ERCP and EUS in children – who should perform it and why?
Douglas Fishman, USA

18:30 – 19:30 Lomond Hall

Evening Symposium

Industry sponsored > Details on page 161

18:30 – 19:30 Hall 2

Evening Symposium

Industry sponsored > Details on page 160

18:30 – 19:30 Hall 3

Evening Symposium

Industry sponsored > Details on page 160
## Programme Overview

**Friday, 07 June 2019**

<table>
<thead>
<tr>
<th>Clyde Hall</th>
<th>Lomond Hall</th>
<th>Hall 1</th>
<th>Hall 2</th>
<th>Hall 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:15</strong></td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
<td>Breakfast Symposium</td>
</tr>
<tr>
<td></td>
<td>see page 162</td>
<td>see page 161</td>
<td>see page 162</td>
<td></td>
</tr>
<tr>
<td><strong>08:15</strong></td>
<td>Plenary Session Gastroenterology 1</td>
<td>Plenary Session Nutrition</td>
<td>Plenary Session Hepatology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 48</td>
<td>see page 49</td>
<td>see page 50</td>
<td></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td>Keynote Lecture Nutrition</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:15</strong></td>
<td>Clinical Practice in Gastroenterology</td>
<td>Parallel Session Nutrition 2</td>
<td>Parallel Session Gastroenterology 3</td>
<td>Parallel Session Hepatology 1</td>
</tr>
<tr>
<td></td>
<td>see page 52</td>
<td>see page 53</td>
<td>see page 54</td>
<td>see page 55</td>
</tr>
<tr>
<td><strong>12:15</strong></td>
<td>Parallel Session Nutrition 3</td>
<td>Parallel Session Gastroenterology 4</td>
<td>Parallel Session Hepatology 2</td>
<td>Parallel Session Gastroenterology 6</td>
</tr>
<tr>
<td></td>
<td>see page 51</td>
<td>see page 56</td>
<td>see page 58</td>
<td>see page 59</td>
</tr>
<tr>
<td><strong>12:30</strong></td>
<td>Lunch Break &amp; Poster Walks (Poster only)</td>
<td>Lunch Break &amp; Poster Walks (Poster only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:30</strong></td>
<td>Parallel Symposium Functional GI-disorders</td>
<td>Parallel Symposium Contemporary management of PIBD</td>
<td>Parallel Symposium Liver transplantation</td>
<td>Parallel Symposium Donor human milk</td>
</tr>
<tr>
<td></td>
<td>see page 60</td>
<td>see page 61</td>
<td>see page 62</td>
<td>see page 63</td>
</tr>
<tr>
<td><strong>15:15</strong></td>
<td>ESPGHAN AGM (Members Only)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*as of 2 May 2019 subject to change*
### Friday, 07 June 2019

#### 07:15 – 08:15  Lomond Hall
**Breakfast Symposium**

Industry sponsored > Details on page 162

#### 07:15 – 08:15  Hall 2
**Breakfast Symposium**

Industry sponsored > Details on page 161

#### 07:15 – 08:15  Hall 3
**Breakfast Symposium**

Industry sponsored > Details on page 162

#### 08:30 – 10:00  Clyde Hall
**Plenary Session: Gastroenterology 1**

Chairs Rok Orel, Slovenia · Carmen Ribes Koninckx, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>G-O-026</td>
<td>Maternal gluten and fibre intake during pregnancy and risk of childhood celiac disease: the Norwegian mother and child cohort study</td>
<td>Ketil Størdal, Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>08:40</td>
<td>G-O-027</td>
<td>Potential celiac disease patients fail to express activating NK receptors and epithelial stress markers even those who will evolve to full-blown CD</td>
<td>Valentina Discepolo, USA</td>
<td>USA</td>
</tr>
<tr>
<td>08:50</td>
<td>G-O-028</td>
<td>Current treatment of Helicobacter pylori infected children and adolescents in Europe: interim results of the new EuroPedHp registry</td>
<td>Thu Giang Le Thi, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>09:00</td>
<td>G-O-029</td>
<td>Intestinal-specific Reg4 deficiency ameliorates intestinal inflammation</td>
<td>Yongtao Xiao, China</td>
<td>China</td>
</tr>
<tr>
<td>09:10</td>
<td>G-O-030</td>
<td>Top-down Infliximab superior to step-up in children with moderate-to-severe Crohn’s disease – a multicenter randomized controlled trial</td>
<td>Lissy de Ridder, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>09:20</td>
<td>G-O-031</td>
<td>Alterations in T and B cell receptor repertoires patterns in patients with deleterious IL10/IL10 receptor mutations and history of infantile-onset IBD</td>
<td>Dror Shouval, Israel</td>
<td>Israel</td>
</tr>
</tbody>
</table>

---

#### 08:30 – 10:00  Lomond Hall
**Plenary Session: Nutrition**

Chairs Mary Fewtrell, United Kingdom · Magnus Domellöf, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>N-O-014</td>
<td>Fecal metabolite profiles of mixed-fed infants are more similar to formula-fed than breastfed infants</td>
<td>Sharon Donovan, USA</td>
<td>USA</td>
</tr>
<tr>
<td>08:40</td>
<td>N-O-015</td>
<td>Annuurca apple extracts in treatment of children’s hypercholesterolemia: double blind placebo controlled cross-over randomized study</td>
<td>Michele di Toma, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>08:50</td>
<td>N-O-016</td>
<td>Milk-derived exosomes (MDE) have a different biological effect on normal fetal epithelial colonic cells compared to colonic tumor cells in a miRNA-dependent manner</td>
<td>Shimon Reif, Israel</td>
<td>Israel</td>
</tr>
<tr>
<td>09:00</td>
<td>N-O-017</td>
<td>Dietary choline-containing phospholipids are associated with cognitive performance in school-aged children</td>
<td>Jian Yan, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>09:10</td>
<td>N-O-018</td>
<td>Early intervention with hydrolysed formulas is not protective against functional gastrointestinal disorders in adolescence – the GINI Study</td>
<td>Carla Patricia Harris, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>09:20</td>
<td>N-O-019</td>
<td>Effects of infant formula enriched with milk fat globule membrane (MFGM) and lactoferrin on the gastrointestinal microbiome and metabolome</td>
<td>Steven Wu, USA</td>
<td>USA</td>
</tr>
<tr>
<td>09:30</td>
<td>N-O-020</td>
<td>Effect of long-chain polyunsaturated fatty acid supplementation of preterm infants on infection. A systematic review and meta-analysis</td>
<td>Miguel Saenz de Pipoan, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>09:40</td>
<td>N-O-021</td>
<td>Maternal and child gluten intake and risk of type 1 diabetes: the Norwegian mother and child cohort study</td>
<td>Ketil Størdal, Norway</td>
<td>Norway</td>
</tr>
</tbody>
</table>
### Plenary Session: Hepatology

**Chairs**: Ulrich Baumann, Germany · Jian She Wang, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>H-O-005</td>
<td>The contribution of variants in genes involved in bile acid metabolism to the progression of Non-alcoholic fatty liver disease in a paediatric cohort</td>
<td>Teresa Brunetti,</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:40</td>
<td>H-O-006</td>
<td>Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: phase 2 study results</td>
<td>Ulrich Baumann,</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:50</td>
<td>H-O-007</td>
<td>Factors associated with the natural course of disease in patients with FIC1-deficiency: the NAPPED-consortium</td>
<td>Daan van Wessel,</td>
<td>The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>H-O-008</td>
<td>Biallelic mutations in RINT1 – a new cause of recurrent acute liver failure with onset in infancy and dysostosis multiplex</td>
<td>Dominic Lenz,</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:10</td>
<td>H-O-009</td>
<td>Functional rescue of an ABCB11 variant by ivacaftor: a new targeted pharmacotherapy approach in bsep deficiency</td>
<td>Elodie Mareux,</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:20</td>
<td>H-O-010</td>
<td>Bile duct injury in a toxic model of biliary atresia is mediated by genes in WNT and NOTCH signaling pathways</td>
<td>Orith Waisbourd-Zinman,</td>
<td>Israel</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>H-O-011</td>
<td>Biodegradable biliary stent placement as treatment of anastomotic biliary strictures in paediatric patients with liver transplantation</td>
<td>Javi Juampérez,</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:40</td>
<td>H-O-012</td>
<td>Impact of donor CYP3A5 genotype and graft size on tacrolimus pharmacokinetics in paediatric liver transplant patients</td>
<td>Michele Pinon,</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Friday, 07 June 2019**

### Keynote Lecture: Nutrition

**Chair**: Magnus Domellöf, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td></td>
<td>The gut microbiome – maternal/fetal factors and health outcomes</td>
<td>Lars Engstrand,</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Clinical Practice in Gastroenterology

**Chairs**: Rok Orel, Slovenia · Andrew Barclay, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td></td>
<td>Polyposis: topline from the guidelines</td>
<td>Warren Hyer,</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td></td>
<td>Eosinophilic GI disease beyond the esophagus – to treat or not to treat?</td>
<td>Jorge Amil Dias,</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td>Paediatric functional GI disorders: if drugs don’t work... what else?</td>
<td>Marc Benninga,</td>
<td>The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td></td>
<td>Fecal microbiota transplantation – beyond C Diff</td>
<td>Richard Kellermayer,</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:05</td>
<td></td>
<td>Gastrointestinal allergy: contemporary approaches to diagnosis and management</td>
<td>Sibylle Koletzko,</td>
<td>Germany</td>
</tr>
</tbody>
</table>
### Parallel Session: Nutrition 2

**Chairs:** Lorenzo Norsa, Italy · Jiri Bronsky, Czech Republic

**Location:** Lomond Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>N-O-022</td>
<td>Results of a 24-week phase III study of teduglutide in children with short bowel syndrome-associated intestinal failure (SBS-IF)</td>
<td>Susan Protheroe, United Kingdom</td>
</tr>
<tr>
<td>11:25</td>
<td>N-O-023</td>
<td>Low FODMAP diet is not effective in reducing symptoms of functional abdominal pain in children: a randomized, double-blind study</td>
<td>Katarzyna Mirosława Boradyn, Poland</td>
</tr>
<tr>
<td>11:35</td>
<td>N-O-024</td>
<td>Effects of fish oil lipid emulsion compared with MCT/LCT lipid emulsion on intestinal failure associated liver disease (IFALD) in children</td>
<td>Ying Wang, China</td>
</tr>
<tr>
<td>11:45</td>
<td>N-O-025</td>
<td>Third trimester maternal choline supplementation improves child memory, attention, and problem-solving at age 7 years</td>
<td>Richard L. Canfield, USA</td>
</tr>
<tr>
<td>11:55</td>
<td>N-O-026</td>
<td>Serum bile acids perturbations induced by disturbed gut microbiota in a rat model of parenteral nutrition-associated liver disease</td>
<td>Ying Wang, China</td>
</tr>
<tr>
<td>12:05</td>
<td>N-O-027</td>
<td>The overload gut syndrome</td>
<td>Cecile Lambe, France</td>
</tr>
</tbody>
</table>

---

### Parallel Session: Gastroenterology 3

**Chairs:** Paolo Lionetti, Italy · Javier Martín de Carpi, Spain

**Location:** Hall 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>G-O-34</td>
<td>CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm</td>
<td>Vaios Svolos, United Kingdom</td>
</tr>
<tr>
<td>11:25</td>
<td>G-O-35</td>
<td>Crohn’s disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in mild to moderate active paediatric Crohn’s disease: a prospective randomized controlled trial</td>
<td>Arie Levine, Israel</td>
</tr>
<tr>
<td>11:35</td>
<td>G-O-36</td>
<td>Exclusive enteral nutrition versus corticosteroid induction therapy for new onset paediatric Crohn’s disease: comparison of 18 month outcomes in a Canadian prospective multi-centre inception cohort</td>
<td>Thomas D. Walters, Canada</td>
</tr>
<tr>
<td>11:45</td>
<td>G-O-37</td>
<td>Not so simple perianal Crohn’s Disease! – operative intervention for perianal fissuring disease in South-East Scotland: an 18 year population-based cohort study</td>
<td>Cher-Antonia Khedim, United Kingdom</td>
</tr>
<tr>
<td>11:55</td>
<td>G-O-38</td>
<td>Efficacy, pharmacokinetics and immunogenicity is not affected by switching from Infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease</td>
<td>Karen van Hoeve, Belgium</td>
</tr>
<tr>
<td>12:05</td>
<td>G-O-39</td>
<td>Thiopurine enhancement using Allopurinol in the short and medium term in paediatric inflammatory bowel disease (pIBD) – paediatric IBD Porto group of ESPGHAN</td>
<td>Ali Hakizimana, United Kingdom</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>11:15</td>
<td>Hall 2</td>
<td>H-O-013 Growth trajectories in Alagille syndrome from birth to early childhood: towards condition specific growth charts</td>
<td>Koen Huysentruyt, Belgium</td>
</tr>
<tr>
<td>11:25</td>
<td>Hall 2</td>
<td>H-O-014 Cholestasis decreases hippocampal dendritic spine density in an organotypic rat model</td>
<td>Laurianne Giovannoni, Switzerland</td>
</tr>
<tr>
<td>11:35</td>
<td>Hall 2</td>
<td>H-O-015 ATP7B and copper homeostasis genes in Wilson's disease by targeted next-generation sequencing</td>
<td>Annamaria Sapuppo, Italy</td>
</tr>
<tr>
<td>11:45</td>
<td>Hall 2</td>
<td>H-O-016 Predicting long-term outcome after surgical biliary diversion in BSEP-deficiency patients: results from the NAPPED consortium</td>
<td>Daan van Wessel, The Netherlands</td>
</tr>
<tr>
<td>11:55</td>
<td>Hall 2</td>
<td>H-O-017 Hepatoadrenal syndrome in cirrhotic children: does it exist?</td>
<td>Moinak Sen Sarma, India</td>
</tr>
<tr>
<td>12:05</td>
<td>Hall 2</td>
<td>H-O-018 Endoscopic variceal ligation as primary prophylaxis for upper gastrointestinal bleeding in children</td>
<td>Maria Mercadal-Hally, Spain</td>
</tr>
</tbody>
</table>

**Parallel Session: Gastroenterology 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Hall 3</td>
<td>G-O-041 Prospective longitudinal gut metagenomic analysis suggests altered microbiome composition and function in infants prior to coeliac disease onset</td>
<td>Francesco Valitutti, Italy</td>
</tr>
<tr>
<td>11:25</td>
<td>Hall 3</td>
<td>G-O-042 Growth of children with coeliac disease is compromised before the onset of the disease</td>
<td>Renata Auricchio, Italy</td>
</tr>
<tr>
<td>11:35</td>
<td>Hall 3</td>
<td>G-O-043 Helicobacter pylori infection in children with concomitant coeliac disease and type 1 diabetes mellitus</td>
<td>Burcu Volkan, Turkey</td>
</tr>
<tr>
<td>11:45</td>
<td>Hall 3</td>
<td>G-O-044 Analysis of glycated hemoglobin values in coeliac patients, compared with those of general population: a possible marker of an increased health risk?</td>
<td>Maria Bavastrelli, Italy</td>
</tr>
<tr>
<td>11:55</td>
<td>Hall 3</td>
<td>G-O-045 A novel homozygous CARMIL2 variant causes infantile colitis and eosinophilic disease without recurrent infections</td>
<td>Orly Eshach Adiv, Israel</td>
</tr>
</tbody>
</table>
### Parallel Session: Nutrition 3

**Chairs:** Cristina Campoy, Spain · Elvira Verduci, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>N-O-028</td>
<td>Frequency of gene variants of the leptin / melanocortin pathway in severe obesity</td>
<td>Béatrice Dubern, France</td>
</tr>
<tr>
<td>12:40</td>
<td>N-O-029</td>
<td>Validity of LATCH Score in predicting exclusive breast feeding and weight velocity at 6 weeks in healthy term Indian infants</td>
<td>Mubashir Hassan Shah, India</td>
</tr>
<tr>
<td>12:50</td>
<td>N-O-030</td>
<td>Pre-pubertal amino acid and lipid metabolism associates with glycaemic traits at adolescence</td>
<td>Francois-Pierre Martin, Switzerland</td>
</tr>
<tr>
<td>13:00</td>
<td>N-O-031</td>
<td>Adiponectin agonist treatment during pregnancy improves glycaemia but not lipid profile in diabetic rats and their offspring</td>
<td>Antonio Gázquez, Spain</td>
</tr>
<tr>
<td>13:10</td>
<td>N-O-032</td>
<td>Effectiveness of individual vs. group-based lifestyle intervention on anthropometric and metabolic profile of obese children</td>
<td>Elvira Verduci, Italy</td>
</tr>
<tr>
<td>13:20</td>
<td>N-O-033</td>
<td>Dietary patterns established early in life and their associations with cardiovascular risk factors in late childhood</td>
<td>Veronica Luque, Spain</td>
</tr>
</tbody>
</table>

### Parallel Session: Gastroenterology 5

**Chairs:** Jutta Koeglmeier, United Kingdom · Andreas Jenke, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>G-O-046</td>
<td>Early feeding in acute pancreatitis in children – a prospective randomised controlled trial</td>
<td>Shlomi Cohen, Israel</td>
</tr>
<tr>
<td>12:40</td>
<td>G-O-047</td>
<td>The way from abdominal pain to pediatric pancreatitis – the PINEAPPLE study</td>
<td>Dóra Mosztbacher, Hungary</td>
</tr>
<tr>
<td>12:50</td>
<td>G-O-048</td>
<td>The utility of ultrasound in cystic fibrosis related liver disease</td>
<td>Julie Dobbin, United Kingdom</td>
</tr>
<tr>
<td>13:00</td>
<td>G-O-049</td>
<td>An international multicentre validation study of the Toronto listing criteria for pediatric intestinal transplant</td>
<td>Amin J. Roberts, New Zealand</td>
</tr>
<tr>
<td>13:10</td>
<td>G-O-050</td>
<td>Developmental and cognitive profile of children with intestinal failure</td>
<td>Riikka Gunnar, Finland</td>
</tr>
<tr>
<td>13:20</td>
<td>G-O-051</td>
<td>Muscle mass after intestinal transplantation in children is greater than in those on home parenteral nutrition</td>
<td>Kushila Rupasinghe, United Kingdom</td>
</tr>
</tbody>
</table>
### Parallel Session: Hepatology 2

**Chairs:** Mohammad Ali Shaghrani, Saudi Arabia · Ekkehard Sturm, Germany

**12:30 – 13:30 Hall 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>H-O-019</td>
<td>Shortened 8-weeks course of Sofosbuvir/Ledipasvir therapy in adolescents with chronic Hepatitis C infection: a real-word experience</td>
<td>Daniele Serranti, Italy</td>
</tr>
<tr>
<td>12:40</td>
<td>H-O-020</td>
<td>Development and Validation of a novel, dynamic, etiology specific prognostic model (Peds-HAV) in 100 children with Hepatitis A induced pediatric acute liver failure</td>
<td>Bikrant Bihariyal Raghuvanshi, India</td>
</tr>
<tr>
<td>12:50</td>
<td>H-O-021</td>
<td>A combined blood and MR imaging risk score for monitoring liver inflammation in paediatric AIH</td>
<td>Kamil Janowski, Poland</td>
</tr>
<tr>
<td>13:00</td>
<td>H-O-022</td>
<td>Cellular infiltrate and expression of IL-37 in pediatric AIH, PSC and ASC</td>
<td>Lucas Griessmair, Germany</td>
</tr>
<tr>
<td>13:10</td>
<td>H-O-023</td>
<td>Functional and immunometabolic analysis of liver derived MAIT cells in autoimmune liver disease</td>
<td>Suz Warner, United Kingdom</td>
</tr>
<tr>
<td>13:20</td>
<td>H-O-024</td>
<td>Preventative strategies against cytomegalovirus in paediatric liver transplantation: results from the European prospective multi-centre ChilSFree cohort study</td>
<td>Emanuele Nicastro, Italy</td>
</tr>
</tbody>
</table>

---

### Parallel Session: Gastroenterology 6

**Chairs:** Lissy de Ridder, The Netherlands · Rut Anne Thomassen, Norway

**12:30 – 13:30 Hall 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>G-O-052</td>
<td>Treatment failure, safety, and immunogenicity of anti-TNF treatment in biologic-naïve children and adolescents with Crohn’s disease: a subgroup analysis of the PANTS cohort</td>
<td>Neil Chanchlani, United Kingdom</td>
</tr>
<tr>
<td>12:40</td>
<td>G-O-053</td>
<td>Tolerability, safety, and efficacy of varicella-zoster-virus vaccination in immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis</td>
<td>Carsten Posovszky, Germany</td>
</tr>
<tr>
<td>12:50</td>
<td>G-O-054</td>
<td>Nephrotoxicity of aminosalicylates in children and adolescents with inflammatory bowel disease (IBD)-data excerpt of CEDATA GPGE®</td>
<td>Angeliki Pappa, Germany</td>
</tr>
<tr>
<td>13:00</td>
<td>G-O-055</td>
<td>Neurological adverse events induced by tumour necrosis factor alpha inhibitors in paediatric inflammatory bowel diseases: an analysis based on the French National Pharmacovigilance Database</td>
<td>Valerie Bertrand, France</td>
</tr>
<tr>
<td>13:10</td>
<td>G-O-056</td>
<td>Final growth in paediatric Crohn’s Disease is impaired also in the era of biologics: a population based analysis from the epilIRN administrative cohort</td>
<td>Amit Assa, Israel</td>
</tr>
<tr>
<td>13:20</td>
<td>G-O-057</td>
<td>An ongoing safety registry to identify rare and severe complications in paediatric-onset IBD</td>
<td>Martine A. Aardoom, The Netherlands</td>
</tr>
</tbody>
</table>

**13:30 – 15:15 Lunch Break & Poster Session incl. Poster Walks**
Friday, 07 June 2019

Parallel Symposium: Functional GI-disorders

Chairs: Nikhil Thapar, United Kingdom · Silvia Salvatore, Italy

15:15 – 17:15 Clyde Hall

15:15 Functional nausea, diagnosis and treatment
Katja Kovacic, USA

15:40 G-O-058 Pediatric PPI use and fracture risk
Nathan Fleishman, USA

15:50 G-O-059 Genetic factors influence on the development of functional constipation (FC) disease in children
Elżbieta Czkwianianc, Poland

16:00 Pain modulation in functional abdominal pain disorders
Qasim Aziz, United Kingdom

16:25 The effect of placebo in FGIDs
Arine Vlieger, Belgium

16:50 Allergy and FGIDs a true association?
Yvan Vandenplas, The Netherlands

Parallel Symposium: Contemporary management of PIBD

Chairs: David Wilson, United Kingdom · Dan Turner, Israel

15:15 – 17:15 Hall 1

15:15 Managing PIBD in low resource setup
Almuthe Christina Hauer, Austria · Michael Lentze, Germany

15:40 PIBD ahead: predicting disease course in IBD and how to select children requiring biologics at disease onset
Anne Griffiths, Canada

16:05 Predicting response to anti-TNF in children
Nicholas Kennedy, United Kingdom

16:30 G-O-060 Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
Dan Turner, Israel

16:40 G-O-061 Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in pediatric patients with Crohn’s disease: the pediatric Crohn’s disease adalimumab level-based optimization treatment (PAILOT) randomized controlled trial
Amit Assa, Israel

16:50 Will the new UC guidelines help me look after my patients? Examples from practice
Javier Martín de Carpi, Spain
## Parallel Symposium: Liver transplantation

**Chairs:** Françoise Smets, Belgium · Marianne Samyn, United Kingdom

**15:15 – 17:15 Hall 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>The late post-transplant liver biopsy: towards standardisation</td>
<td>Stefan G. Hübscher, United Kingdom</td>
</tr>
<tr>
<td>15:48</td>
<td>H-O-025 Evolution of liver transplantation for children and adolescents in Europe – a report of the European liver transplant registry</td>
<td>Ulrich Baumann, Germany</td>
</tr>
<tr>
<td>15:58</td>
<td>Late graft injury – natural history and mechanisms</td>
<td>Steffen Hartleif, Germany</td>
</tr>
<tr>
<td>16:31</td>
<td>H-O-026 Early emergence of de novo donor specific antibodies in pediatric liver recipients are associated with T cell mediated rejection</td>
<td>Come Tissandier, Switzerland</td>
</tr>
<tr>
<td>16:41</td>
<td>Noninvasive assessment of fibrosis after liver transplantation: where do we stand?</td>
<td>Jonathan Fallowfield, United Kingdom</td>
</tr>
</tbody>
</table>

## Parallel Symposium: Donor human milk

**Chairs:** Judith Simpson, United Kingdom · Nicholas Embleton, United Kingdom

**15:15 – 17:15 Hall 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>What is the evidence base for the use of donor milk in preterm infants?</td>
<td>Nicholas Embleton, United Kingdom</td>
</tr>
<tr>
<td>15:45</td>
<td>N-O-034 Postnatal longitudinal growth and reference growth charts for very preterm infants on predominant human milk feeding</td>
<td>Srinivas Murki, India</td>
</tr>
<tr>
<td>15:55</td>
<td>N-O-035 The preparation and storage of fortified expressed breast milk in neonatal units in England - a survey</td>
<td>Mandy Davies, United Kingdom</td>
</tr>
<tr>
<td>16:05</td>
<td>Protection of functional components during donor milk pasteurization</td>
<td>Jean-Charles Picaud, France</td>
</tr>
<tr>
<td>16:35</td>
<td>N-O-036 Effects of early use of donor human milk on growth, development and neonatal morbidity in very low birth weight infants: comparison to mother’s own milk and preterm formula</td>
<td>Deepa Hariharan, India</td>
</tr>
<tr>
<td>16:45</td>
<td>Discussion: examples and challenges of national organisation of milk banking</td>
<td>Sertac Arslanoglu, Turkey, Hans van Goudoever, The Netherlands, Jean-Charles Picaud, France, Magnus Domellöf, Sweden</td>
</tr>
</tbody>
</table>
### Programme Overview

#### Saturday, 08 June 2019

<table>
<thead>
<tr>
<th>Clyde Hall</th>
<th>Lomond Hall</th>
<th>Hall 1</th>
<th>Hall 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30</strong></td>
<td><strong>08:30</strong></td>
<td><strong>08:30</strong></td>
<td><strong>08:30</strong></td>
</tr>
<tr>
<td><strong>Parallel Symposium</strong></td>
<td><strong>Parallel Symposium</strong></td>
<td><strong>Parallel Symposium</strong></td>
<td><strong>Parallel Symposium</strong></td>
</tr>
<tr>
<td>Organoids: Cutting edge translational research tools in paediatric Gastroenterology</td>
<td>Probiotics for infants</td>
<td>Novelties in Hepatology</td>
<td>Coeliac disease: Diagnosis and screening for everybody</td>
</tr>
<tr>
<td>see page 66</td>
<td>see page 66</td>
<td>see page 67</td>
<td>see page 68</td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td><strong>Coffee Break &amp; ePoster Session</strong></td>
<td><strong>Coffee Break &amp; ePoster Session</strong></td>
<td></td>
</tr>
<tr>
<td><strong>11:40</strong></td>
<td><strong>Keynote Lecture</strong></td>
<td>Gastroenterology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 68</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:10</strong></td>
<td><strong>Clinical Practice in Nutrition: Feeding disorders</strong></td>
<td><strong>Joint Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>Gastroenterology 2</td>
<td></td>
<td>Nutrition and Gastroenterology</td>
<td></td>
</tr>
<tr>
<td>see page 70</td>
<td>see page 69</td>
<td>see page 71</td>
<td>see page 69</td>
</tr>
<tr>
<td><strong>13:25</strong></td>
<td><strong>13:30</strong></td>
<td><strong>Closing &amp; Awards</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>see page 71</td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, 08 June 2019

#### Clyde Hall

**Parallel Symposium: Organoids: Cutting edge translational research tools in paediatric Gastro**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Intestinal epithelial organoids in GI health and disease</td>
<td>Matthias Zilbauer, United Kingdom</td>
</tr>
<tr>
<td>08:55</td>
<td>Genetic engineering of intestinal organoids</td>
<td>Bon-Kyoung Koo, Austria</td>
</tr>
<tr>
<td>09:20</td>
<td>Lin-28/Occludin axis: an aberrant signal leading to impaired intestinal barrier function under total parenteral nutrition</td>
<td>Junkai Yan, China</td>
</tr>
<tr>
<td>09:30</td>
<td>Drug development and personalised medicine in cystic fibrosis using intestinal organoids</td>
<td>Jeffrey M. Beekman, The Netherlands</td>
</tr>
<tr>
<td>09:55</td>
<td>Liver organoids as models to study human development and disease</td>
<td>Alexander Ross, United Kingdom</td>
</tr>
</tbody>
</table>

#### Lomond Hall

**Parallel Symposium: Probiotics for infants**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>The normal development of the infant gut microbiota</td>
<td>Christopher Stewart, United Kingdom</td>
</tr>
<tr>
<td>08:50</td>
<td>Daily administration of Lactobacillus plantarum improves mouse juvenile growth kinetics by sustaining somatotropic axis activity upon undernutrition</td>
<td>Pierre Poinson, France</td>
</tr>
<tr>
<td>09:00</td>
<td>Probiotics in infant formula – what is the evidence?</td>
<td>Hania Szajewska, Poland</td>
</tr>
</tbody>
</table>

#### Hall 1

**Parallel Symposium: Novelties in Hepatology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Surgical developments in liver transplantation: what has changed and what is expected to change shortly</td>
<td>Dieter Clemens Broering, Saudi Arabia</td>
</tr>
<tr>
<td>09:03</td>
<td>USP53 mutation manifest as low-GGT intrahepatic cholestasis</td>
<td>Ye Yang, China</td>
</tr>
<tr>
<td>09:13</td>
<td>Liver directed gene therapy: current results</td>
<td>Amit C. Nathwani, United Kingdom</td>
</tr>
<tr>
<td>09:46</td>
<td>Mayo PSC risk score: a prognostication tool for Biliary Atresia outcomes in adulthood</td>
<td>Vandana Jain, United Kingdom</td>
</tr>
<tr>
<td>09:56</td>
<td>The liver and enzyme replacement therapy: to give or not to give?</td>
<td>Roshni Vara, United Kingdom</td>
</tr>
</tbody>
</table>
### Parallel Symposium: Coeliac disease: Diagnosis and screening for everybody?

**Chairs**: Luisa Mearin, The Netherlands · Daniel Agardh, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Population screening: pros and cons</td>
<td>Carlo Catassi, Italy/Kalle Kurppa, Finland</td>
</tr>
<tr>
<td>09:20</td>
<td>The ethics of screening</td>
<td>Martine de Vries, The Netherlands</td>
</tr>
<tr>
<td>09:45</td>
<td>G-O-064 Value of anti-tTG IgA in screening of coeliac disease in asymptomatic children with high-risk</td>
<td>Ozlem Kalaycik Sengül, Turkey</td>
</tr>
<tr>
<td>09:55</td>
<td>G-O-065 How long children with a first-degree coeliac relative should be followed by antibody screening?</td>
<td>Ilma R. Korponay-Szabó, Hungary</td>
</tr>
<tr>
<td>10:05</td>
<td>The 2019 ESPGHAN guidelines for coeliac disease: consolidation of the no-biopsy approach</td>
<td>Steffen Husby, Denmark</td>
</tr>
</tbody>
</table>

### Coffee Break & ePoster Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>Coffee Break &amp; ePoster Session</td>
</tr>
</tbody>
</table>

### Clyde Hall

#### Keynote Lecture: Gastroenterology

**Chair**: Nikhil Thapar, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40</td>
<td>The brain in the gut: master conductor of the orchestra</td>
<td>Vassilis Pachnis, United Kingdom</td>
</tr>
</tbody>
</table>

### Lomond Hall

#### Clinical Practice in Nutrition: Feeding disorders

**Chairs**: Jessie Hulst, Canada · Iva Hojsak, Croatia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10</td>
<td>Feeding disorders: diagnosis, classification – a practical approach</td>
<td>Gillian Harris, United Kingdom</td>
</tr>
<tr>
<td>12:40</td>
<td>Feeding disorders: treatment (and the utility of a feeding team)</td>
<td>Tena Nisetteo, Croatia</td>
</tr>
<tr>
<td>13:05</td>
<td>N-O-040 ARFID is a common diagnosis at a paediatric eating observation clinic</td>
<td>Lotta Söderberg, Sweden · Emma Gotthardtsson, Sweden</td>
</tr>
<tr>
<td>13:15</td>
<td>N-O-041 Improving swallowing function due to electrical stimulation in group of children – preliminary results from an innovative method of treatment</td>
<td>Ewa Winnicka, Poland</td>
</tr>
</tbody>
</table>

### Hall 2

#### Joint Symposium: Nutrition and Gastroenterology

**Chairs**: Erasmo Miele, Italy · Konstantinos Gerasimidis, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10</td>
<td>Food additives and food industrialisation in the aetiology and progression of IBD</td>
<td>Arie Levine, Israel</td>
</tr>
<tr>
<td>12:30</td>
<td>The epidemiology of the role of diet in the aetiology of IBD</td>
<td>Andrew Hart, United Kingdom</td>
</tr>
<tr>
<td>12:50</td>
<td>G-O-073 Rapid reversion to baseline microbiome during food reintroduction after successful course of exclusive enteral nutrition (EEN) in paediatric Crohn’s disease (CD)</td>
<td>Michael Logan, United Kingdom</td>
</tr>
<tr>
<td>13:00</td>
<td>N-O-042 Dietary intake and adherence to mediterranean diet in a cohort of pediatric patients with Inflammatory Bowel Diseases (IBD)</td>
<td>Caterina Strisciuglio, Italy</td>
</tr>
<tr>
<td>13:10</td>
<td>Exclusion diets in the management of IBD: how much and how good is the evidence?</td>
<td>Vaios Svolos, United Kingdom</td>
</tr>
</tbody>
</table>
### Chronological Programme

**Plenary Session: Gastroenterology 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>G-O-066</td>
<td>SOMAscan as a discovery platform to identify predictive serum proteomic biomarkers of infliximab response in pediatric patients with Crohn's disease</td>
<td>Tina Morhardt</td>
<td>USA</td>
</tr>
<tr>
<td>12:25</td>
<td>G-O-067</td>
<td>Panallergens in natural history of EoE: are they predictive of diet failure?</td>
<td>Monica Malamisura</td>
<td>Italy</td>
</tr>
<tr>
<td>12:35</td>
<td>G-O-068</td>
<td>Standard dosing of infliximab dosing not sufficient in young paediatric IBD patients – a multicenter study</td>
<td>Maria Myrthe Jongsma</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>12:45</td>
<td>G-O-069</td>
<td>SERPINB12 as a possible marker of steroid dependency in children with Eosinophilic Esophagitis: A pilot study</td>
<td>Salvatore Oliva</td>
<td>Italy</td>
</tr>
<tr>
<td>12:55</td>
<td>G-O-070</td>
<td>Correlation between antroduodenal manometry and histopathology in paediatric intestinal pseudo-obstruction</td>
<td>Atchariya Chanpong</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>13:05</td>
<td>G-O-071</td>
<td>Constitutive alterations of vesicular trafficking predispose to innate immune response to gliadin in celiac disease</td>
<td>Maria Vittoria Barone</td>
<td>Italy</td>
</tr>
<tr>
<td>13:15</td>
<td>G-O-072</td>
<td>Characterization of Eosinophilic Esophagitis in a multicenter patient population from the European Pediatric Eosinophilic Esophagitis Registry (pEER) of ESPGHAN</td>
<td>Salvatore Oliva</td>
<td>Italy</td>
</tr>
</tbody>
</table>

**Parallel Session: Hepatology 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:25</td>
<td>H-O-029</td>
<td>Characterisation of different sources of stromal cells as support for primary human hepatocytes to improve the outcome of hepatocyte transplantation</td>
<td>Teresa Brunetti</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>12:35</td>
<td>H-O-030</td>
<td>How to infuse heterologous human adult liver-derived progenitor cells safely?</td>
<td>Louise Coppin</td>
<td>Belgium</td>
</tr>
<tr>
<td>12:45</td>
<td>H-O-031</td>
<td>Hepatopulmonary syndrome in children: a two-decades experience at a single liver transplantation referral centre</td>
<td>Emanuele Nicastro</td>
<td>Italy</td>
</tr>
<tr>
<td>12:55</td>
<td>H-O-032</td>
<td>Biallelic complete loss-of-function ZFYVE19 mutations: congenital hepatic fibrosis, sclerosing cholangiopathy, and high-GGT cholestasis</td>
<td>Chen-Zhi Hao</td>
<td>China</td>
</tr>
<tr>
<td>13:05</td>
<td>H-O-033</td>
<td>Magnetic resonance elastography in evaluation of hepatic fibrosis in children with chronic liver disease</td>
<td>Duygu Demirtas</td>
<td>Guner, Turkey</td>
</tr>
<tr>
<td>13:15</td>
<td>H-O-034</td>
<td>Gallstone disease and heart rhythm disorders in children</td>
<td>Kseniya Yurchyk</td>
<td>Belarus</td>
</tr>
</tbody>
</table>

**Closing Session and Award Ceremony**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Clyde Hall</td>
</tr>
<tr>
<td>13:30</td>
<td>Closing Session and Award Ceremony</td>
</tr>
</tbody>
</table>
List of Invited Speakers, Chairpersons and Tutors

A
Daniel Agardh, Sweden
Marina Aloï, Italy
Jorge Amil Dias, Portugal
Sertac Arslanoglu, Turkey
Amit Assa, Israel
Marcus Auth, United Kingdom
Qasim Aziz, United Kingdom

B
Andrew Barclay, United Kingdom
Ulrich Baumann, Germany
Jeffrey Beekman, The Netherlands
Marc Benninga, The Netherlands
Vishnu Biradar, India
Frank Bodewes, The Netherlands
Patrick Bontems, Belgium
Osvaldo Borrelli, United Kingdom
Billy Bourke, Ireland
Ronald Bremner, United Kingdom
Iris Broekaert, Germany
Dieter Clemens Broering, Saudi Arabia
Jiri Bronsky, Czech Republic
Elaine Buchanan, United Kingdom
Su Bunn, United Kingdom

C
Samy Cadranel, Belgium
Cristina Campoy, Spain
Tracey Cardigan, United Kingdom
Carlo Catassi, Italy
Iain Chalmers, United Kingdom
Altchariya Chanpong, United Kingdom
Shlomi Cohen, Israel
Paula Crespo-Escobar, Spain
Nicholas Croft, United Kingdom
Piotr Czubkowski, Poland

D
Luigi Dall’Oglio, Italy
Giulia D’Arcangelo, Italy
Suzanne Davison, United Kingdom
Ruth De Bruyne, Belgium
Lissy de Ridder, Netherlands
Martine de Vries, The Netherlands
Dominique Debry, France
Marco Deganello Saccomani, Italy
Anil Dhawan, United Kingdom
Jernej Dolinšek, Slovenia
Magnus Domellöf, Sweden
Sarah Durnan, United Kingdom

E
Muftah Eltumi, United Kingdom
Nicholas Embleton, United Kingdom
Lars Engstrand, Sweden

F
Jackie Falconer, United Kingdom
Jonathan Fallowfield, United Kingdom
Simona Faraci, Italy
Mary Fewtrell, United Kingdom
Douglas Fishman, USA
Diana Flynn, United Kingdom
Raoul Furlano, Switzerland
Stéphanie Franchi-Abella, France

G
Diana García Tirado, Spain
Victoria Garrick, United Kingdom
Konstantinos Gerasimidis, United Kingdom
Peter Gillett, United Kingdom
Frédéric Gottrand, France
Tassos Grammatikopoulos, United Kingdom
Heather Grant, United Kingdom
Anne Griffiths, Canada
Grish Gupte, United Kingdom

H
Nedim Hadzic, United Kingdom
Richard Hansen, United Kingdom
Gillian Harris, United Kingdom
Andrew Hart, United Kingdom
Steffen Hartleif, Germany
Almuthe Christina Hauser, Austria
Paul Henderson, United Kingdom
Jonathan Hind, United Kingdom
Iva Hojsak, Croatia
Matjaž Homan, Slovenia
David Hoole, United Kingdom
Stefan G. Hübischer, United Kingdom

J
Jörg Jahnel, Austria
Andreas Jenke, Germany
Tracey Johnson, United Kingdom
Norman Junge, Germany

K
Jochen Kammermeier, United Kingdom
Saul Karpen, USA
Richard Kellermayer, USA
Deirdre Kelly, United Kingdom
Nicholas Kennedy, United Kingdom
Jutta Koeglmeier, United Kingdom
Sanja Kolaček, Croatia
Sibylle Koletzko, Germany
Bon-Kyoung Koo, Austria
Katja Kovacic, USA
Kalle Kurppa, Finland

L
Alexandre Lapillonne, France
Sally Lawrence, Canada
Jessie Hulst, Canada
Steffen Husbøl, Denmark
Koen Huysentruyt, Belgium
Warren Hyer, United Kingdom
<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lentze</td>
<td>Germany</td>
</tr>
<tr>
<td>Arie Levine</td>
<td>Israel</td>
</tr>
<tr>
<td>Delphine Ley</td>
<td>France</td>
</tr>
<tr>
<td>Keith Lindley</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Paolo Lionetti</td>
<td>Italy</td>
</tr>
<tr>
<td>Zuzana Londt</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Eberhard Lurz</td>
<td>Germany</td>
</tr>
<tr>
<td>Tena Niseteo</td>
<td>Croatia</td>
</tr>
<tr>
<td>Lorenzo Norsa</td>
<td>Italy</td>
</tr>
<tr>
<td>Jan Nowak</td>
<td>Poland</td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>Salvatore Oliva</td>
<td>Italy</td>
</tr>
<tr>
<td>Rok Orel</td>
<td>Slovenia</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Vassilis Pachnis</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Alexandra Papadopoulou</td>
<td>Greece</td>
</tr>
<tr>
<td>Catherine Paxton</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Jean-Charles Picaud</td>
<td>France</td>
</tr>
<tr>
<td>Corina Pienar</td>
<td>Romania</td>
</tr>
<tr>
<td>Susan Protheroe</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Sarah MacDonald</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sara Mancell</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Javier Martin de Carpi</td>
<td>Spain</td>
</tr>
<tr>
<td>Emmanuel Mas</td>
<td>France</td>
</tr>
<tr>
<td>Paraic McGrogan</td>
<td>Qatar</td>
</tr>
<tr>
<td>Iain B. McInnes</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Valérie McClain</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Luisa Mearin</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Erasmo Miele</td>
<td>Italy</td>
</tr>
<tr>
<td>Peter Milla</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Nurul Husna Mohd Shukri</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Sissel Moltu</td>
<td>Norway</td>
</tr>
<tr>
<td>Aleixo Muise</td>
<td>Canada</td>
</tr>
<tr>
<td>Simon Murch</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Karen Murray</td>
<td>USA</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Priya Narula</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Amit C. Nathwani</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Natalia Nedelkopolou</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Emanuele Nicastro</td>
<td>Italy</td>
</tr>
<tr>
<td>Tena Niseteo</td>
<td>Croatia</td>
</tr>
<tr>
<td>Isabelle Scheers</td>
<td>Belgium</td>
</tr>
<tr>
<td>Detlef Schuppan</td>
<td>Germany</td>
</tr>
<tr>
<td>Daniele Serranti</td>
<td>Italy</td>
</tr>
<tr>
<td>Mohammad Ali Shagran</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Raanan Shamir</td>
<td>Israel</td>
</tr>
<tr>
<td>Shishu Sharma</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Debbie L. Shawcross</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Rotem Sigall Bone</td>
<td>Israel</td>
</tr>
<tr>
<td>Ari Silbermanz</td>
<td>Israel</td>
</tr>
<tr>
<td>Judith Simpson</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Maartje Singendon</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Karin Sipido</td>
<td>Belgium</td>
</tr>
<tr>
<td>François Smets</td>
<td>Belgium</td>
</tr>
<tr>
<td>Etienne Sokal</td>
<td>Belgium</td>
</tr>
<tr>
<td>Annamaria Staiano</td>
<td>Italy</td>
</tr>
<tr>
<td>Christopher Stewart</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ekkehard Sturm</td>
<td>Germany</td>
</tr>
<tr>
<td>Vaios Svolos</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Hania Szajewska</td>
<td>Poland</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Jenna Tarr</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Rachel Taylor</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Nikhil Thapar</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Rut Anne Thomassen</td>
<td>Norway</td>
</tr>
<tr>
<td>Mike Thomson</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>David Trondle</td>
<td>USA</td>
</tr>
<tr>
<td>Riccardo Troncone</td>
<td>Italy</td>
</tr>
<tr>
<td>Dan Turner</td>
<td>Israel</td>
</tr>
<tr>
<td>Christos Tzivinikos</td>
<td>United Arab Emirates</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Holm Uhlig</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Vaidotas Urbonas</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Arun Urs</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Wendy van der Woerd</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Hans van Goudeover</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Patrick van Rheenen</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Michiel P. van Wijk</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Yvan Vandenplas</td>
<td>Belgium</td>
</tr>
<tr>
<td>Roshni Vara</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Elvira Verduci</td>
<td>Italy</td>
</tr>
<tr>
<td>Gábor Veres</td>
<td>Hungary</td>
</tr>
<tr>
<td>Henkjan Verkade</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Jérôme Viala</td>
<td>France</td>
</tr>
<tr>
<td>Arine Vlieger</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Orith Waisbourd-Zinman</td>
<td>Israel</td>
</tr>
<tr>
<td>Gregor Walker</td>
<td>United Kindom</td>
</tr>
<tr>
<td>Jian She Wang</td>
<td>China</td>
</tr>
<tr>
<td>Michael Wilschanski</td>
<td>Israel</td>
</tr>
<tr>
<td>David Wilson</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Victorien Wolters</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Jarod Wong</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Anat Yerushalm-Feler</td>
<td>Israel</td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Tsili Zangen</td>
<td>Israel</td>
</tr>
<tr>
<td>Aглая Zellos</td>
<td>Greece</td>
</tr>
<tr>
<td>Matthias Zilbauer</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
We would like to thank all abstract submitters for submitting 1180 abstracts from 66 countries for the ESPGHAN 52nd Annual Meeting! We are very grateful for these efforts being made.

We are happy to share some further facts about this year’s abstract handling. The following numbers of abstracts have been submitted per field:

All submitted abstracts underwent a blinded review. The following illustration highlights the ranking structure as well as explains the way of the presentation of all accepted abstracts.

**Oral presentation**
- **RANKING**: The top 15% abstracts
- **WAY OF PRESENTATION**:
  - Oral presentation included in the symposia of the Scientific Programme

**ePoster**
- **RANKING**: The subsequent 9% of abstracts qualified for presentation as ePoster
- **WAY OF PRESENTATION**:
  - Available at ePoster stations and as printed poster in the poster exhibition
  - Oral presentation in the ePoster Session on Saturday morning during coffee break

**Poster selected for Poster Walk**
- **RANKING**: The subsequent 9% of abstracts qualified for presentation as posters, complimented with a poster walk presentation
- **WAY OF PRESENTATION**:
  - Available in the poster exhibition
  - Short oral presentation during the Poster Walk on Friday during lunch break

**Posters**
- **RANKING**: 67% of abstracts were rated above the cut-off score for presentation as poster
- **WAY OF PRESENTATION**:
  - Available in the poster exhibition
The 95 best scored posters will be presented as ePosters. These posters will be shown electronically at ten ePoster stations during the whole meeting starting on Wednesday, 5 June, during the Welcome Reception (18:30 – 20:30) to Saturday, 08 June 2019, in the ePoster area (Hall 4). Furthermore, a printed version of each ePoster will be accessible in the Poster Exhibition during the opening times.

The ePosters will be presented in the ePoster Session on Saturday, 08 June 2019, from 10:40 to 11:30.

### Session 1
**Chairs:** Diana García Tirado, Spain  
Jernej Dolinšek, Slovenia

<table>
<thead>
<tr>
<th>G-P-003</th>
<th>Ingrid Renes, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Native whey protein improves maturation of the immature intestine of preterm and near term piglets</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-015</th>
<th>Donatella Cielo, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipidomic profile predicts celiac disease in at-risk infants</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-023</th>
<th>Mariangela Conte, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undigested gliadin P31-43 delays celiac disease-associated Neisseria flavescens in early endocytic vesicles in CaCo-2 epithelial cells: role of Lactobacillus paracasei CBA L74</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-030</th>
<th>Rita Elek, Hungary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establishing kit-independent calibrators for measuring serum transglutaminase antibody concentrations for the prediction of celiac disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-059</th>
<th>Petra Rižnik, Slovenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>The influence of diagnostic delays on growth of children with coeliac disease in Central-Europe</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-061</th>
<th>Orit Rozenberg, Israel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Automated analyzers are suited for diagnosing celiac disease following the ESPGHAN 2012 criteria</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-072</th>
<th>Sebastian Stricker, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcellular localization of transglutaminases and the regulatory proteins ERp57 and protein disulphide isomerase in coeliac disease</td>
<td></td>
</tr>
</tbody>
</table>

### Session 2
**Chairs:** Marina Aloi, Italy  
Marcus Auth, United Kingdom

<table>
<thead>
<tr>
<th>G-P-086</th>
<th>Raphaël Enaud, France</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early microbiota disturbances and intestinal inflammation in children with cystic fibrosis</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-096</th>
<th>Jan Krzysztof Nowak, Poland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Navigating between subclinical atherosclerosis and arterial stiffness in cystic fibrosis: a cross-sectional study</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-099</th>
<th>Andrea Pánitzky, Hungary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explore the childhood onset pancreatitis with the support of APPLE (Analysis of Pediatric Pancreatitis) multicenter, observational, clinical trial</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-100</th>
<th>María Roca Llorens, Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faecal calprotectin levels in children with cystic fibrosis are higher as compared to healthy controls</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-101</th>
<th>Gillian Smith, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>How Vitamin D levels in children with cystic fibrosis have been increased through supplementation regimens</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-131</th>
<th>Frances Lee, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>The effect of audit and feedback on ileal and cecal intubation rates in pediatric colonoscopy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-146</th>
<th>Chantal A. ten Kate, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successful treatment of severe recurrent anastomotic strictures with intralesional steroid injections in children with oesophageal atresia: a case series</td>
<td></td>
</tr>
</tbody>
</table>
Session 3

Chairs: Susan Protheroe, United Kingdom
Camilla Salvestini, United Kingdom

G-P-179
Marcus Auth, United Kingdom
Differences in implementation of guidelines on diagnosis and treatment of Eosinophilic Esophagitis (EoE). An overview of current pediatric and adult GI practice in Europe

G-P-198
Juan J. Diaz, Spain
Gut changes with milk introduction in infants with outgrowing non-IgE cow’s milk protein allergy

G-P-206
Eun Hye Lee, Republic of Korea
Nationwide epidemiologic study on childhood intussusception in South Korea: on the emphasis of treatment and outcomes

G-P-210
Jan Lukasik, Poland
Prenatal and early postnatal exposure to antibiotics and autism spectrum disorders – a systematic review

G-P-216
Ji Sook Park, Republic of Korea
Macrophage migration inhibitory factor as a predictive factor of necrotizing enterocolitis in premature infants

G-P-232
Yang Wang, China
Contribution of common genetic variants in Armadillo Repeat gene deleted in Velo-Cardio-Facial syndrome (ARVCF) and related gene-gene interaction networks to the risk of hirschspring disease

G-P-255
Teresa Di Chio, United Kingdom
Lack of agreement between colonic manometry and colonic transit studies in classifying children with chronic constipation

G-P-257
John E. Fortunato, USA
Evaluation of paediatric nausea: time to think outside the gastroenterology box?

G-P-278
Luca Marciani, United Kingdom
Novel mini-capsules markers and methods for magnetic resonance imaging of gastrointestinal transit in paediatric constipation (the MAGIC study)

G-P-286
Robyn Rexwinkel, The Netherlands
Long-term follow-up of gut-directed hypnotherapy self-exercises at home using CD versus individual therapy by qualified therapists in children with irritable bowel syndrome or functional abdominal pain syndrome

G-P-291
Renato Tambucci, Italy
Scintigraphic colonic transit in children with severe constipation: a retrospective chart review

G-P-293
Erick M. Toro-Monjaraz, Mexico
Anorectal manometry in children with retentive faecal incontinence: what parameters should we evaluate?

G-P-309
Sana Barakat, Egypt
Role of bovine colostrum in the treatment of acute diarrhea in Egyptian children: a randomised double-blinded, placebo-controlled trial

G-P-331
Ting Zhang, China
Clinical efficacy and microbiome changes following fecal microbota transplantation in children with recurrent clostridium difficile infection

G-P-355
Roberto Berni Canani, Italy
Bifidobacteriumanimalissubsp.lactis BB-12 is effective in the treatment of infant colic: result of a randomized controlled trial

Session 4

Chairs: Ilse Broekaert, Germany
Emmanuel Mas, France

G-P-332
Myrthe M. E. Jongma, The Netherlands
Trough levels and efficacy of Vedolizumab in refractory PIBD patients

G-P-339
David Devadason, United Kingdom
Current practice in UK centres providing surgery in paediatric inflammatory bowel disease - a survey from the BSPGHAN IBD working group

G-P-343
Felipe Briglia, Canada
Infliximab dose optimization during maintenance therapy in children with IBD

G-P-344
Christopher J. Burgess, United Kingdom
Paediatric patients account for less than 1.5% of all prevalent inflammatory bowel disease cases within a defined Scottish health board

G-P-345
Daniela Knafelz, Italy
Inflammatory bowel diseases associated with primary sclerosing cholangitis in children: a ten years case-control retrospective study

G-P-353
Eileen Crowley, Canada
Pouchitis and microscopic inflammation at ileal resection margin in children with PIBD

G-P-354
Giulia D’Arcangelo, Italy
Outcome of pediatric Crohn’s disease (CD) before vs after 2014 – is there an impact of the pediatric guidelines on the medical management of CD?

G-P-355
Roberto Berni Canani, Italy
Bifidobacteriumanimalissubsp.lactis BB-12 is effective in the treatment of infant colic: result of a randomized controlled trial

G-P-356
Jan de Laffolie, Germany
Evaluation of gender-specific differences in the course of disease of paediatric patients with Inflammatory Bowel Disease based on data of the CEDATA-GPGE-register

G-P-358
Jasbir Dhaliwal, Canada
Excess adiposity is a common finding in children and adolescents with inflammatory bowel disease

G-P-373
Jair Gonzalez Marques Junior, Germany
GC QTOF profile of stool metabolome and machine learning algorithms – a pilot study to diagnose Crohn’s disease

Session 5

Chairs: Frank Bowedes, The Netherlands
Isabelle Scheers, Belgium

G-P-375
Patrick F. van Rheenen, The Netherlands
Time to reach target calprotectin level and sustained remission in newly diagnosed patients with IBD: first results of the fast forward care prospective registry

G-P-379
Rachel Harris, United Kingdom
A study of post-induction Infliximab trough levels demonstrates most paediatric patients are being underdosed

G-P-384
Sara Isoldi, Italy
Pouchitis and microscopic inflammation at ileal resection margin in children with Ulcerative Colitis: is there a relationship?
### Hepatology

#### Session 6

**Chairs:** Tassos Grammatikopoulos, United Kingdom  
Anil Dhawan, United Kingdom

<table>
<thead>
<tr>
<th>G-P-401</th>
<th>Sara Lega, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diagnostic approach to monogenic inflammatory bowel disease in clinical practice: a ten-year multicentric experience</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-428</th>
<th>Sahana Shankar, Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tacrolimus has superior efficacy in thiopurine naïve as compared to thiopurine experienced children with steroid dependant or refractory colitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-446</th>
<th>Dan Turner, Israel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First report of national childhood-onset IBD in Israel: an epiIRN study</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-449</th>
<th>Johan Van Limbergen, Canada</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Exclusive enteral nutrition (EEN) and Crohn’s disease exclusion diet (CDED) produce broadly similar taxonomic and functional changes during the induction of remission, with EEN showing a pattern of rebound after return to free diet + partial enteral nutrition (PEN)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-451</th>
<th>Marta Velasco Rodríguez-Belvis, Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost-effectiveness of the use of HLA-DQA1-DRB1 polymorphism to identify pediatric patients with inflammatory bowel disease at risk for azathioprine-induced acute pancreatitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G-P-468</th>
<th>Marieke Zijlstra, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Comparison of Infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology</td>
</tr>
</tbody>
</table>

#### Session 7

**Chairs:** Eberhard Lurz, Germany  
Wendy van der Woerd, The Netherlands

<table>
<thead>
<tr>
<th>H-P-002</th>
<th>Kai-Chi Chang, Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alterations of gut microbiota in biliary atresia patients with liver cirrhosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-013</th>
<th>Steffeni Mountford, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Interleukin-37 reduces pro-inflammatory and pro-fibrotic properties of murine and human hepatic stellate cells</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-024</th>
<th>Marion Almes, France</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Targeted-capture next-generation sequencing in the diagnosis of pediatric cholestasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-026</th>
<th>Aspasia Angelakopoulou, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hepatic manifestations of X-linked Lymphoproliferative Syndrome (XLP)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-034</th>
<th>Marie-Eve Chartier, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hepatic copper concentration mimicking Wilson disease in children with cholestatic and non-cholestatic chronic liver disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-042</th>
<th>Jemma Day, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mastery of self-management skills in young people with chronic liver disease and liver transplants in the United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-044</th>
<th>Ruth De Bruyne, Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-invasive assessment of liver abnormalities in pediatric Fontan patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-049</th>
<th>Fabiola Di Dato, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Spectrum and prevalence of neuro-radiological features in neurologically asymptomatic children with Alagille Syndrome</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-053</th>
<th>Laura Draijer, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Serum lipidsomics profiling as a diagnostic tool for NAFLD in children. A matched case-control pilot study</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-055</th>
<th>Maurizio Giuseppe Fuoti, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Recurrent intrahepatic cholestasis and tight junction protein 2 (TJP2) mutation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-069</th>
<th>Giuseppe Iorio, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fertility evaluation in Wilson’s disease patients diagnosed in childhood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-070</th>
<th>Vandana Jain, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intestinal barrier function in Biliary Atresia post-Kasai Portoenterostomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-093</th>
<th>Jake Mann, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>European Paediatric Non-Alcoholic Fatty Liver Disease (EU-PNAFLD) Registry: design and rationale</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-111</th>
<th>Corina Pienar, Romania</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Feasibility and reproducibility of point shear wave elastography in children</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-116</th>
<th>Bikrant Biharilal Raghuvanshi, India</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Acute Kidney Injury alters the natural course and is associated with poor outcome in children with acute liver failure: Analysis of 227 cases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-120</th>
<th>Nathalie Rock, Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intracranial hypertension and papilledema in a large cohort of pediatric Alagille syndrome</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-128</th>
<th>Daniele Serranti, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sofosbuvir/Ledipasvir in adolescents 12-17 years old with Hepatitis C virus genotype 1, 3 or 4 infection: a real-world experience</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-169</th>
<th>Piotr Socha, Poland</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Acute liver failure due to DGUOK deficiency – five cases in Poland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H-P-187</th>
<th>Michele Pinon, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The role of immunosuppression in post-transplant idiopathic hepatitis, liver fibrosis and antibody-mediated rejection in paediatric liver transplant patients</td>
</tr>
</tbody>
</table>
Nutrition

Session 8
Chairs: Elaine Buchanan, United Kingdom
Konstantinos Gerasimidis, United Kingdom

N-P-020
Angela Campanozzi, Italy
Iodine deficiency among children and adolescents assessed through 24-h urinary iodine excretion

N-P-074
Paul Tadeo Ríos Gallardo, Mexico
The stratified waist-height ratio (W/H ratio) and its association with hypertransaminasemia and hyperuricemia in children and adolescents with obesity

N-P-120
Zahra Khan, Pakistan
Role of gestational age at birth on growth and body composition of preterm infants

N-P-134
Charlotte A. Ruys, The Netherlands
Neurodevelopment of children born very preterm and/or with a very low birth weight: 8-year follow-up of a nutritional RCT

N-P-147
Kanar Ahmed, United Kingdom
Dietitians’ experiences of mental health problems in paediatric obesity: a qualitative study

N-P-153
Roberto Berni Canani, Italy
How junk food can contribute to the food allergy epidemic: the potential role of advanced glycation endproducts

N-P-157
Hans Demmelmair, Germany
The effect of Atlantic salmon consumption on the cognitive performance of preschool children – a randomized controlled trial

N-P-172
Carla Morgado, Portugal
Predicting NAFLD in overweight paediatric population: the role of puberty

N-P-187
Itay Zamir, Sweden
Postnatal determinants of blood pressure at 6.5 years of age in children born extremely preterm

Session 9
Chairs: Jutta Koeglmeier, United Kingdom
Jiri Bronsky, Czech Republic

N-P-015
Ardy van Helvoort, The Netherlands
Mineral bioaccessibility from amino acid based medical nutrition formulas for infants and children under different digestive conditions in vitro

N-P-112
Bertram Fong, New Zealand
Milk fat globule membrane (MFGM) proteins: comparison of human MFGM protein classes and functions with MFGM-rich dairy ingredients for improvement of infant formula composition

N-P-114
Kauother Ben-Amor, The Netherlands
Combination of short chain galacto-oligosaccharides and long chain fructo-oligosaccharides (scGOS/ICFOs 9:1) with 2’-fucosyllactose (2’-FL) positively impact the infant gut microbiota composition and metabolic activity in a simulator of the human intestinal microbial ecosystem (SHIME®)

N-P-126
Marka Manx, The Netherlands
Label free targeted LC-ESI-MS2 analysis of 3’- and 6’-galactosyllactose in human milk with enhanced structural selectivity

N-P-127
Sarah D. Maria, USA
A global view of human milk B vitamin content and contribution to recommended infant intake

N-P-128
Nurul Husna Mohd Shakri, Malaysia
Breast milk hormones and infant appetite as predictors of infant growth

N-P-132
Edoardo Pisa, Italy
Presence of 6’SL in pre-weaning milk or mutation of St6gal1 gene modulated microbiota composition and improved cognitive functions in adult offspring

N-P-137
Bernd Stahl, The Netherlands
Fatty acid profile during lactation of Chinese women: a pooled data analysis

Session 10
Chairs: Magnus Domellöf, Sweden
Sunita Amar Rajani, United Kingdom

N-P-047
Susan Hill, United Kingdom
A prospective, open-label, long-term safety and efficacy study of teduglutide in paediatric patients with short bowel syndrome associated-intestinal failure: 6-month interim analysis (SHP633-303)

N-P-055
Jannie Anita Kvammen, Norway
Bone health and vitamin D in paediatric intestinal failure patients receiving home parenteral nutrition

N-P-089
Ivana Trivić, Croatia
Central venous catheter related sepsis in children on long-term parenteral nutrition

N-P-093
Charlotte Wright, United Kingdom
Overdiagnosis of non IgE cows milk allergy in primary care

N-P-098
Katerína Bajerová, Czech Republic
Our experience with cow’s milk-related symptoms scoring (CoMiSS™)

N-P-113
Ajoy Garg, India
Evolution of auditory-neural maturation from birth to 4 - 6 months of age in infants ≥ 35 weeks gestation with normal iron status and latent iron deficiency
The presenters of the posters are requested to set-up their posters in the Poster Area (Hall 4) on Wednesday evening, 05 June, from 18:30 to 20:30 and on Thursday, 06 June from 8:00 and take them down by Saturday, 08 June, 14:15. Any posters not removed by this time will be disposed of by the meeting organisers. Please note that missing poster numbers in this programme have been previously withdrawn.

The Poster Session will take place on Friday, 07 June 2019, from 14:00 to 14:45. All poster presenters should stand by their posters during this session in order to talk about their research work with other delegates.

The Poster Walk will take place during the poster session. All presenters of a Poster selected for Poster Walk should stand by their posters during this session and will be visited by the poster walk chairs who will be glad to involve all presenters and delegates in an interactive discussion about their posters.
Posters selected for Poster Walk

Gastroenterology

Session 1

Chairs: Giulia D’Arcangelo, Italy
Peter Milla, United Kingdom

G-P-002
Marianna Lucafò, Italy
Long non-coding RNA GAS5 as a regulator of intestinal MMP9 and MMP2 expression and tissue damage in pediatric patients with IBD

G-P-029
Neslihan Eksi Bozbult, Turkey
Determination of growth and dietary adequacy status for Celiac disease patients

G-P-036
Ida Gustafsson, Finland
Prevalence of seronegative celiac disease and non-celiac duodenal histopathology in children

G-P-041
Ozlem Kalaycik Sengul, Turkey
Does serologic tests reliably reflect mucosal recovery in coeliac children?

G-P-048
Carla Maia, Portugal
Long term follow up of a coeliac disease population

G-P-052
Nazareth Martinon-Torres, Spain
Comorbid autoimmunity and selective immunoglobulin A deficiency favour persisten tissue-transglutaminase antibody seropositivity in coeliac disease

Session 2

Chairs: Atchariya Chanpong, United Kingdom
Arun Urs, United Kingdom

G-P-077
Anil Verma, Italy
Comparison of RS and G12 antibody-based ELISA methods for the determination of gluten concentration in routine gluten-free food products

G-P-091
Natália Lásztity, Hungary
Clinical signs of severity and therapeutic intervention in pediatric acute pancreatitis – data from APPLLe multicentre, observational clinical trial

G-P-097
Grzegorz Oracz, Poland
Prevalence rate of diabetes mellitus in children with chronic pancreatitis

G-P-107
Harriet Barraclough, United Kingdom
Acquisition of paediatric gastroscopy competence: how many endoscopies do trainees actually need to do?

G-P-121
Luciano Guerra, Italy
“Push bougie” percutaneous endoscopic gastrostomy: a new method of placement

G-P-122
Warren Hyer, United Kingdom
Outcomes from gastrointestinal surveillance in children and teenagers with Peutz-Jeghers syndrome - reducing the need for laparotomy

Session 3

Chairs: Petra Rižnik, Slovenia
Nicholas Croft, United Kingdom

G-P-139
Marleena Repo, Finland
Prevalence and clinical significance of H.pylori negative gastritis in children

G-P-154
Ziqing Ye, China
Domperidone does not alter transit time in paediatric video capsule endoscopy: a randomized controlled trial

G-P-157
Elisa Cavalleri, Italy
Target therapy for refractory autoimmune enteropathy in two cases of primary immune deficiency - preliminary report

G-P-171
Marc McNulty, United Kingdom
Paediatric Eosinophilic oesophagitis outcomes following the introduction of a dedicated clinic

G-P-173
Arati Rao, United Kingdom
In children with eosinophilic oesophagitis, high rates of symptom resolution do not correspond with endoscopic or histological improvement

Session 4

Chairs: Ian Sanderson, United Kingdom
Anat Yerushalmy-Feler, Israel

G-P-202
Ishak Isik, Turkey
Investigation of the efficacy of Lactobacillus rhamnosus GG in infants with cow’s milk protein allergy: a randomised double blind placebo controlled trial

G-P-212
Lara Navarro, Portugal
Baby-led weaning: a trend in complementary feeding? A population based cross-sectional study

G-P-228
Raquel Vecino López, Spain
Prognostic value of the isolated determination of plasma citrulline in a Spanish cohort or children with intestinal failure due to short intestine syndrome

G-P-230
Raquel Vecino López, Spain
Plasma citrulline within the first year after pediatric small bowel transplantation in a Spanish cohort

G-P-231
Marta Velasco Rodríguez-Belvís, Spain
Faecal calprotectin in healthy children: are there factors affecting levels other than age?

G-P-234
Tian Zhang, China
Autophagy deficiency induced intestinal barrier dysfunction contributes to liver fibrosis in a cholestasis rat model
<table>
<thead>
<tr>
<th>Session 5</th>
<th>Chairs: Su Bunn, United Kingdom Jan Nowak, Poland</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-P-244</td>
<td>Ignacio Ros Arnal, Spain</td>
</tr>
<tr>
<td>G-P-246</td>
<td>Marc Benninga, The Netherlands</td>
</tr>
<tr>
<td>G-P-248</td>
<td>Pamela D. Browne, The Netherlands</td>
</tr>
<tr>
<td>G-P-256</td>
<td>Antonio Di Mauro, Italy</td>
</tr>
<tr>
<td>G-P-272</td>
<td>Lok Hin Adrian Lee, Australia</td>
</tr>
<tr>
<td>G-P-277</td>
<td>Cecilia Mantegazza, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 6</th>
<th>Chairs: Vishnu Biradar, India Vaidotas Urbonas, Lithuania</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-P-279</td>
<td>Alex Moretti, Italy</td>
</tr>
<tr>
<td>G-P-294</td>
<td>Erick M. Toro-Monjaraz, Mexico</td>
</tr>
<tr>
<td>G-P-296</td>
<td>Rossella Turco, Italy</td>
</tr>
<tr>
<td>G-P-316</td>
<td>Theresa Greimel, Austria</td>
</tr>
<tr>
<td>G-P-327</td>
<td>Rodrigo Vazquez-Frias, Mexico</td>
</tr>
<tr>
<td>G-P-370</td>
<td>Gili Focht, Israel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 7</th>
<th>Chairs: Marco Deganello Saccomani, Italy Hania Szajewska, Poland</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-P-371</td>
<td>Junko Fujiyama, Japan</td>
</tr>
<tr>
<td>G-P-387</td>
<td>Ben Kang, Republic of Korea</td>
</tr>
<tr>
<td>G-P-405</td>
<td>Mikkel Matham, Denmark</td>
</tr>
<tr>
<td>G-P-410</td>
<td>Gemma Pujol Muncunnill, Spain</td>
</tr>
<tr>
<td>G-P-416</td>
<td>Laura Maria Palomino, Spain</td>
</tr>
<tr>
<td>G-P-438</td>
<td>Dominique Turk, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 8</th>
<th>Chairs: Tsili Zangen, Israel Zuzana Londt, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-P-439</td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>G-P-445</td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>G-P-448</td>
<td>Karen van Hoeve, Belgium</td>
</tr>
<tr>
<td>G-P-471</td>
<td>Bilge Akkelle, Turkey</td>
</tr>
<tr>
<td>G-P-480</td>
<td>Nelgin Gerenli, Turkey</td>
</tr>
<tr>
<td>G-P-487</td>
<td>Kallirroi Kotilea, Belgium</td>
</tr>
<tr>
<td>G-P-489</td>
<td>Cam Tu Nguyen, Belgium</td>
</tr>
</tbody>
</table>

**Gastroenterology 244 – 370**
**Posters selected for Poster Walk**
**ESPGHAN 52nd Annual Meeting**

**Gastroenterology 371 – 489**
**Posters selected for Poster Walk**
**www.espghancongress.org**
Hepatology

Session 9
Chairs: Orith Waisbourd-Zinman, Israel Victorien Wolters, The Netherlands

**H-P-009**
Kishwer Kumar, Saudi Arabia
Long term disease free survival after treating PFIC-2 recurrence with modified protocol of Plasmapheresis, Intravenous Immunoglobulin, Rituximab and immune suppression modification

**H-P-017**
Georg-Friedrich Vogel, Austria
Understanding and salvaging hepatocyte ER-stress in Wolcott-Rallison syndrome associated acute liver failure

**H-P-031**
Kimberley J. Brook, New Zealand
Ultrasound-guided percutaneous liver biopsy is a safe procedure in children: a retrospective review of practice

**H-P-038**
Aurélie Comte, France
Prevalence of autoimmune hepatitis in APECED, a nationwide multicenter descriptive study

**H-P-039**
Eduardo Couchonnal, France
Wilson disease: the French paediatric cohort

**H-P-051**
Angelo Di Giorgio, Italy
Bile ducts involvement in paediatric autoimmune liver disease: a challenging matter

**H-P-063**
Winita Hardikar, Australia
Early onset cholestatic liver disease associated with novel biallelic ERCC1 variants

Session 10
Chairs: Sara Mancell, United Kingdom Daniele Serranti, Italy

**H-P-079**
Aditi Kumar, India
Non invasive prediction of varices in children with portal hypertension: is splenic stiffness by shear wave elastography the answer?

**H-P-081**
Noemie Laverdure, Canada
Liver stiffness measurement by transient elastography, a marker of hepatic venous congestion in children after Fontan procedure

**H-P-101**
Line Modin, United Kingdom
Single center experience with Budd-Chiari syndrome at Birmingham children’s hospital

**H-P-106**
Gema Muñoz Bartolo, Spain
The study of children with a suspicion of Wilson disease

**H-P-112**
Isabel Pinto Pais, Portugal
Application of a NGS MultiGene panel in Biliary Atresia: preliminary results

**H-P-126**
Moinak Sen Sarma, India
Poor outcome of hyponatremia in cirrhotics: correlation with plasma renin activity. Prospective longitudinal study

**H-P-136**
Margarita Maria Suarez Galvis, Spain
Features of biliary lithiasis in a paediatric hepatology department

Nutrition

Session 11
Chairs: Steffen Hartleif, Germany Emanuele Nicastro, Italy

**H-P-141**
Natalia Wasilewska, Poland
Serum concentration of fatty acids in obese children with nonalcoholic fatty liver disease

**H-P-156**
Daniela Liccardo, Italy
Multi-drug resistant germs in pediatric liver transplantation: prevention, treatment strategies and outcomes from a prospective single center study

**H-P-178**
Daniela Liccardo, Italy
Identification of risk factors for late graft fibrosis and application of the liver allograft fibrosis score in pediatric liver transplantation

**H-P-183**
Line Modin, United Kingdom
Renal dysfunction after paediatric intestinal transplantation

**H-P-184**
Line Modin, United Kingdom
Diverse outcome of liver transplantation in children with Niemann-Pick Disease type C cannot be predicted by mutation analysis

**H-P-196**
Sunitha Vimalesvaran, United Kingdom
Allograft histology and biopsychosocial health 10 years after liver transplantation in children

Session 12
Chairs: Jiri Bronsky, Czech Republic Nurul Husna Mohd Shukri, Malaysia

**N-P-005**
Elizabeth Carpenter, New Zealand
Exploring the link between the skin and gut in allergy

**N-P-007**
Federica Giachero, Germany
MicroRNAs in breast milk: a possible vector for species-specific maturation signals

**N-P-013**
Emma M. Savilahti, Finland
Daily lactose intake in children with lactase non-persistent genotype is associated with greater abundance of Bifidobacteria in the gut compared to low-lactose diet or lactase persistence

**N-P-016**
Soheil Varasteh, The Netherlands
Human milk oligosaccharide 3’-galactosylactose can protect the intestinal barrier to challenges

**N-P-019**
Tatiana Bushueva, Russia
The nutritional value of lactose free diets in infants with classical galactosaemia compared with healthy breastfed babies

**N-P-028**
Xiaopan Chang, China
Extensively hydrolysed formula reduces the preoperative nutritional risk in Hirschsprung’s disease
Session 13
Chairs: Tena Niseteo, Croatia
Sissel Moltu, Norway

N-P-064
Alex Moretti, Italy
Test and validation of the Cow’s Milk-related Symptom Score (CoMiSS®) in a population of symptomatic and healthy infants

N-P-065
Sjoerd C. J. Nagelkerke, The Netherlands
Standardized versus individualized parenteral nutrition mixtures in a paediatric home parenteral nutrition population

N-P-080
Ghada Said, United Kingdom
Intestinal failure associated liver disease in patients receiving home parenteral nutrition: experience from a large tertiary Referral Hospital in United Kingdom

N-P-100
Reeta Bora, India
Efficacy of oral sugar in management of neonatal hypoglycaemia in small for date neonates is comparable to intravenous sugar in resource poor setting

N-P-102
Cristina Campoy, Spain
Long-term influence of a milk fat globule membrane (MFGM)-enriched formula on brain structure in healthy children at 6 years old

N-P-117
Jonas Hauser, Switzerland
Availability of 6`SL in pre-weaning milk influences caecal microbiota and plasma molecular phenotype in pre-weaning offspring

Session 14
Chairs: Andrew Barclay, United Kingdom
Delphine Ley, France

N-P-130
Srinivas Murki, India
Enablers for ‘enteral feeding with exclusive mother own milk at hospital discharge’ in preterm very low birth weight infants

N-P-141
Janna A. van Diepen, The Netherlands
Brain lipidome from milk fat globule membrane supplemented rodents parallels changes in plasma lipid patterns

N-P-149
Akshay Batra, United Kingdom
Paediatric e-BANS: establishing a national database of children requiring home parenteral nutrition (HPN) in England

N-P-152
Cristina Campoy, Spain
Effects of maternal gestational diabetes and sustained attention in the offspring at 6 years old

N-P-159
Laura Flannagan, United Kingdom
A retrospective case review of a structured dietetic intervention in infants with hypoplastic left heart syndrome

N-P-168
Victoria Kuryaninova, Russia
Level of vitamin D and proinflammatory cytokines in children born from mothers with carbohydrate metabolism disorders

Session 15
Chairs: Jutta Koeglmeier, United Kingdom
Nathalie Rock, Switzerland

N-P-170
Yoo Min Lee, Republic of Korea
Nutrition day survey on nutritional status of hospitalized children in Korea

N-P-176
Jie Shao, China
Outcome of growth pattern and neurodevelopment in premature infants in one-year old post-discharge

N-P-177
Tali Sinai, Israel
Decline in age at menarche and associations with nutritional status: results from two representative national surveys of Israeli adolescents, 2003 to 2016

N-P-178
Norbert Sprenger, Switzerland
HMO stimulated bifidobacteria contribute to risk reduction for lower respiratory tract illnesses with a 2-HMO containing infant formula through protective effects on mucosal barrier function

N-P-182
Yvan Vandenplas, Belgium
The cow’s milk-related symptoms score (CoMiSS™): a useful tool in the clinical setting – results from an observational study

N-P-186
Bartłomiej Mateusz Zalewski, Poland
No effect of glucomannan on body weight reduction in children with overweight and obesity: a randomized controlled trial
Posters

**Gastroenterology**

**Basic and/or Translational Science**

**G-P-001**
Clara Coppola, Italy
Narrative medicine in gastrointestinal diseases: a brand new approach

**G-P-004**
Mihriban Ö兹soy, Austria
Expression of respiratory chain complexes in the human intestinal epithelium in ageing

**G-P-005**
Alexander Potapov, Russia
Informativeness of immunological parameters in assessing of the efficacy of anti-TNF-α treatment (Infliximab) in children with inflammatory bowel diseases (IBD)

**G-P-006**
Christopher Stewart, United Kingdom
Developing preterm gut ex vivo co-culture models to explore microbiome-host crosstalk in health and disease

**G-P-007**
Bélint Tél, Hungary
Azathioprine and mesalamine impair pancreatic ductal bicarbonate secretion in mice

**G-P-008**
Intan Faizura Yeop, United Kingdom
Intestinal microbiota, its corresponding short chain fatty acids and host immune responses in children with Inflammatory Bowel Disease

**Coeliac Disease**

**G-P-009**
Abdelhak Abkari, Morocco
Early infant feeding practices may influence the onset of symptomatic coeliac disease

**G-P-011**
Souhaila Al-Khodor, Qatar
Characterization of gut microbiota in children with type 1 diabetes and coeliac disease

**G-P-012**
Wesam Al-Masri, Qatar
High prevalence of micronutrient deficiencies in patients with coeliac disease

**G-P-013**
Pegah Amir Yazdani, Canada
A systematic review of disease-specific quality of life questionnaires in children and adults with coeliac disease

**G-P-014**
Daniela Araújo, Portugal
Comparison between the percentage of undiagnosed celiac disease children in ESPGHAN coeliac disease awareness day 2018 manifest and in an European Region

**G-P-016**
Josefa Barrio, Spain
Cross-cultural adaptation to Euskera language of the disease-specific, health related quality of life questionnaire CDDUX for its use in coeliac children from the Basque Country

**Gastroenterology**

**Coeliac Disease**

**G-P-017**
Elif Gokce Basa, Turkey
Evaluation of nutritional characteristics with Mediterranean diet in coeliac patients

**G-P-018**
Efrat Broide, Israel
Revealing the puzzle of adherence in pediatric patients with coeliac disease

**G-P-019**
Andres Bodas-Pinedo, Spain
Differences in the geographical distribution of genotypes at risk in pediatric patients with coeliac disease (CD) in Spain

**G-P-020**
Filipa Briosa, Portugal
Oedemas in a teenager: an atypical coeliac disease and/or primary intestinal lymphangiectasia?

**G-P-021**
Tracey Cardigan, United Kingdom
Outcomes of high dose of vitamin D in children with vitamin D deficiency and coeliac disease

**G-P-022**
Gemma Castillejo, Spain
Prospective longitudinal study: use of fecal gluten immunogenic peptides to monitor children diagnosed with celiac disease during transition to a gluten-free diet

**G-P-024**
Mehmet Enes Coskun, Turkey
Performance of the proposed ESPGHAN score based diagnostic approach and possible contribution of bone mineral density value

**G-P-025**
Luigina De Leo, Italy
Prospective study on celiac disease prevalence in children with severe food allergy

**G-P-026**
Ádám Diós, Hungary
Investigation of binding properties and kinetics of antibodies against deamidated gliadin peptides from coeliac and non-coeliac subjects

**G-P-027**
Esther Donat, Spain
Screening detected positive serology for Celiac Disease: a real clinical challenge

**G-P-028**
Hazel Duncan, United Kingdom
Review following an introduction of You Tube videos to provide education for newly diagnosed patients with Coeliac Disease

**G-P-031**
Nabil El-Lababidi, Czech Republic
Effect of gluten-free diet on growth and anti-tissue transglutaminase antibody levels in newly diagnosed coeliac children using the biopsy and non-biopsy pathways

**G-P-032**
Jade Fokkens, The Netherlands
Short stature in coeliac disease: a tall problem

**G-P-033**
Elisa Franceschini, Italy
Screening of celiac disease: adherence to the ESPGHAN guidelines

**G-P-034**
Caterina Grosso, Italy
Yield and costs of point-of-care screening test versus case finding to diagnose pediatric coeliac disease

**G-P-035**
Alejandro Guzman, Argentina
Epidemiological and genetic aspects in 20 patients with Type 1 Diabetes and Celiac Disease
G-P-037
Anat Guz Mark, Israel
High rates of testing for coeliac disease serology, and low rates of endoscopy in children and adults. Lessons from a large real-world database

G-P-038
Omer Haber, Israel
Hypertransaminasemia in newly diagnosed paediatric patients with coeliac disease in Israel

G-P-039
Şamil Hatl, Turkey
Determination of duration and frequency of medical follow up, dietary compliance rates and assessment of the quality of life in celiac patients between 8-18 years of age in Ankara

G-P-040
Donatella Iorfida, Italy
Neurotensin: any clue in paediatric coeliac disease?

G-P-041
Muhammad Rehan Khan, USA
The utility of Iga based serologic markers in diagnosing celiac disease in children ≤ 24 months of age

G-P-042
Laura Kivelä, Finland
Coexisting type 1 diabetes and experiences of gluten-free diet are associated with long-term dietary adherence in paediatric coeliac disease

G-P-043
Vinod Kolimarala, United Kingdom
Outcomes of children with borderline tTG in Hampshire

G-P-045
Maciej Kołodziej, Poland
Association between early life (prenatal and postnatal) antibiotic administration and celiac disease. A systematic review

G-P-046
Marina Stoyan, Russia
Level of vitamins D, parathormone, bone tissue metabolites in children with coeliac disease and bone fractures

G-P-047
Sadhna Lal, India
Spectrum of coeliac disease in children at a tertiary care centre in the coeliac belt of India

G-P-049
Rohan Malik, India
Validation of an indigenous point-of-care test for celiac disease among children and adults in a tertiary hospital in North India

G-P-050
Roberta Mandile, Italy
Quantitative histology of small intestinal mucosa: validation of morphometrical parameters in control, non-celiac children

G-P-051
Maria Angeles Martinez Ibeas, Spain
Faecal calprotectin concentration in paediatric coeliac disease: correlation with clinical, serological and histopathological findings

G-P-052
Nazareth Martinon-Torres, Spain
Quantify the risk of overnutrition: nutritional status in coeliac disease at diagnosis and after a five year follow-up in a tertiary hospital

G-P-054
Lucy McDermott, United Kingdom
A dietetic-led coeliac clinic patient service review in a tertiary paediatric centre

G-P-055
Cong Minh Tam Nguyen, Canada
Validation of the ESPGHAN guidelines for the diagnosis of coeliac disease in a Canadian population

G-P-056
Hadas Paz, Israel
Does short segment coeliac disease confined to the duodenal bulb have a unique clinical, serological or histological profile?

G-P-057
Olivia Portolese, Canada
Trends in the clinical presentation of celiac disease at diagnosis in children in Quebec

G-P-058
Luigina De Leo, Italy
Detection of anti-TG2 deposits in the myocardial tissue of a child affected by dilated cardiomyopathy associated to celiac disease

G-P-059
Petra Rižnik, Slovenia
The impact of clinical presentation of celiac disease on diagnostic delays in children in Central-Europe

G-P-060
Yasin Sahin, Turkey
The frequency of coeliac disease in siblings of coeliac patients

G-P-061
Yasin Sahin, Turkey
The frequency of coeliac disease in children with chronic constipation

G-P-062
Ilgiz Sahin, Turkey
Prevalence of celiac disease diagnosed by screening in children with type 1 diabetes: is it different?

G-P-063
Maria Camila Sanchez, Argentina
Impact of associated diseases on quality of life of children with coeliac disease: a multicenter study in Argentina

G-P-064
Bilge Sahin Akkelle, Turkey
Detection of anti-TG2 deposits in the myocardial tissue of a child affected by dilated cardiomyopathy associated to celiac disease

G-P-065
Olivia Portolese, Canada
Trends in the clinical presentation of celiac disease at diagnosis in children in Quebec

G-P-066
Caterina Strisciuglio, Italy
Celiac patients with low adherence to gluten free diet can have negative serology, but their nutritional status is impaired

G-P-067
Sadhna Lal, India
Coeliac disease in children with selective immunoglobulin A deficiency: do we know how to diagnose?

G-P-068
Chiara Maria Trovato, Italy
Utility of serology in the follow-up of coeliac children with selective immunoglobulin A deficiency
Gastroenterology 078 – 098

G-P-078
Anil Verma, Italy
Distribution of HLA-DQ2 and HLA-DQ8 alleles in native South Indian population

G-P-079
Radim Vyhnánek, Czech Republic
Adherence to the gluten-Free diet of children with coeliac disease assessed by measuring gluten-related immunogenic peptides: pilot study

G-P-080
Mozhgan Zahmatkeshan, Iran
Prevalence of coeliac disease in infertile women

Gastroenterology 099 – 102

G-P-081
Victor Aguiriano-Moser, Austria
Correlations between bile acid values and biomarkers of coagulation and inflammation in cystic fibrosis liver disease

G-P-082
Susana Almeida, Portugal
Hereditary pancreatitis in children: three different mutations

G-P-083
Omer Faruk Beser, Turkey
Evaluation and follow-up of nutritional status in children with cystic fibrosis

G-P-084
Liron Birimberg-Schwartz, Canada
Management of acute pancreatitis in children: a single center experience

G-P-085
Constanza Beatriz Camargo Santacruz, Colombia
The challenge of diagnosing cystic fibrosis in a Colombian hospital

G-P-087
Marta García Quijada, Spain
Study of hepatic fibrosis in children with liver disease associated with cystic fibrosis using a non-invasive technique: quantitative elastography type ARFI

G-P-088
Panagiota Kafritsa, Greece
Simultaneous resolution of two pancreatic pseudocysts by endoscopic cyst gastrostomy in hereditary pancreatitis

G-P-089
Adnaan Kala, United Kingdom
PRSS1 pancreatitis presenting as pleural effusion with mediastinal shift

G-P-090
Sadhna Lal, India
Paediatric acute pancreatitis: clinical profile and natural history of collections

G-P-092
Julie Lemale, France
Acute pancreatitis secondary to hypertriglyceridaemia in children: a rare cause to discuss

G-P-093
Rohan Malik, India
Autoimmune pancreatitis presenting as a pancreatic head mass in a 5 year old boy

G-P-094
Thi Viet Ha Nguyen, Vietnam
Evaluation of treatment efficacy for acute pancreatitis in children at the national children’s hospital, Vietnam

G-P-095
Jan Krzysztof Nowak, Poland
Serum myoglobin is elevated in cystic fibrosis: a cross-sectional study

G-P-098
Grzegorz Oracz, Poland
Chronic pancreatitis associated with toxic-metabolic risk factors in large pediatric cohort

ENDOSCOPY

G-P-102
Sinan Sari, Turkey
Pancreatitis in Turkish children: A single center experience

G-P-103
Venkatesh Vybhav, India
Spectrum of paediatric pancreatitis in a tertiary care centre of North India

G-P-104
Sabina Wiecek, Poland
Evaluation of the selected parameters of liver fibrosis and inflammation in patients with cystic fibrosis

G-P-105
Ulas Emre Akbulut, Turkey
A comparison of sedation with midazolam-ketamine versus propofol-fentanyl during colonoscopy in children

G-P-106
Patcharin Amornvipas, Thailand
Endoscopic balloon dilatation in a child with pyloric stenosis post corrosive agent

G-P-108
Tal Berger, Israel
The yield of upper gastrointestinal endoscopy in a paediatric tertiary care center

G-P-109
Ilse Broekaert, Germany
Arginine-induced esophagitis in children: a preliminary experience

G-P-110
Estefanía Carrión-Jaramillo, Ecuador
Endoscopic balloon dilatation for treatment of congenital antral web

G-P-111
Busara Charoenwat, Thailand
Cap-assisted colonoscopy in pediatric population

G-P-112
Marco Deganello Saccomani, Italy
Endoscopic management of esophageal stenosis in patients with congenital esophageal atresia: the experience of our center

G-P-113
Christopher Eke, South Africa
Medical gastrointestinal endoscopy in children: experience in red cross war memorial children’s hospital

G-P-114
Simona Faraci, Italy
Safety and feasibility of endoscopic management of anastomotic biliary stricture after ortho-topic liver transplant in children: a preliminary experience

G-P-115
Sergio Fernández, Mexico
Arginine-induced esophagitis in children and adolescents: A case series

G-P-116
Douglas S. Fishman, USA
Early presentation in Peutz-Jeghers Syndrome: a single-center study

G-P-117
Jan Stanisław Bukowski, Poland
Endoscopic stenting of grade III pancreatic pseudocysts by endoscopic cyst gastrostomy

G-P-118
Estefanía Carrión-Jaramillo, Ecuador
Endoscopic balloon dilatation for treatment of congenital antral web

G-P-119
Marco Deganello Saccomani, Italy
Endoscopic management of esophageal stenosis in patients with congenital esophageal atresia: the experience of our center

G-P-120
Ayesha Girach, United Kingdom
The current status of paediatric endoscopy in Italy: a national survey

G-P-123
Prevost Jantchou, Canada
Worldwide survey of current digestive endoscopy practice in children
Eosinophilic Esophagitis

G-P-168
Sita Tarini Clark, New Zealand
Eosinophilic esophagitis - audit of practice since establishment of combined gastroenterology/immunology paediatric clinic and introduction of a new joint management protocol

G-P-169
Odul Egritas Gurkan, Turkey
Eosinophilic esophagitis might be the first finding of eosinophilic gastrointestinal system disorders

G-P-170
Buket Dalgic, Turkey
The characteristics of Turkish children with eosinophilic esophagitis

G-P-172
Diana Marcela Montoya Villa, Spain
Oral salbutamol therapy for food impaction in patients with Eosinophilic Esophagitis - An alternative to endoscopy?

G-P-174
Amin J Roberts, New Zealand
Eosinophilic Oesophagitis in New Zealand: 3-year prospective study

G-P-175
James Taylor, United Kingdom
Adherence to biopsy guidelines in children diagnosed with eosinophilic oesophagitis

G-P-176
James Taylor, United Kingdom
Incidence of eosinophilic oesophagitis in a UK paediatric population over a 10-year period

G-P-177
James Taylor, United Kingdom
Eosinophilic oesophagitis frequency in children undergoing upper gastrointestinal endoscopy

G-P-178
Meltem Ugras, Turkey
Eosinophilic esophagitis and H pylori in children

Gastroenterology Other

G-P-180
Shokoufeh Ahmadipour, Iran
Prognosis and treatment of allergic proctocolitis in infants; according feeding

G-P-181
Inês Aires Martins, Portugal
Infantile colic: episodic syndrome that may be associated with migraine?

G-P-182
Ahmed Al-Salem, Saudi Arabia
Congenital pyloric atresia: the spectrum

G-P-183
Alfiia Aminova, Russia
Factor analysis in pediatric gastroenterology

G-P-184
Mirno Natalija Anicic, Croatia
Protein losing enteropathy-extremely rare presentation of Langerhans cell histiocytosis

G-P-185
Katerina Bajerova, Czech Republic
Cow’s milk-related symptoms scoring – values in healthy breastfed infants under 6 months of age

G-P-186
Hany Banoub, United Kingdom
Evaluation and treatment of gastrointestinal and nutritional complications in children with neurological impairment, a U.K. district general hospital model for improvement

G-P-187
Claudia Banzato, Italy
Food Protein Enterocolitis syndrome: single tertiary care centre experience

G-P-188
Catarina Barroso, Portugal
Gastroenterological audit of the program of thoracoscopic repair of esophageal atresia by the ESPGHAN references

G-P-189
Amir Ben Tov, Israel
Adoption of paediatric gastroenterology societal guidelines regarding coeliac disease and helicobacter pylori infection among general paediatricians

G-P-190
Maya Beazawada, United Kingdom
Autism spectrum disorder and the gut microbiota in children: a systematic review

G-P-191
Carolin Sigrid Blueml, Germany
Collagenous gastritis and colitis – a rare clinical entity in children

G-P-192
Christopher J. Burgess, United Kingdom
Infantile colic: episodic syndrome that may be associated with migraine?

G-P-193
Tomislav Caleta, Croatia
Short-term outcome of patients with gastroschisis treated at the Clinical Hospital Center in Zagreb – a ten-year review

G-P-194
Sanchari Chakravarty, India
Impact of acidemia at birth on gut circulation in term neonates

G-P-195
Jeng Haw Cheng, United Kingdom
Experience of gastro-jejunal tube placement in children intolerant to gastrostomy feeding

G-P-196
Silvana Dodan, Colombia
10 years’ experience in multidisciplinary management of patients with food allergies and its impact on the nutritional status in an outpatient medical center of paediatric gastroenterology, hepatology and nutrition (gastronutripe) of Colombia

G-P-197
Svetlana Denisova, Russia
Biochemical markers of the functional condition of neonatal gut microbiome

G-P-199
Valentina Discepolo, USA
Training in paediatric gastroenterology: a survey among Italian trainees

G-P-200
Elizabeth Griffiths, United Kingdom
Lysozyme activity of gut microbiota in children aged 1-3 years: analysis of intestinal mucosal integrity and nutrition absorption

G-P-203
Jooyoung Jang, Republic of Korea
IgE patterns to common food allergens in younger infants with allergic proctocolitis

G-P-204
Mizu Jiang, China
Analysis of risk factors and development of scoring system to predict severity of upper gastrointestinal bleeding in children

G-P-205
Muzal Kadim, Indonesia
Benefits of zinc, glutamine, fiber and probiotics supplementation formula on the growth and morbidity of children 1-3 years: analysis of intestinal mucosal integrity and nutrition absorption

G-P-207
Rosaura Leis, Spain
Diagnosis of lactose malabsorption by exhaled hydrogen test and polymorphism haplotypes C/T-13910

G-P-208
Rosaura Leis, Spain
Study of C/T-13910 polymorphism haplotypes in patients with suspected lactose intolerance. Can the genetic study be the gold standard for its diagnosis?
G-P-209  
Maria Janelle Liwanag, Singapore  
Cost analysis and healthcare resource utilization in home parenteral nutrition for paediatric chronic intestinal failure: data from the early experience of a single-centre intestinal rehabilitation program in Southeast Asia

G-P-211  
Alex Moretti, Italy  
Gastrointestinal symptoms after antibiotic treatment: risk and protective factors in children

G-P-214  
Suchandra Pande, United Kingdom  
Drainage of a complex pancreatic pseudocyst with an endoscopic ultrasound-guided metal stent

G-P-215  
Laura Paradiso, Italy  
Utility of sIgE in the diagnostic work-up of cow’s milk allergy in a tertiary referral centre

G-P-217  
Pierre Poinrat, Canada  
Acute paediatric hypertrophic disease or a benign type of Menetrier disease

G-P-218  
Esra Polat, Turkey  
Heterotopic gastric mucosa in adolescent girls

G-P-219  
Celeste Lidia Raguseo, Italy  
Evaluation of the intestinal microbiota of pediatric patients in therapy with proton pump inhibitor

G-P-220  
Erica Rezende, Brazil  
Caucal ingestion in childhood: still a problem in countries in development

G-P-221  
Elif Sag, Turkey  
Ileocolonic lymhonodular hyperpilasia in children

G-P-222  
Vilma Alexandra Salvador Medina, Ecuador  
Prevalence of eosinophilic digestive diseases in Hospital de Niños Dr. Roberto Gilbert in Guayaquil-Ecuador

G-P-223  
Moinak Sen Sarma, India  
Gastrointestinal polyps and polyposis syndromes in children

G-P-224  
Mubashir Hassan Shah, India  
Superior mesenteric artery Doppler on first day of life in very low birth weight neonates and prediction of necrotizing enterocolitis; a prospective blinded cohort study

G-P-225  
Polittiya Sintusek, Thailand  
Intussusception in children: the value of combined clinical presentation and abdominal x-ray

G-P-226  
Jose Carlos Salazar-Quero, Spain  
Importance of speech and language therapist in the treatment of oro-pharyngeal dysphagia

G-P-227  
Andrea Vasconez, Ecuador  
Food protein induced enterocolitis syndrome to quinoa – a usually safe food

G-P-229  
Raquel Vecino López, Spain  
Prognostic value of the serial determination of plasma citrulline during the intestinal rehabilitation process in children with intestinal failure due to short intestinal syndrome

G-P-233  
Ting Zhang, China  
Safety of fecal microbiota transplantation in Chinese single-center children: a retrospective analysis

G-P-235  
Bhawati Acharya, India  
Should all children with functional oesophagastroduodenal symptoms be evaluated for small intestinal bacterial overgrowth?

G-P-236  
Majid Aflatoonian, Iran  
Sleep disorder in children with functional abdominal pain

G-P-237  
Annalisa Alessandrella, Italy  
High resolution anorectal manometry in children with functional constipation with or without fecal incontinence

G-P-239  
Mirna Natalija Anicic, Croatia  
Functional gastrointestinal disorders in children with achalasia

G-P-240  
Sun Hwan Bae, Republic of Korea  
Pelvic floor dysfunction in chronic constipated children

G-P-241  
Simona Faraci, Italy  
Utility of a modified dysphagia score in the diagnosis and the management of children with achalasia

G-P-242  
Marcin Banasiuk, Poland  
3D high resolution manometry and balloon expulsion test in diagnosis of dyssynergic defecation in children

G-P-243  
Anna M. Banc-Husu, USA  
High-resolution oesophageal manometry to diagnosis achalasia in infants: a case series

G-P-247  
Omer Faruk Beser, Turkey  
Prevalence and clinical characteristics of functional gastrointestinal disorders in infants

G-P-249  
Florence Campeotto, France  
Prevalence and management of functional gastrointestinal disorders in French infants – the Rome study in France

G-P-251  
Isabel Casas Gallegos, Spain  
Breath test in children with gastrointestinal diseases in primary care

G-P-253  
Silvana Dadan, Colombia  
Improvement of digestive symptoms with a partially hydrolyzed serum, reduced lactose and Lactobacillus reuteri DSM 17938 – based functional infant formula in infants younger than 5 months old with infantile colic, in outpatient pediatric centers of Bogota, Colombia

G-P-254  
Lissa De la Vega Morales, Mexico  
A novel mutation TYMP gene causes mitochondrial neurogastrointestinal encephalopathy syndrome

G-P-258  
Tanja Fritz, Germany  
Assessment of whole gut motility in children using the wireless motility capsule test
G-P-260
Tut Galai, Israel
Children with functional abdominal pain disorders have higher prevalence of obesity

G-P-261
Frédéric Gattrand, France
First year risk factors of mortality and morbidity in esophageal atresia with tracheo-esophageal fistula: data from a population-based national register

G-P-262
Azin Gouran, Iran
Evaluation of the effects of lactobacillus reuteri on children with recurrent abdominal pain (RAP)

G-P-263
Rafael Guerrero-Lozano, Colombia
Water load test in school children with functional gastrointestinal disorders

G-P-264
Johann Hammer, Austria
Development and validation of a test-specific perception questionnaire for the assessment of carbohydrate induced gastrointestinal symptoms during breath tests: the paediatric carboception questionnaire (PCCQ)

G-P-265
Noora Helin, Finland
The role of upper endoscopy in small children with undiagnosed gastrointestinal or respiratory symptoms

G-P-266
Michelle Higuera, Colombia
Alleviation of symptoms of uncomplicated gastroesophageal reflux in infants under 12 months old with a functional infant formula based in partially hydrolyzed serum protein thickened with potato starch and with added Lactobacillus reuteri DSM 17938, in outpatient paediatric centers of Colombia

G-P-267
Karen Ignorosa Arellano, Mexico
Main causes of dyspepsia in mexican children and adolescents from a tertiary hospital

G-P-268
Mikki Ives, United Kingdom
Multidisciplinary assessment of paediatric chronic refractory constipation

G-P-269
Hyo-Heung Jang, Republic of Korea
National survey of management for functional constipation in Korean children

G-P-270
Muzal Kadim, Indonesia
Factors affecting recurrent abdominal pain in junior high school students in South Jakarta

G-P-271
Charlotte Knatten, Norway
Outcome after Roux-En-Y used for antireflux and jejunal feeding purposes

G-P-273
Anna Liber, Poland
Double-blind placebo-controlled trial of omeprazole in children with cystic fibrosis and gastroesophageal reflux disease

G-P-274
Lina Lu, China
Mutations of ACTG2 in 16 Chinese children with intestinal pseudo-obstruction

G-P-275
Thomas Ludwig, Singapore
Quantification of infant crying and fussing by parental electronic diaries versus automated machine based learning: an in-home observational study

G-P-276
Thomas Ludwig, Singapore
Observational study shows high degree of inter-observer agreement for the Brussels Infant and toddler stool scale for non-toilet trained children

G-P-280
Kornilia Nikaki, United Kingdom
Distal oesophageal mucosa innervation in children: preliminary report

G-P-281
Kornilia Nikaki, United Kingdom
Rumination syndrome in children: a distinct diagnostic pattern during ambulatory reflux monitoring with impedance pH-metry

G-P-282
Alicia Isabel Pascual Pérez, Spain
Paediatric Intestinal Pseudo-obstruction: The experience of a national reference hospital

G-P-283
Ujjal Poddar, India
Solitary Rectal Ulcer Syndrome (SRUS) in children: is it really uncommon?

G-P-284
Rebecca Poole, United Kingdom
The role of fundoplication in ameliorating the need for transpyloric feeding in children with gastroesophageal reflux disease and complex enteral nutritional needs: a single centre experience

G-P-285
Paolo Quitadamo, Italy
Influence of body positioning on gastroesophageal reflux in pediatric age

G-P-287
Robyn Rexwinkel, The Netherlands
Diagnostic value of inflammatory parameters in the work-up of functional abdominal pain

G-P-288
Maddalena Riva, Italy
Abdominal migraine: epidemiology, clinical features, response to therapy and evolution in 44 children

G-P-289
Eylem Sevinc, Turkey
The association of gastroesophageal reflux and chest pain in children with mitral valve prolapse

G-P-290
Adam Smith, United Kingdom
A meta-analysis to evaluate the effect of feed thickeners and alginate-based products in infants with gastro-esophageal reflux

G-P-292
Erin Cathrina Tayag-Lacsina, Philippines
The effectiveness of a constipation pamphlet in improving outcomes among paediatric patients with functional constipation: a single blinded randomised controlled trial

G-P-293
Erick M. Toro-Monjaraz, Mexico
Safety of sucralfate suspension in children aged 1 to 13 years with esophagitis and erosive gastropathy

G-P-295
Marinde van Lennep, The Netherlands
The Eckardt score in paediatric achalasia patients: is assessing weight loss in the developing child of added value?

G-P-298
Joanneke van Summeren, The Netherlands
Physiotherapy for children with functional constipation: a pragmatic randomized controlled trial in primary care

G-P-299
Joanneke van Summeren, The Netherlands
Cost-effectiveness of physiotherapy in childhood functional constipation: a pragmatic randomized controlled trial in primary care
G-P-300
Yvan Vandenplas, Belgium
Safe use of fibers in infant anti-regurgitation formulas: compiled analysis of 4 clinical trials

G-P-301
Jan Vanderhoof, USA
The value of breath test in the diagnosis of fructose malabsorption as a cause of recurrent abdominal pain in children

G-P-302
Ilaria Venezia, Italy
Psycho-gastroenterological profile in paediatric outpatients affected by disorders of gut-brain interaction

G-P-303
Raluca Maria Vlad, Romania
Functional gastrointestinal disorders, up to date topic. Applying Rome iv criteria to a Romanian cohort of young children

G-P-304
Mana H. Vriesman, The Netherlands
Health related quality of life in childhood constipation: a systematic review and meta-analysis

G-P-305
Mana H. Vriesman, The Netherlands
Prevalence of child abuse in children with functional constipation

G-P-306
Dae Yong Yi, Republic of Korea
The effects of proton pump inhibitor therapy on small bowel bacterial overgrowth development in children as assessed by fecal calprotectin

G-P-307
Marc Benninga, The Netherlands
Functional gastrointestinal disorders and behavioral problems in adolescents with a history of infant colic

G-P-308
Adel Al Shahrani, Saudi Arabia
Infiltrating, quasi-cancerous rectal lesions: unique manifestation of visceral basidiobolus ranarum

G-P-311
Maria Victoria Bovo, Spain
Role of Dientamoeba fragilis in gastrointestinal symptoms in paediatric patients: a case – control study

G-P-312
Fabiola Di Dato, Italy
Diarrhea in children with Plasmodium falciparum malaria: preliminary data of a case-control study

G-P-313
Anna Falszewska, Poland
Accuracy of laboratory parameters in identifying dehydration in children with acute gastroenteritis: a systematic review

G-P-314
George Fowler, United Kingdom
Intestinal Spirochaetosis: an infectious colitis with normal calprotectin

G-P-315
Steven Frese, USA
Gut barrier function is improved in infants colonized by Bifidobacterium longum subsp. infantis EVC001

G-P-317
Alfredo Guarino, Italy
Medical attitudes toward probiotics and antibiotics co-prescription in children living in Asian pacific region

G-P-318
Cristina Oana Marginean, Romania
The role of TLR4 rs4986790 gene polymorphism in determining Helicobacter pylori gastritis in children

G-P-319
Smaragdi Fessatou, Greece
Faecal biomarkers in paediatric gastroenteritis versus inflammatory bowel disease

G-P-320
Sara Elisa Ortega-Alonzo, Mexico
Lactose restriction and dietary modification for the management of acute diarrhea, a single-blinded study

G-P-321
Carlos Ivan Oyervides-Garcia, Mexico
Lactose-free milk formula usefulness supplemented added with pectin and S. boulardii in children’s with not complicated acute gastroenteritis (LFPS)

G-P-322
Marcos Perez, Philippines
Coddle study: bacillus clausii as an adjunctive treatment of acute community-acquired diarrhea in Filipino children

G-P-323
Marcos Perez, Philippines
The probiotic bacillus clausii in the prevention of antibiotic-associated diarrhea in children: a pooled analysis of controlled clinical trials

G-P-325
Kinga Cristina Slavescu, Romania
How big is the gap between guidelines and clinical practice in antimicrobial therapy? – How frequent is acute pancreatitis due to rotavirus gastroenteritis in children?

G-P-326
Burcu Volkan, Turkey
How frequent is acute pancreatitis due to rotavirus gastroenteritis in children?

G-P-327
Yuhuan Wang, China
Cytomegalovirus colitis with intractable diarrhea in immunocompetent infants from a tertiary care center in China

G-P-328
Alvaro Vega, Chile
Diagnostic performance of two oesophageal tissue sampling techniques for etiological study of infectious esophagitis in children with cancer

G-P-329
Oluwafumilayo Adeniyi, Nigeria
Inflammatory bowel disease in African children: experience and challenges in a tertiary centre in Nigeria

G-P-330
David Devadaso, United Kingdom
Performance of unrestricted faecal calprotectin in paediatric inflammatory bowel disease

G-P-331
Sara Elisa Ortega-Alonzo, Mexico
Lactose-free milk formula usefulness supplemented added with pectin and S. boulardii in children’s with not complicated acute gastroenteritis (LFPS)

G-P-332
Marcos Perez, Philippines
Coddle study: bacillus clausii as an adjunctive treatment of acute community-acquired diarrhea in Filipino children

G-P-333
Oluwafumilayo Adeniyi, Nigeria
Inflammatory bowel disease in African children: experience and challenges in a tertiary centre in Nigeria

G-P-334
David Devadaso, United Kingdom
Performance of unrestricted faecal calprotectin in paediatric inflammatory bowel disease

G-P-335
Marina Aloi, Italy
Clinical outcomes of 2012 ECCO/ESPGHAN guidelines in a large cohort of children with ulcerative colitis

G-P-336
Marina Aloi, Italy
Quality of life and disease activity in children and adolescents with inflammatory bowel disease

G-P-337
Patrizia Alvisi, Italy
Abdominal surgery in pediatric Crohn disease: a real life experience of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition

G-P-338
Gayane Amaryan, Armenia
The frequency of MEFV gene mutations and familial mediterranean fever in Armenian children with inflammatory bowel disease
**G-P-340**
**Amit Assa, Israel**
Nutritional deficiencies in children with inflammatory bowel diseases

**G-P-341**
**Hemant Bhavsar, United Kingdom**
Exclusive enteral nutrition uptake rates in treatment naive Crohn’s disease patient

**G-P-342**
**Kriszta Katinka Boros, Hungary**
Characteristics and follow up on body composition, physical activity and quality of life in paediatric patients with inflammatory bowel disease

**G-P-346**
**Jeng Haw Cheng, United Kingdom**
Incidence and outcome of surgical intervention in our paediatric crohn’s patients over 5 years

**G-P-347**
**Jeng Haw Cheng, United Kingdom**
A home infusion programme for Infliximab (RemiCare) in paediatric Crohn’s patients is feasible, safe and cost-saving

**G-P-348**
**Jie Chien, China**
Lower efficacy and safety of infliximab therapy in very early onset Crohn’s disease

**G-P-349**
**Mu-Ming Chien, Taiwan**
The characteristics of ulcerative colitis of paediatric primary sclerosing cholangitis: a single-centre study in Asia

**G-P-350**
**Lucia Cococcioni, United Kingdom**
Safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)

**G-P-351**
**Lucia Cococcioni, United Kingdom**
Experience with therapeutic Drug Monitoring (TDM) on Infliximab (IFX) in Paediatric Inflammatory Bowel Disease (pIBD)

**G-P-352**
**Daniela Knafelz, Italy**
Observational study on transition care for young adults with inflammatory bowel disease: results and perspectives

**G-P-355**
**Chiara De Carlo, Italy**
The role of anxiety, depression and catastrophizing in quality of life of children with inflammatory bowel disease: a prospective multi-centre study

**G-P-357**
**Nazi Deveci, Turkey**
Anti-inflammatory and anti-oxidant effects of thiamine in dextran sulfate-induced colitis in rats

**G-P-359**
**Anna Dilillo, Italy**
A new therapeutic approach: top down vs step up in paediatric Crohn’s disease

**G-P-360**
**Theonymfi Doudouliaki, United Kingdom**
Experience and outcomes in Paediatric Inflammatory Bowel Disease (pIBD) on Vedolizumab with Biomarker and Therapeutic Drug Monitoring (TDM)

**G-P-361**
**Hazel Duncan, United Kingdom**
Quality of life improvement following completion of induction remission Crohn’s disease via exclusive enteral nutrition

**G-P-362**
**Mohammad El Mouzan, Saudi Arabia**
Diagnostic delay of paediatric inflammatory bowel disease in Saudi Arabia: a multicenter national study

**G-P-363**
**Johanna Escher, The Netherlands**
Health care transition outcomes in inflammatory bowel disease: an international Delphi study

**G-P-364**
**Johanna Escher, The Netherlands**
Effect of cognitive behavioural therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomised trial

**G-P-365**
**Sylwia Fabiszewska, Poland**
Vedolizumab induction therapy after failure of TNF-alfa antagonists in children

**G-P-366**
**Sergio Fernández Ortiz, Mexico**
Nailfold videoAapillaroscopy in juvenile Inflammatory bowel disease pilot Study. NAILS pilot study

**G-P-367**
**Smaragdi Fessatou, Greece**
Faecal biomarkers in the diagnosis and follow-up of children with inflammatory bowel disease

**G-P-368**
**Aleksandra Filimoniuk, Poland**
Lactosylceramide as a non-invasive marker in diagnosis of ulcerative colitis in children – preliminary study

**G-P-369**
**Maria Teresa Fioretti, Italy**
Predictors of outcome in children with Crohn’s Disease

**G-P-372**
**Maria Julia Gallo, Argentina**
Inflammatory bowel disease in three pediatric centers in Latin America: outcome of patients with early onset disease

**G-P-374**
**Ersin Gumus, Turkey**
Children with very early-onset inflammatory bowel disease: a tertiary centre experience

**G-P-376**
**Rumneek Hampal, United Kingdom**
Clinical outcomes in a prospective cohort of children with Crohn’s disease (CD) commenced on anti-TNF therapy – A single tertiary centre experience

**G-P-378**
**Maryam Haneef, United Kingdom**
Surgical management of paediatric inflammatory bowel disease in the era of biological therapy - a single centre experience

**G-P-380**
**Rachel Harris, United Kingdom**
Utilising a steroid sparing tool in >200 paediatric IBD patients demonstrates low rates of steroid dependency compared to adult practice

**G-P-381**
**Zuzana Havičeková, Slovakia**
Urinary concentration of 8-isoprostane as marker of severity of paediatric inflammatory bowel disease

**G-P-382**
**James Guoxian Huang, Singapore**
Clinical differences at diagnosis between South East Asian (SEA) children with very early onset (VEO) inflammatory bowel disease (IBD) and non-VEO IBD

**G-P-383**
**Takashi Ishige, Japan**
Use and efficacy of enteral nutrition as maintenance therapy for paediatric Crohn’s disease: analysis of a Japanese nationwide registry

**G-P-385**
**Martyna Jasielska, Poland**
Lactose intolerance in children with inflammatory bowel disease

**G-P-386**
**Adnaan Kala, United Kingdom**
Use of Vedolizumab in paediatric IBD: experience in royal Manchester childrens hospital
G-P-389
Hyun Jin Kim, Republic of Korea
Clinical characteristics of pediatric Crohn’s disease patients with perianal fistula: a single-center experience

G-P-390
Mijn Kim, Republic of Korea
Top-down strategy is superior to step-up strategy in deep remission in pediatric ulcerative colitis patients

G-P-391
Aelita Kalitkova, Russia
Evaluation of nutritional status and body composition in children with inflammatory intestinal disease

G-P-392
Zoltan Kiss, Hungary
Characteristics of the microbiome under biological therapy in pediatric patients with inflammatory bowel disease

G-P-393
Daniela Knafelz, Italy
Chronic non-bacterial osteomyelitis and SAPHO as extraintestinal manifestation of paediatric inflammatory bowel disease (IBD), results from a national survey of the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP) IBD Group

G-P-394
Michał Kolejwa, Poland
The life quality assessment in IBD children in regards the treatment method

G-P-395
Marta Kotkowicz-Szczur, Poland
The influence of children’s inflammatory bowel disease (IBD) on the relationship between parents and their married life

G-P-396
Kinga Kowalska-Duplaga, Poland
Dependence of colonization of the large intestine by Candida on the treatment of Crohn’s disease

G-P-397
Paulina Krawiec, Poland
Clinical utility of hepcidin in diagnosis of iron deficiency anaemia in children with inflammatory bowel disease

G-P-398
Paulina Krawiec, Poland
Zonulin in children with newly diagnosed inflammatory bowel disease – a pilot study

G-P-399
Milena Krzyżanowska, Poland
Clostridium difficile in newly diagnosed children with inflammatory bowel disease: carriage or infection

G-P-400
Sung Hee Lee, Republic of Korea
Reclassification of Korean pediatric onset inflammatory bowel disease using the revised Porto criteria: a single-center experience

G-P-402
Batia Weiss, Israel
Longitudinal follow up of bone density and anthropometry of children with inflammatory bowel diseases

G-P-403
Joana Lima, Portugal
Vitamin d deficiency and its association with clinical outcomes in children, adolescents and young adults with inflammatory bowel disease

G-P-404
Svetlana Makarova, Russia
The use of allergy-focused history questionnaire allows to suspect cow’s milk allergy in children with inflammatory bowel diseases

G-P-406
Massimo Martinelli, Italy
Post-induction Infliximab trough levels in severe and moderate pediatric Ulcerative Colitis: preliminary data of a retrospective, population cohort-based study

G-P-407
Monika Meglicka, Poland
Safety and efficacy of Budesonide MMX in children with ulcerative colitis

G-P-408
Annette Mulchay, United Kingdom
Gamma Interferon based latent Tuberculosis testing prior to commencing biologic treatment in children with IBD is more cost-effective with risk based testing strategies

G-P-409
Katalin Müller, Hungary
Diagnostic work-up and frequency of IBD-U in a nation-wide Hungarian Pediatric Inflammatory Bowel Disease Registry (HUPIR)

G-P-411
Lorenzo Norsa, Italy
Congenital chloride diarrhea and inflammatory bowel disease: an emerging association

G-P-412
Jane Oba, Brazil
Double balloon enteroscopy for decision diagnosis and therapy in paediatric Crohn’s disease and 10 years follow up

G-P-413
Christine Olbjørn, Norway
Combining biological agents in severe paediatric inflammatory bowel disease, an experience of fourteen cases

G-P-414
Joyce Omatseye, United Kingdom
Effects of nutritional status on the onset of liver abnormalities in children starting methotrexate maintenance in IBD

G-P-415
Marcin Osiecki, Poland
The risk of cardio-vascular complications in paediatric inflammatory bowel disease

G-P-417
Alicia Isabel Pascual Pérez, Spain
Paradoxical cutaneous manifestations associated to biological treatment in paediatric inflammatory bowel disease

G-P-418
Julia Pazmandi, Austria
Systems biology based analysis of early-onset and adult inflammatory bowel disease

G-P-419
Giacomo Perrone, Italy
Endoscopic dilation in Crohn’s disease strictures

G-P-420
Gema Pujol Muncunill, Spain
Safety and efficacy of Budesonide MMX in children with ulcerative colitis

G-P-421
Rosalind Rabone, United Kingdom
A case report on the role of exclusive enteral nutrition and CDED as remission maintenance in a severely atopic teen with Crohn’s disease

G-P-422
Gillian Rivlin, United Kingdom
A single centre experience in the use of Vedolizumab in paediatric inflammatory bowel disease

G-P-423
Marta Ruszkani-Bakun, Poland
Colonization in children with Crohn’s disease: histopathology characterisation at diagnosis and correlation with clinical parameters

G-P-424
Rosalind Rabone, United Kingdom
The prevalence in coeliac related hla haplotypes in paediatric IBD patients
| G-P-425 | Natasha Sasankan, United Kingdom  
Ferric carboxymaltose across all indications and ages in paediatric gastroenterology shows efficacy with increased safety concerns |
| G-P-426 | Luca Scarallo, Italy  
Predictive factors for surgery in pediatric inflammatory bowel diseases: a national referral center experience |
| G-P-427 | Rafeeq Muhammed, United Kingdom  
Higher adalimumab drug levels during maintenance therapy for paediatric Crohn’s disease are not associated with better endoscopic healing or biologic remission |
| G-P-429 | Rayna Shentova-Eneva, Bulgaria  
Risk factors for complicated disease in paediatric patients with crohn’s disease |
| G-P-430 | Rayna Shentova-Eneva, Bulgaria  
Extraintestinal manifestations in paediatric patients with inflammatory bowel diseases |
| G-P-431 | Engy Shokry, Germany  
MTX and 5-ASA affect metabolic profiles of paediatric Crohn’s disease patients in remission |
| G-P-432 | Rotem Sigall Boneh, Israel  
Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease |
| G-P-433 | Yasmine Sobeih, Qatar  
Screening and prevalence of iron deficiency anaemia in children with inflammatory bowel disease |
| G-P-434 | Lewis Steell, United Kingdom  
High-resolution MRI assessment of the muscle-fat-bone unit in young adults with childhood onset Crohn’s disease |
| G-P-435 | Caterina Strisciuglio, Italy  
Exclusive Enteral Nutrition therapy induces immunological tolerance in Crohn disease children: potential impact on immunometabolic asset and T regulatory cells function |
| G-P-436 | Zifei Tang, China  
The cause and risks factors of death in Chinese infantile-onset inflammatory bowel disease patients with IL10RA gene mutation |
| G-P-437 | Christopher Todd, United Kingdom  
Thiopurine-induced hepatotoxicity in paediatric inflammatory bowel disease (IBD) patients |
| G-P-440 | Dan Turner, Israel  
The effect of nutritional therapy on bone mineral density and bone metabolism in pediatric Crohn’s disease |
| G-P-441 | Dan Turner, Israel  
A nationwide quality improvement program in children with Crohn’s disease improves outcomes within 12 months |
| G-P-442 | Dan Turner, Israel  
Diagnostic criteria for IBD subtype classification: a multicenter validation cohort |
| G-P-443 | Dan Turner, Israel  
Prediction factors for low bone mineral density in children with Crohn’s disease |
| G-P-444 | Dan Turner, Israel  
Half of children with acute severe colitis have predominant single fecal bacterial species, mostly Escherichia coli: microbiome results from the PRASCO trial |
| G-P-447 | Joris J. van Ginkel, The Netherlands  
A 6-month period of concomitant immunomodulators is as effective as a 12-month period in the treatment of pediatric inflammatory bowel disease with Infliximab |
| G-P-450 | Elsa A. van Wassenaer, The Netherlands  
Premedication with steroids does not influence the incidence of Infusion Reactions after Infliximab Infusions in paediatric IBD patients – a retrospective case-control study |
| G-P-452 | Angharad Vernon-Roberts, New Zealand  
A novel self-report symptom assessment tool for children with inflammatory bowel disease: IBNow |
| G-P-453 | Angharad Vernon-Roberts, New Zealand  
Validation of a newly revised knowledge assessment tool for children with inflammatory bowel disease: IBDnow |
| G-P-454 | Alejandro Viquez Viquez, Costa Rica  
Paediatric inflammatory bowel disease in Costa Rica: a 15-year study |
| G-P-455 | Burcu Volkan, Turkey  
Vitamin deficiencies in children with inflammatory bowel disease |
| G-P-456 | David Wands, Australia  
Exclusive enteral nutrition in the management of paediatric Crohn’s disease: an Australian cohort |
| G-P-457 | Lin Wang, China  
Long-term outcomes of thalidomide treatment for children and adolescents inflammatory bowel disease |
| G-P-458 | Batia Weiss, Israel  
Mucosal healing with methotrexate versus azathioprine treatment in pediatric Crohn’s disease patients |
| G-P-459 | Thomas Whitby, United Kingdom  
A retrospective review of tertiary management of paediatric crohn’s disease |
| G-P-460 | Talty Wittmann Dayagi, Israel  
Characterisation of IL10 and IL10 receptor expression patterns in paediatric patients with ulcerative colitis |
| G-P-462 | Yuan Xiao, China  
Two cases of GSD Ib complicated with Crohn-like colitis |
| G-P-463 | Aijuan Yue, China  
Longitudinal development of intestinal microbiome after haematopoietic stem cell transplantation in IL10RA-deficient patients |
| G-P-464 | Dilay Yerlioglu, United Kingdom  
Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Infliximab |
| G-P-465 | Dilay Yerlioglu, United Kingdom  
Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Adalimumab |
| G-P-466 | Anat Yerushalmi-Feler, Israel  
Longitudinal follow up of body mass index as a predictor for severe disease course in children with inflammatory bowel disease |
G-P-467  
Anat Yerushalmy-Feler, Israel  
Predictors for poor outcome of hospitalizations in children with Inflammatory bowel disease

G-P-469  
Joachim Zobel, Austria  
Serum zinc concentration: a biomarker for mucosal inflammation in children with Crohn’s disease

G-P-470  
Maha Abouzekri, Egypt  
Helicobacter pylori in children: prevalence, predictors and effect on growth

G-P-472  
Derya Altay, Turkey  
Is H.pylori infection a risk factor for functional constipation?

G-P-473  
Sana Barakat, Egypt  
Comparative study of H.pylori eradication rates of high and frequent dose of Omeprazole and Amoxicillin dual therapy versus standard triple therapy in children

G-P-474  
Josefa Barrio, Spain  
Can the diagnosis of Helicobacter pylori infection be improved by taking samples from stomach corpus in addition to those from the antrum?

G-P-475  
Josefa Barrio, Spain  
Helicobacter pylori infection in a group of Spanish children

G-P-476  
Gilad Ben-Yehudah, Israel  
Efficacy and safety of breath ID® diagnostic for HP detection in children

G-P-477  
Otto Gerardo Calderon-Guerrero, Colombia  
Paediatric H.pylori infection and its relationship with low weight

G-P-478  
Felicia Galas, Romania  
Correlation between bacterial culture and histological findings in children with Helicobacter pylori gastritis

G-P-479  
Felicia Galas, Romania  
Correlation between clinical and endoscopic aspects in children with Helicobacter pylori gastritis

G-P-480  
Hacer Fulya Gulerman, Turkey  
Comparison of histopathology and PCR in the diagnosis of Helicobacter pylori infection and determination of Helicobacter pylori sensitivity to clarithromycin and fluoroquinolone in the pediatric population in Kırıkkale, Turkey

G-P-481  
Hayriye Hizarcioglu-Gulsen, Turkey  
Evaluation of ghrelin and leptin levels in sera and gastric tissues of paediatric patients with chronic gastritis

G-P-482  
Mizu Jiang, China  
Helicobacter pylori infection alters gastric and duodenal microbiotas of children

G-P-483  
Nicolas Kalach, France  
Systematic review and meta-analysis of histological gastritis according to the updated Sydney classification in Helicobacter pylori positive and negative children

G-P-484  
Kotilea Kallirroi, Belgium  
Low efficacy of second line treatments for H. pylori eradication in children
**BASIC AND/OR TRANSLATIONAL SCIENCE**

**H-P-001**
Vibhor Borkar, India
Porto-pulmonary hypertension in children with portal hypertension. Is routine screening required?

**H-P-003**
Eduardo Couchonnal, France
The influence of chelators on total blood copper isotopic composition in Wilson’s disease patients

**H-P-004**
Miri Dotan, Israel
The effect of bile acids on the sub-epithelial layer of mouse extrahepatic bile ducts

**H-P-005**
Paola Francalanci, Italy
Progressive familial intrahepatic cholestasis: new pieces of the puzzle

**H-P-006**
Nelgin Gerenli, Turkey
Gilbert syndrome: testing or not? Is genetic testing is necessary?

**H-P-007**
Theresa Greimel, Austria
Bile acids trigger coagulation activation potential in hepatocytes: a contributor to progression of paediatric cholestatic liver diseases?

**H-P-008**
Srikanth Kadyada Puttaiah, India
Normal gamma-glutamy-transferase cholestasis, ABCD3 mutation; response to Rifampicin: is this a new PFIC?

**H-P-010**
Kishwer Kumar, Saudi Arabia
A diagnostic dilemma: Copper metabolism in MDR3 deficiency causing false laboratory and clinical presentation resembling Wilson disease

**H-P-011**
Yu-Cheng Lin, Taiwan
Therapeutic effects of lactobacillus rhamnosus GG plus bifidobacterium lactis Bb12 and lactobacillus reuteri DSM 17938 on fatty liver in high-fat diet induced obese mice

**H-P-012**
Katharina Meinel, Austria
Active paediatric inflammatory bowel disease: lack of secondary and taurine-conjugated bile acids in serum

**H-P-014**
Onne Ronda, The Netherlands
Relationship between liver size and liver function in mice

**H-P-015**
Ira Shah, India
Hepatic interferon gamma and TNF alpha expression in infants with neonatal cholestasis and cytomegalovirus infection

**H-P-016**
Eyal Shteyer, Israel
Alginate biomaterial for stabilization after hepatic injury in abdominal trauma

**H-P-018**
Jie Wen, China
Sodium butyrate prevents liver injury and fibrosis by promoting liver stem cell-mediated repair and regeneration

**H-P-019**
Mozhgan Zahmatkeshan, Iran
The combined effect of recombinant human erythropoietin and human growth factor on liver regeneration after partial hepatectomy in rats

**H-P-020**
Linnea Äärelä, Finland
First Scandinavian case of successful pregnancy during nitisinone treatment for tyrosinemia type 1

**H-P-021**
Hala Abdullatif, Egypt
Drug-Drug interactions in children and adolescents receiving Ledipasvir/Sofosbuvir for treatment of Hepatitis C virus infection

**H-P-022**
Ulas Emre Akbulut, Turkey
Evaluation of plasma microRNA expressions in obese children with non-alcoholic fatty liver disease

**H-P-023**
Rubaiyat Alam, Bangladesh
Association between severity of chronic liver disease with grading of oesophageal varices in children

**H-P-025**
Monerah Alsaleh, Saudi Arabia
Arthrogryposis – renal dysfunction – cholestasis syndrome, single center experience

**H-P-027**
Aline Azabdaftari, Germany
Homozygous DCDC2 splice site mutation causing neonatal sclerosing cholangitis

**H-P-028**
Mohamed Bar, Saudi Arabia
Next generation sequencing reveals a homozygous ABCB4 gene mutation as a cause of cholestasis in a girl with coeliac disease and suspected autoimmune hepatitis vs Overlap syndrome

**H-P-029**
Ulrich Baumann, Germany
Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results

**H-P-030**
Vishnu Biradar, India
Budd chiary syndrome in infants: single centre experience of radiological intervention from Western India

**H-P-032**
Yeliz Cengan Appak, Turkey
Renal-hepatic-pancreatic dysplasia: an ultra rare ciliopathy with a novel NPHP3 genotype

**H-P-033**
Elif Sag, Turkey
Etiology and long-term outcome of extrahepatic portal vein thrombosis in children

**H-P-035**
Jeng Haw Cheng, United Kingdom
Single centre experience of congenital portosystemic shunts

**H-P-036**
Jeng Haw Cheng, United Kingdom
Radiological management of a complex congenital porto-systemic shunt

**H-P-037**
Youngsun Cho, Republic of Korea
The association of BMI and seropositivity of hepatitis B antibody in children who vaccinated in infancy with three doses of hepatitis B vaccine

**H-P-040**
Piotr Czubkowski, Poland
Farnesoid X receptor deficiency causing progressive familial intrahepatic cholestasis

**H-P-041**
Nedim Hadzic, United Kingdom
Epidemiology of biliary atresia in England and Wales (1999-2015)

**H-P-042**
Jemma Day, United Kingdom
Barriers to medication adherence in individuals with chronic liver disease and post-liver transplant: a comparison of those in paediatric and adult services
H-P-045  
Tim De Maayer, South Africa  
Hepatic sinusoidal obstruction syndrome – report of a South African outbreak

H-P-046  
Anna Degtyareva, Russia  
Long-term outcome of the Kasai procedure in children with biliary atresia

H-P-047  
Adrian Delgado, Spain  
Prevalence of hepatobiliary disease associated with cystic fibrosis in paediatrics

H-P-048  
Fabiola Di Dato, Italy  
Wilson disease and metabolic syndrome: is there a link?

H-P-050  
Fabiola Di Dato, Italy  
Elastography in children with Biliary Atresia surviving with native liver

H-P-052  
Laura Di Michele, Italy  
High incidence of overlooked Metabolic syndrome in subjects addressed to a liver steatosis and obesity clinic

H-P-054  
Emilie Faye, France  
Neurocognitive phenotype of children with liver form of Wilson disease

H-P-056  
Diana Garcia Tirado, Spain  
Endoscopic prophylaxis for upper digestive bleeding prevention in patients with portal cavernoma

H-P-057  
Muhammad Umer Ghafoor, United Kingdom  
Case reports about two patients with Abernethy malformation (congenital portosystemic shunts)

H-P-058  
Haytham Ghita, Egypt  
Secondary hepatic dysfunction in pediatric intensive care unit: a single center experience

H-P-059  
Lynette Goh, Singapore  
Effect of peri-operative intravenous antibiotic use at Kasai portoenterostomy on cholangitis rates and outcomes in children with biliary atresia at a single centre

H-P-060  
Theresa Greimel, Austria  
Revising the nomenclature of paediatric sclerosing cholangitis: results of an international poll

H-P-061  
Erin Gusus, Turkey  
Tenofovir in the management of chronic hepatitis B infection in children: a single center experience

H-P-062  
Patrick F. van Rheenen, The Netherlands  
Disease progression in paediatric patients with sclerosing cholangitis: results from two independent Dutch registries

H-P-064  
Corina Hartman, Israel  
Prevalence of elevated hepatocellular liver enzymes in obese/overweight pediatric population in Israel

H-P-065  
Paul Henderson, United Kingdom  
The epidemiology of conjugated hyperbilirubinaemia in the first year of life: a population-based cohort study

H-P-066  
Paul Henderson, United Kingdom  
The epidemiology of non-alcoholic fatty liver disease in children: a real world regional cohort study

H-P-067  
Kai O. Hensel, United Kingdom  
Outcome of sclerosing cholangitis in paediatric inflammatory bowel disease: do early diagnosis and treatment improve outcome?

H-P-068  
Eliska Hlauskova, Czech Republic  
Autoimmune sclerosing cholangitis and inflammatory bowel disease in children: experience from single University centrum

H-P-071  
Wojciech Janczyk, Poland  
Autoimmunity in children with Wilson’s disease

H-P-072  
Kamil Janowski, Poland  
Quantitative MRCP imaging: preliminary observations in a cohort of paediatric patients with liver and biliary diseases

H-P-073  
Kavitha Jayaprakash, United Kingdom  
Hepatitis C treatment in children optimism justified

H-P-074  
Norman Junge, Germany  
Dubin-Johnson syndrome and neonatal cholestasis – single center experience for an ultra rare disease as cause for neonatal cholestasis

H-P-075  
Aikaterini Kakotrichi, United Kingdom  
Liver involvement in infants with hyperinsulinaemic hypoglycaemia

H-P-076  
Yunkoo Kang, Republic of Korea  
Validation of the baveno vi criteria to identify low risk of biliary atresia patients not requiring endoscopic surveillance for esophageal varix

H-P-077  
Simone Kathemann, Germany  
Is it autoimmune hepatitis or Wilson’s disease – diagnostic dilemma in paediatric liver disease?

H-P-078  
Denizta Kofinova, Bulgaria  
Non-invasive methods for assessment of liver fibrosis in paediatric patients

H-P-079  
Nagendra Kumar, India  
Langerhans cell histiocytosis with sclerosing cholangitis in children: an entity for recognition

H-P-082  
Usha Krishnan, Australia  
Cholestatic jaundice in neonates: how common is biliary atresia? Experience at an Australian tertiary centre

H-P-083  
Patryk Lipiński, Poland  
Next-generation sequencing in diagnostic approach to cholestatic liver disease – one-centre experience

H-P-084  
Zuzana Londt, United Kingdom  
Thiopurine drug monitoring in paediatric patients with autoimmune liver disease

H-P-085  
Olha Lukianenko, Ukraine  
Liver and pancreatic stiffness in obese children

H-P-086  
Olha Lukianenko, Ukraine  
Liver and pancreatic ultrasound attenuation coefficient in obese children

H-P-087  
Olha Lukianenko, Ukraine  
Quality of life and features of eating behavior in children with non-alcoholic fatty liver disease

H-P-088  
Isobel Makin, United Kingdom  
Depression, anxiety and health related quality of life in paediatric non-alcoholic fatty liver disease; under-recognised and under-managed?

H-P-089  
Isobel Makin, United Kingdom  
Systematic review of studies assessing the effect of psychological intervention on clinical outcomes in patients with non-alcoholic fatty liver disease
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-P-090</td>
<td>Autoimmune hepatitis in children: initial experience from an Indian tertiary pediatric centre</td>
<td>Rohan Malik, India</td>
<td>India</td>
</tr>
<tr>
<td>H-P-091</td>
<td>Balloon-occluded retrograde transvenous obliteration (BRTO) – an under-utilised treatment option in children</td>
<td>Rohan Malik, India</td>
<td>India</td>
</tr>
<tr>
<td>H-P-092</td>
<td>Retrospective analysis of effects of lipoprotein levels on length of hospital stay in children with concurrent hypertransaminasemia</td>
<td>Claudia Mandato, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-094</td>
<td>Long-term linear growth in children and young people with autoimmune liver disease treated with daily maintenance dose of prednisolone</td>
<td>Karishma Manwani, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>H-P-095</td>
<td>Early growth patterns of infants following Kasai portoenterostomy: QI update of single center standardized nutrition protocol</td>
<td>Inez Martincevic, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>H-P-096</td>
<td>Oral N-acetyl-cysteine as a sulphur donor in a child with TRMU-associated liver disease</td>
<td>Greta Mastrangelo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-097</td>
<td>Hepatitis D in children: a long-term follow-up</td>
<td>Lorenzo Matarazzo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-098</td>
<td>Myelodysplastic syndrome in children with autoimmune hepatitis</td>
<td>Lorenzo Matarazzo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-099</td>
<td>Oral N-acetyl-cysteine as a sulphur donor in a child with TRMU-associated liver disease treated with daily maintenance dose of prednisolone</td>
<td>Valérie McLin, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>H-P-100</td>
<td>Improving engagement of young people with liver disease: the role of youth worker</td>
<td>Ajuah Mensah, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>H-P-102</td>
<td>Predictors for fibrosis in obese pediatric fatty liver patients and the effect of low carbohydrate diet on steatosis and fibrosis</td>
<td>Hadar Moran-Lev, Israel</td>
<td>Israel</td>
</tr>
<tr>
<td>H-P-103</td>
<td>Long term outcome of pediatric autoimmune liver disease: current challenges and new directions</td>
<td>Gisela Silva, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>H-P-104</td>
<td>Is there a role for bioelectric impedance analysis in managing non-alcoholic fatty liver disease?</td>
<td>Helen Mortimer, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>H-P-105</td>
<td>Severe citrin deficiency in a European country</td>
<td>Gemma Muñoz Bartolo, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>H-P-107</td>
<td>Effect of food on pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis</td>
<td>Satoshi Nakano, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>H-P-108</td>
<td>Epidemiology of chronic hepatitis C in children – the experience of a paediatrics department</td>
<td>Daniela Pacurar, Romania</td>
<td>Romania</td>
</tr>
<tr>
<td>H-P-109</td>
<td>Biochemical markers of copper metabolism in Wilson disease heterozygotes</td>
<td>Martina Peluso, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-110</td>
<td>Clinical characteristics and influencing factors of nonalcoholic fatty liver disease in obese children and adolescents</td>
<td>Luting Peng, China</td>
<td>China</td>
</tr>
<tr>
<td>H-P-111</td>
<td>Acute liver Failure in children – a 10 year single center experience from India</td>
<td>Prabhas Prasun Giri, India</td>
<td>India</td>
</tr>
<tr>
<td>H-P-112</td>
<td>Transjugular liver biopsy is feasible and safe in high risk children older than 5 years: largest pediatric experience in 75 children</td>
<td>Yi-Ling Qiu, China</td>
<td>China</td>
</tr>
<tr>
<td>H-P-113</td>
<td>Transjugular liver biopsy is feasible and safe in high risk children older than 5 years: largest pediatric experience in 75 children</td>
<td>Eberhard Luz, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>H-P-114</td>
<td>Sarcopenia as an independent outcome marker in children with hepatoblastoma</td>
<td>Alessia Rizzo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>H-P-115</td>
<td>Transjugular liver biopsy is feasible and safe in high risk children older than 5 years: largest pediatric experience in 75 children</td>
<td>Bikrant Biharih Raghuvashti, India</td>
<td>India</td>
</tr>
<tr>
<td>H-P-116</td>
<td>Transjugular liver biopsy is feasible and safe in high risk children older than 5 years: largest pediatric experience in 75 children</td>
<td>Cisela Silva, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>H-P-117</td>
<td>Sarcopenia as an independent outcome marker in children with hepatoblastoma</td>
<td>Gisela Silva, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>H-P-118</td>
<td>Synchronous diagnosis of liver ALK-positive histiocytosis and Cystic Fibrosis: an infant case</td>
<td>Valérie McLin, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>H-P-119</td>
<td>Contrast-enhanced echocardiogram for the detection of intrapulmonary shunts in children with portal hypertension or portosystemic shunt</td>
<td>Satoshi Nakano, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>H-P-120</td>
<td>Long-term neurodevelopmental outcomes in children with biliary atresia</td>
<td>Daniela Pacurar, Romania</td>
<td>Romania</td>
</tr>
<tr>
<td>H-P-121</td>
<td>Wilson disease: a novel mutation in the ATP7B gene</td>
<td>Norberto Rodriguez-Baez, USA</td>
<td>USA</td>
</tr>
<tr>
<td>H-P-122</td>
<td>A case of w obligination among two novel lipa gene mutations</td>
<td>Elena Roslavevskaya, Russia</td>
<td>Russia</td>
</tr>
<tr>
<td>H-P-123</td>
<td>Has the time come to include molecular genetics in the evaluation of cryptogenic/undiagnosed metabolic liver disease?</td>
<td>Srinivas Sankaranarayanan, India</td>
<td>India</td>
</tr>
<tr>
<td>H-P-124</td>
<td>Polyomar variants of the gene of dsfroebin lambda 3 and features of immune response in children with chronic viral hepatitis C</td>
<td>Tatyana Sentsova, Russia</td>
<td>Russia</td>
</tr>
<tr>
<td>H-P-125</td>
<td>Gallstone disease in children: an evolving entity?</td>
<td>Gisela Silva, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>H-P-126</td>
<td>Impact of an ileal bile acid transporter inhibitor versus partial external biliary diversion in progressive familial intrahepatic cholestasis - a case providing direct comparison of medical and surgical therapies</td>
<td>Christoph Slavetinsky, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>H-P-127</td>
<td>Molecular diagnosis of glycogen storage disease type IX using GSD gene panel</td>
<td>Min Ji Sohn, Republic of Korea</td>
<td>Korea</td>
</tr>
<tr>
<td>H-P-128</td>
<td>Significance of hepatitis A virus related pediatric liver disease burden and its sero prevention analysis in Indian subcontinent</td>
<td>Vikrant Sood, India</td>
<td>India</td>
</tr>
</tbody>
</table>
H-P-133
Vikrant Sood, India
Changing spectrum and predictors of severity of pediatric liver abscess in Indian subcontinent

H-P-134
Vikrant Sood, India
Pediatric Gilbert’s syndrome in Indian subcontinent - an analysis of 170 cases

H-P-135
Eleana Stasinou, Greece
Atherosclerosis risk and genetic variants in adiponutrin gene in Greek children and adolescents

H-P-137
Harry Sutton, United Kingdom
A Scotland-wide analysis of children with autoimmune hepatitis: a retrospective prevalence study

H-P-138
Richard J. Thompson, United Kingdom
Development of patient- and observer-reported outcome measures for paediatric cholestatic liver diseases

H-P-139
Sinan Sari, Turkey
The liver disease and gene mutations of Alpha-1 Antitrypsin deficiency in Turkish children: a single center experience

H-P-140
Nafiye Urganci, Turkey
Rare complications of hepatitis A virus infection

H-P-142
Ye Yang, China
Discovery of an intronic long-interspersed-element 1 insertion in SLCO1B3 by next generation sequencing

H-P-143
May Yip, United Kingdom
Use of transcutaneous bilirubinometer to determine the need for prolonged jaundice screen

H-P-144
Jung Min Yoon, Republic of Korea
Usefulness of transient elastography in pediatric nonalcoholic steatohepatitis

H-P-146
Nataliya Zavhorodnia, Ukraine
Assessment of liver stiffness and cytokine profile sex-specific differences in pediatric non-alcoholic fatty liver disease patients

H-P-147
Nataliya Zavhorodnia, Ukraine
Faecal short chain fatty acids in children with obesity and nonalcoholic fatty liver disease

H-P-148
Ting Ge, China
Novel compound heterozygote mutations of TJP2 in a Chinese child with progressive cholestatic liver disease

H-P-149
Rayna Alamurova, United Kingdom
A single center experience in using Sirolimus in paediatric liver transplant

H-P-150
Roberta Angelico, Italy
Early referral to transplant centers is a prognostic factor influencing outcomes of pediatric liver transplantation

H-P-151
Cigdem Arikans, Turkey
Living donor liver transplantation for PFIC type 3

H-P-152
Cigdem Arikans, Turkey
Frequency, characteristics and outcome of Eosinophilic Eosinophagitis and gastrointestinal disease after liver transplantation

H-P-153
Sergio Assia-Zamora, United Kingdom
Pancreatic tumours in children

H-P-154
Sema Aydogdu, Turkey
Aplastic anemia insidance and management in paediatric liver transplantations due to non A-E hepatitis

H-P-155
Zeren Barış, Turkey
Evaluation of spleen volume with computed tomography after liver transplantation in pediatric recipients

H-P-157
Maciej Dadalski, Poland
Basiliximab treatment for steroid and anti-CD3 resistant rejection in paediatric patients after liver transplantation

H-P-158
Lorenzo D’Antiga, Italy
Long-term outcome of portal vein thrombosis after paediatric liver transplantation

H-P-159
Ruth De Bruyne, Belgium
The presence of serum autoantibodies and donor-specific anti-HLA antibodies in pediatric liver transplant recipients is associated with histological and biochemical parameters of graft dysfunction

H-P-160
Lev Dorfman, Israel
ABO-incompatible paediatric liver transplantation: a single center experience

H-P-161
Paola Francalanci, Italy
Vascular disorders: uncommon indications for liver transplantation in pediatric age

H-P-162
Songpan Getsuwan, Thailand
Cognitive and behavioural issues in paediatric liver transplant recipients

H-P-163
Imeke Goldschmidt, Germany
Factors associated with subclinical cardiovascular damage after pediatric liver transplantation: a longitudinal observational study

H-P-164
Charleen Gravenberch, The Netherlands
Management of portal vein anastomotic stenosis after paediatric liver transplantation: evaluation of single centre experience

H-P-165
Orith Waisbourd-Zinman, Israel
Biliary strictures in pediatric liver transplant recipients – a single center experience

H-P-166
Christian Hudert, Germany
Mycophenolate motefil monotherapy in paediatric primary liver transplant patients

H-P-167
Homin Huh, Republic of Korea
Risk factors of hepatopulmonary syndrome in children

H-P-168
Vandana Jain, United Kingdom
Early transient elastography for prediction of clinical outcomes in Biliary Atresia post-Kasai Portocenterostomy: a pilot study

H-P-169
Diana Kamińska, Poland
MBOAT7, PNPLA3 and TM6SF2 polymorphism in liver donor and recipient as potential modifiers of outcome in children post liver related transplantation – the preliminary study

H-P-170
Sivaramakrishnan Venkatesh Karthik, Singapore
Idiopathic post-transplant hepatitis, graft fibrosis and histological changes in long-term survivors after paediatric liver transplantation – the Singapore experience

H-P-171
Yu Bin Kim, Republic of Korea
A comparison study: fulminant Wilson’s disease vs. acute liver failure in children
| H-P-173 | Ezgi Kiran Tasci, Turkey | Evaluation of hepatitis B- antibody titration loss after liver transplantation in children |
| H-P-174 | Kishwer Kumar, Saudi Arabia | Familial hypercholanemia presenting with severe progressive intrahepatic cholestasis, secondary to homozygous mutation of TJP2 and BAAT |
| H-P-175 | Tobias Laue, Germany | Biomarkers for Immune function after liver transplantation in children and adolescents with standard calcineurin inhibitor-based versus reduced minimal immunosuppression |
| H-P-176 | Christoph Leiskau, Germany | Low dose steroids do make a difference - failure to thrive after pediatric liver transplantation |
| H-P-177 | Daniela Liccardo, Italy | The multidisciplinary management and the early referral to a specialized center improve outcomes after liver transplantation in children with metabolic disease |
| H-P-179 | Eberhard Lurz, Germany | Reference charts of total psoas muscle area in children (TPMA) |
| H-P-180 | Maciej Dadalski, Poland | Problems with antibody mediated rejection after pediatric liver transplantation |
| H-P-181 | Maria Mercadal-Hally, Spain | Endovascular treatment of early thrombosis of the hepatic artery in paediatric patients with liver transplantation |
| H-P-182 | Maria Mercadal-Hally, Spain | Food allergy in paediatric patients with liver transplantation |
| H-P-183 | Katheryn Louise Mullaney, Australia | A tale of two patients: adverse effects of low dose oral glucocorticoids in two paediatric liver transplant recipients |
| H-P-186 | Natasha Su Lynn Ng, United Kingdom | Paediatric liver transplantation for inherited metabolic disorders: experience from Leeds children’s hospital |
| H-P-187 | Ioannis Rolidis, United Kingdom | Diagnosis and management of antibody mediated rejection in paediatric liver transplantation |
| H-P-188 | Politiya Sintusek, Thailand | Humoral and cellular response to standard and double dose of hepatitis B vaccine in children after liver transplantation |
| H-P-189 | Politiya Sintusek, Thailand | Prevalence of hepatitis E infection in liver transplanted children: a single centre experience |
| H-P-190 | Yildiz Tütüncü, Turkey | Does accelerated vaccination schedule achieves same seroconversion rate as conventional schedule in infants with chronic liver disease? |
| H-P-191 | Sharat Varma, India | 3 year follow up after liver transplantation for mitochondrial depletion syndrome associated with MPV17 mutation |
| H-P-192 | Sharat Varma, India | Significance of intrapulmonary vascular dilatations in paediatric candidates for liver transplant |
| H-P-194 | Silvio Veraldi, Italy | Status of vitamins A, E and D in paediatric patients pre and 1-year post liver transplant: a single center experience |
| H-P-195 | Muhammed Yüksel, Turkey | The significance of panel reactive antibody (PRA) positivity in graft rejection in paediatric orthotopic liver transplantation |
| H-P-196 | Muhammed Yüksel, Turkey | Pretransplant low rate vaccination status of children with liver disease |
| H-P-197 | Mozghan Zahmatkeshan, Iran | Evaluation of correlation between serum eosinophil count and acute cellular rejection in liver transplant recipient in Namazi hospital during 2008-2016 |
### Nutrition

#### BASIC AND/OR TRANSLATIONAL SCIENCE

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-P-001</td>
<td>Betül Aksoy, Turkey: Effects of breastfeeding on growth in preschool children from west region of Turkey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-002</td>
<td>Cristina Campoy, Spain: Gut microbiota is associated with the infant cognitive development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-003</td>
<td>Roberto Berni Canani, Italy: Comparative evaluation of tolerogenic action elicited by protein fraction derived from different hypoallergenic formulas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-004</td>
<td>Roberto Berni Canani, Italy: How breast milk protects against food allergy: the immunoregulatory action of butyrate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-005</td>
<td>Dianne Delsing, The Netherlands: Gut microbiota modulating effects of GOS and 2'-FL studied by in vitro infant and toddler faecal fermentations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-007</td>
<td>Laura Maria Palomino Pérez, Spain: Expanded newborn screening: Seven-year experience in a single centre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-008</td>
<td>Lixin Qian, China: Bile salt-dependent lipase promotes the proliferation and barrier function of Caco-2 cells by activating Wnt/β-catenin signaling via LRPR6 receptor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### CLINICAL NUTRITION

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-P-011</td>
<td>Maria Ramirez, Spain: Synergistic activity of 2’-Fucosyllactose with a blend of lutein and natural vitamin E on intestinal microbiota modulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-012</td>
<td>Krista Salli, Finland: 2’-Fucosyllactose fermentation in an infant gut simulator model</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-013</td>
<td>Nataliya Shilina, Russia: Mothers’ BMI influence on physical development of infants genetically predisposed to obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-014</td>
<td>Renato Augusto Zorzato, Brazil: Methylation patterns of LDLR, APOB and PCSK9 genes in patients with clinical diagnosis of Familial Hypercholesterolemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-015</td>
<td>Irene Bacelo Ruano, Spain: Children feeding difficulties and disorders due to organic disease in a reference Unit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-016</td>
<td>Elvira Cañedo Villarroya, Spain: Effectiveness and safety of the ketogenic diet as a treatment for refractory epilepsy and cerebelar glucose transporter deficit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-017</td>
<td>Elvira Cañedo Villarroya, Spain: Ketogenic diet in patients with deficit of brain glucose transporter type 1: experience in 5 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-018</td>
<td>Elvira Cañedo Villarroya, Spain: Treatment with ketogenic diet in patients with mitochondrial disease and refractory epilepsy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Posters

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-P-019</td>
<td>Elena Cernat, United Kingdom: Is bowel lengthening a step towards enteral autonomy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-020</td>
<td>Charmaine Chai, United Kingdom: Review of weaning strategies in short bowel syndrome intestinal failure patients in a single centre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-021</td>
<td>Charmaine Chai, United Kingdom: 5-year outcome of children with short bowel syndrome (SBS) related intestinal failure (IF) from infancy and dependent on parenteral nutrition(PN) for over 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-022</td>
<td>Shuqing Chi, China: Early enteral nutrition after surgery leads to better nutritional support to children with hirschsprung’s disease: a prospective study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-023</td>
<td>Jie Chien, China: Nutrition therapy in paediatric radiation enteritis with intestinal failure: a case report and literature review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-024</td>
<td>Ky Young Cho, Republic of Korea: The incidence of Intestinal failure associated liver disease (IFALD) in children with intestinal failure during first year of life. Experience in a tertiary reference hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-025</td>
<td>Renato Augusto Zorzato, Brazil: The relationship between socioeconomic status and obesity in Korean children: a cross-sectional observational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-026</td>
<td>Nataliya Shilina, Russia: Early enteral nutrition after surgery leads to better nutritional support to children with hirschsprung’s disease: a prospective study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-027</td>
<td>Maria Ramirez, Spain: Synergistic activity of 2’-Fucosyllactose with a blend of lutein and natural vitamin E on intestinal microbiota modulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-028</td>
<td>Elena Cernat, United Kingdom: Is bowel lengthening a step towards enteral autonomy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-029</td>
<td>Charmaine Chai, United Kingdom: Review of weaning strategies in short bowel syndrome intestinal failure patients in a single centre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-030</td>
<td>Charmaine Chai, United Kingdom: 5-year outcome of children with short bowel syndrome (SBS) related intestinal failure (IF) from infancy and dependent on parenteral nutrition(PN) for over 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-031</td>
<td>Shuqing Chi, China: Early enteral nutrition after surgery leads to better nutritional support to children with hirschsprung’s disease: a prospective study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-032</td>
<td>Jie Chien, China: Nutrition therapy in paediatric radiation enteritis with intestinal failure: a case report and literature review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-033</td>
<td>Ky Young Cho, Republic of Korea: The incidence of Intestinal failure associated liver disease (IFALD) in children with intestinal failure during first year of home parenteral nutrition (HPN) with use of third generation, intravenous lipid emulsion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Posters - Nutrition

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-P-034</td>
<td>Hazel Duncan, United Kingdom: Predictive formulas overestimate resting energy expenditure compared to indirect calorimetry, in teenage girls hospitalized for anorexia nervosa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-035</td>
<td>Claire Dupont-Lucas, France: Blended diet use across Scotland with cost savings on standard dietetic management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-036</td>
<td>Sophia Elmehdi, France: New variant of microsomal triglyceride transfer protein (MTTP) deletion in a child with abetalipoproteinaemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-P-037</td>
<td>Christopher Eke, South Africa: Nutritional monitoring of home parenteral nutrition (HPN) with use of third generation, intravenous lipid emulsion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Posters - Nutrition - Country-wise Distribution

- **Brazil**
- **China**
- **France**
- **Germany**
- **Italy**
- **United Kingdom**
- **Poland**
- **Spain**
- **Turkey**
- **Russia**
- **United States**

---

**www.espgancongress.org**
Nutrition 043 – 061

N-P-043
Camila Garcia-Volpe, Spain
Sitosterolemia: an uncommon cause of hypercholesterolemia in childhood

N-P-044
Dominique Guimber, France
Incidence and prevalence of home artificial nutrition in children in the North of France « Hauts-de-France region »

N-P-045
Ruth Hamblin, United Kingdom
Copper deficiency and the importance of trace element monitoring in jejunally tube fed children

N-P-046
Maria De los Ángeles Hernández López, Mexico
Neck Circumference and its association with the biochemical components of the metabolic syndrome and other markers of systemic involvement in paediatric patients with obesity

N-P-048
Hayriye Hizarcigil-Gulsen, Turkey
Nutritional characteristics of patients with functional constipation aged 4 years and older

N-P-049
Li Hong, China
Computerized data analysis of the nutritional risk screening and clinical outcomes in hospitalized children in Shanghai children’s medical center

N-P-050
Amy-Jo Hooley, United Kingdom
Sub-optimal supplementation of ascorbic acid in parenteral nutrition

N-P-051
Koen Huyssentruyt, Belgium
Day to day and inter-rater variability of the Cow’s Milk-related Symptom Score (CoMISSTM)

N-P-052
Koen Huyssentruyt, Belgium
Case studies on clinical scenarios of paediatric malnutrition: results from an international survey

N-P-053
Hamidreza Kianifar, Iran
Oral budesonide for esophageal stenosis in epidermolysis bullosa: an open-label trial in twenty children

N-P-054
Hilde Krom, The Netherlands
Efficacy and long-term outcomes following a clinical hunger provocation program to wean feeding tube dependent children

N-P-056
Ariada Guadalupe Lara Campos, Mexico
Waist-height ratio as an indicator of blood pressure alterations in obese paediatric patients

N-P-057
Eun Hye Lee, Republic of Korea
A nationwide survey on paediatric nutritional support team activity in South Korea

N-P-058
Dina Levy, Israel
Malnutrition is frequent among children with spinal muscular atrophy

N-P-059
Carla Maia, Portugal
Nutritional support for hospitalized chronic patients – where do we stand?

N-P-060
Hélcio Maranhão, Brazil
Record of anthropometric parameters and the prophylactic supplementation of iron, vitamin A and vitamin D in Brazilian children’s health booklets

N-P-061
Maria Angeles Martinez Ibeas, Spain
Children feeding difficulties and disorders in a reference unit: frequency and diagnostic subtypes

---

Nutrition 062 – 082

N-P-062
Virginia Martínez Jiménez, Spain
Use of omega 3 fatty acids in parenteral nutrition in paediatric patients undergoing hematopoietic stem cell transplantation

N-P-063
Maria Misiou, United Kingdom
Iron status in paediatric patients receiving Home Parenteral Nutrition (HPN)

N-P-066
Shivani Nivedita, India
Association between complimentary feeding practice adherence and nutritional status of children – a cross sectional study from Northern India

N-P-067
Raj Singh Parmar, United Kingdom
Daily intravenous Octreotide to control high output gastrostomy losses in intestinal failure

N-P-068
Aranza Lilian Perea Caballero, Mexico
Anthropometric indicators, body composition and actual nutrition of population specific formulae based on anthropometry

N-P-069
Virginia Martínez Jiménez, Spain
Children feeding difficulties and disorders in a reference unit: Integral approach

N-P-070
Arturo Perea Martínez, Mexico
The waist-height ratio stratified and its association with haematological abnormalities in obese paediatric patients

N-P-071
Sunita Amar Rajani, United Kingdom
Micronutrient levels in intestinal failure(IF) patients dependent on parenteral nutrition(PN) at home over a 5-year period

N-P-072
Sunita Amar Rajani, United Kingdom
The role of parenteral nutrition in children after bone marrow transplantation

---

N-P-073
Raziliya Rakhmaeva, Russia
Anthropometric indicators, body composition and actual nutrition evaluation in children with cerebral palsy

N-P-075
Silvia Rodriguez Manchan, Spain
Children feeding difficulties and disorders in a reference unit: follow up after six months

N-P-076
Silvia Rodriguez Manchan, Spain
Children feeding difficulties and disorders in a reference unit: Integral approach

N-P-077
Silvia Rodriguez Manchan, Spain
Acute dehydration and hypercalcemia in patients with total intestinal aganglionosis on long term parenteral nutrition

N-P-079
Huijuan Ruan, China
The influence factors of energy metabolism of patients with mechanical ventilation after cardiac valve surgery undergoing cardiopulmonary bypass

N-P-081
Lilia Mayrel Santiago Lagunes, Mexico
Metabolic syndrome. Association of biochemical components with the stratified waist-height ratio in obese paediatric patients

N-P-082
Laura Sealy, United Kingdom
Audit of nutrition support for patients undergoing treatment for medulloblastoma (MB) at Bristol children’s hospital. Are we following the children’s cancer and leukaemia group (CCLG) guidelines for this group?
N-P-083
Sara Sila, Croatia
Characteristics of polymeric formula and route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in children with Crohn’s disease.

N-P-084
Fotini Sotiriadou, Greece
Feeding problems in children with gastrointestinal diseases: a controlled study.

N-P-085
Leke Sreedharan, India
Evaluation of semi-elemental formulae vs polymeric formulae as exclusive enteral nutrition in pediatric Crohn’s disease in India.

N-P-086
Margarita M. Suarez Galvis, Spain
Experience in primary trimethylaminuria in a third level paediatric hospital.

N-P-087
Michelle Li Nien Tan, Singapore
A comparison of feeding styles of parents whose children visit the feeding clinic with those who do not attend feeding clinic.

N-P-088
Ramon Tormo, Spain
Lactose intake and brain functions.

N-P-089
Giulia Vizzari, Italy
Circulating salicylic acid and metabolic profile after 1-year nutritional-behavioral intervention in obese children.

N-P-090
Brock Williams, Canada
Serum folate concentrations in Canadian children with sickle cell disease: a pilot project.

N-P-091
Charlotte M Wright, United Kingdom
Weight loss in children being weaned from long term tube feeding.

N-P-092
Zhuoming Xu, China
Growth faltering in Chinese children with congenital heart defects and mid-term follow-up.

N-P-093
Shokoufeh Ahmadipour, Iran
Are synbiotics effective in the treatment of jaundice in neonates?

N-P-094
Ann Anderson-Berry, USA
Maternal and cord serum carotenoid levels and their impact on neonatal hearing screen results.

N-P-095
Kumar Ankur, India
Tongue ties affecting breastfeeding in early term & full term neonates.

N-P-096
Maria Victoria Bovo, Spain
Neonatal and maternal vitamin B12 deficiency detected in the expanded newborn screening.

N-P-097
Jean-Pierre Chouraqui, Switzerland
An evaluation of physician’s advice and parents’ adherence about infant nutrition.

N-P-098
Jemma Cleminson, United Kingdom
Audit of medical staff knowledge of how to support mothers to initiate and to continue providing breastmilk for infants admitted to the neonatal unit.

N-P-099
Sarah Dib, United Kingdom
Does infant sex predict maternal breastfeeding perception, expressed breast milk volume and breastfeeding status at 3 and 6 months in China, Russia and the United Kingdom?

N-P-100
Corrine Hanson, USA
Maternal, social, and demographic factors influence placental concentrations of lutein+zeaxanthin.

N-P-101
Corrine Hanson, USA
Maternal serum nutrient levels are associated with biomarkers of inflammation at the time of delivery.

N-P-102
Joanah Ikobah, Nigeria
Pattern of breastfeeding in a developing African country – A facility based study among mothers attending a tertiary hospital in Calabar, Nigeria.

N-P-103
Hannah Duggan, United Kingdom
Can biochemical variables be used to predict weight gain of very low birth weight preterm infants?

N-P-104
Hannah Duggan, United Kingdom
What impact does gastro-intestinal surgery have on the growth of very low birth weight preterm infants?

N-P-105
Oorporn Dumrongwongsiri, Germany
Intrauterine zinc and iron storage were associated with maternal nutrient status and mode of delivery.

N-P-106
Fabian Eibensteiner, Austria

N-P-107
Rubens Feferbaum, Brazil
Colostrum therapy modulates preterm newborn’s gut microbiome.

N-P-108
Yi Feng, China
Feeding intolerance of hospitalized very low birth weight neonates fed with different types of formula.

N-P-109
Rhian Jones, UK
Does infant sex predict maternal breastfeeding perception, expressed breast milk volume and breastfeeding status at 3 and 6 months in China, Russia and the United Kingdom?

N-P-110
Nadia Liotti, Italy
Osmolality and microbiological assessment of targeted fortified human milk.

N-P-111
Olga Lukoyanova, Russia
The lactoferrin level in the breast milk of Russian mothers and in the feces of their children.

N-P-112
Vijay Mali, United Kingdom
Human milk component administration in preterm neonates: a randomised controlled trial.

N-P-113
Srinivas Murki, India
Availability of an electronic breast pump 24/7 reduces the time to reach full milk in mothers of preterm VLBW infants admitted to the NICU.

N-P-114
Beheshteh Olang, Iran
Validation of the NutriCHEQ tool for identifying children aged 1 to 3 years at nutritional risk.

N-P-115
Jost Manuel Ramos Nieves, Switzerland
Supplementation of human milk oligosaccharides during early life improves the long-term pancreatic insulin content of a preclinical model of intra-uterine growth retardation.

N-P-116
Aydan Kansu, Turkey
Growth, tolerance and compliance of an intended use population of infants with cow milk protein allergy to an extensively hydrolysed casein-based powder infant formula.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Poster Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-P-135</td>
<td>The gut microbiota of exclusively breastfed infants: a world-wide analysis showing a dominance of bifidobacteria, despite pronounced regional differences in species composition</td>
<td>Olga Sakwinska, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>N-P-136</td>
<td>Breastfeeding is associated with a reduced risk of acute respiratory infections in the microbiota and health cohort</td>
<td>Neelam Kler, India</td>
<td>India</td>
</tr>
<tr>
<td>N-P-138</td>
<td>Macronutrient composition of human milk from mothers of very preterm infants ≤ 32 weeks (CTRI/2017/02/007895)</td>
<td>Hiroshi M. Ueno, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>N-P-140</td>
<td>The timing of complementary feeding introduction and feeding difficulties in childhood: a systematic review</td>
<td>Katarzyna Babik, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-142</td>
<td>Respiratory and diarrhoeal infections in the microbiota and health prospective cohort of Bangladeshi infants under two years of age</td>
<td>Karine Vidal, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>N-P-143</td>
<td>Exploration of specific nutritional deficits in very low birth weight infants with extrauterine growth restriction</td>
<td>Yi Xiang, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-144</td>
<td>Maternal feeding attitudes, infant eating behaviour and exclusive breastfeeding: data from a multi-centre study</td>
<td>Jinyue Yu, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>N-P-145</td>
<td>A systematic review: Fatty acid composition of mature human milk in China</td>
<td>MengYa Zhao, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-146</td>
<td>Factors impacting postoperative growth in infants with congenital heart disease</td>
<td>Xu Zhuoming, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-148</td>
<td>The timing of complementary feeding introduction and feeding difficulties in childhood: a systematic review</td>
<td>Ewa Winnicka, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-150</td>
<td>Evaluation of the frequency of obesity and associated Factors in children of obese and overweight mothers</td>
<td>Yeliz Cagan Appak, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>N-P-151</td>
<td>Scurvy during home parenteral nutrition</td>
<td>Elena Cernat, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>N-P-152</td>
<td>Taste development and eating habits of children following complementary feeding with adult food typical of the mediterranean diet</td>
<td>Raffaella de Franchis, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-156</td>
<td>Experience of an obesity and fatty liver disease clinic: application of a personalized mobile based intervention (PediaFit)</td>
<td>Anna Pia Delli Bovi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-158</td>
<td>A comparative study of efficacy and tolerability of micro-dispersed iron and lactoferrin in treatment of iron deficiency anemia</td>
<td>Rania El-Haddad, Egypt</td>
<td>Egypt</td>
</tr>
<tr>
<td>N-P-159</td>
<td>Estimation of vitamin D deficiency in healthy school-age children: current status in Italy</td>
<td>Tiziana Galeazzi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-160</td>
<td>Mediterranean diet: let’s give the scores!</td>
<td>Fulya Gülerman, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>N-P-161</td>
<td>Measurement of body composition using bioelectrical impedance analysis: effects of obesity, physical activity</td>
<td>Anna Kasyanova, Russia</td>
<td>Russia</td>
</tr>
<tr>
<td>N-P-162</td>
<td>Feeding behaviours of healthcare professional mothers for their 0-24 month-old children</td>
<td>Anna Pia Delli Bovi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-163</td>
<td>Evaluation of physical and emotional well-being of children undergoing electrostimulation of swallowing</td>
<td>Ewa Winnicka, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-164</td>
<td>Comparison of school going children’s intake of key vitamins &amp; minerals for cognitive and immune development: a cross-country comparison</td>
<td>Yi Xiang, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-165</td>
<td>Correlation between parathormone level and vitamin D apply in the early childhood</td>
<td>Faran Khan, Pakistan</td>
<td>Pakistan</td>
</tr>
<tr>
<td>N-P-166</td>
<td>Improvement of oral feeding due to electrical stimulation in children with primary dysphagia</td>
<td>Katarzyna Kawalska, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-167</td>
<td>Improvement of oral feeding due to electrical stimulation in children with primary dysphagia</td>
<td>Katarzyna Kawalska, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-168</td>
<td>Improvement of biting skills during feeding therapy</td>
<td>Raluca Maria Vlad, Romania</td>
<td>Romania</td>
</tr>
<tr>
<td>N-P-169</td>
<td>Retrospective evaluation of our patients with percutaneous endoscopic gastrostomy</td>
<td>Maria Del Carmen Rivero de la Rosa, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>N-P-170</td>
<td>Occurrence and levels of aflatoxin M1 and ochratoxin A in human milk of lactating mothers</td>
<td>Nezha Mouane, Morocco</td>
<td>Morocco</td>
</tr>
<tr>
<td>N-P-171</td>
<td>The composition of gut microbiota and its associations with BMI, adiposity and stool short chain fatty acids in obese children</td>
<td>Chonnikant Visuthranukul, Thailand</td>
<td>Thailand</td>
</tr>
<tr>
<td>N-P-172</td>
<td>Glycation level of milk protein strongly modulates post-prandial plasma lysine availability in vivo in humans</td>
<td>Glenn A.A. van Lieshout, The Netherlands</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>N-P-173</td>
<td>The timing of complementary feeding introduction and feeding difficulties in childhood: a systematic review</td>
<td>Anna Pia Delli Bovi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-174</td>
<td>The gut microbiota of exclusively breastfed infants: a world-wide analysis showing a dominance of bifidobacteria, despite pronounced regional differences in species composition</td>
<td>Olga Sakwinska, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>N-P-175</td>
<td>Respiratory and diarrhoeal infections in the microbiota and health prospective cohort of Bangladeshi infants under two years of age</td>
<td>Karine Vidal, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>N-P-176</td>
<td>Exploration of specific nutritional deficits in very low birth weight infants with extrauterine growth restriction</td>
<td>Yi Xiang, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-177</td>
<td>Maternal feeding attitudes, infant eating behaviour and exclusive breastfeeding: data from a multi-centre study</td>
<td>Jinyue Yu, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>N-P-178</td>
<td>A systematic review: Fatty acid composition of mature human milk in China</td>
<td>MengYa Zhao, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-179</td>
<td>Factors impacting postoperative growth in infants with congenital heart disease</td>
<td>Xu Zhuoming, China</td>
<td>China</td>
</tr>
<tr>
<td>N-P-180</td>
<td>Estimation of vitamin D deficiency in healthy school-age children: current status in Italy</td>
<td>Tiziana Galeazzi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-181</td>
<td>Mediterranean diet: let’s give the scores!</td>
<td>Fulya Gülerman, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>N-P-182</td>
<td>Measurement of body composition using bioelectrical impedance analysis: effects of obesity, physical activity</td>
<td>Anna Kasyanova, Russia</td>
<td>Russia</td>
</tr>
<tr>
<td>N-P-183</td>
<td>Feeding behaviours of healthcare professional mothers for their 0-24 month-old children</td>
<td>Anna Pia Delli Bovi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>N-P-184</td>
<td>Improvement of oral feeding due to electrical stimulation in children with primary dysphagia</td>
<td>Katarzyna Kawalska, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-185</td>
<td>Retrospective evaluation of our patients with percutaneous endoscopic gastrostomy</td>
<td>Katarzyna Babik, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>N-P-186</td>
<td>Improvement of biting skills during feeding therapy</td>
<td>Raluca Maria Vlad, Romania</td>
<td>Romania</td>
</tr>
<tr>
<td>N-P-187</td>
<td>Investigation of nutrition management in children with ECMO after congenital heart surgery</td>
<td>Yueyue Zhang, China</td>
<td>China</td>
</tr>
</tbody>
</table>
Abstract Reviewers

ESPGHAN would like to thank all Abstract Reviewers for their contribution to a successful Annual Meeting:

Mona Abdel-Hady
Elie Abi Nader
Nadeem Afzal
Daniel Agardh
Carlo Agostoni
Mansoor Ahmed
Rayna Alamurova
Fatima Safira Alatas
Irena Aldhoon-Hainerova
Matthieu Allez
Marina Aloï
Jorge Amil Dias
Mirna Natalija Anicic
Andras Arato
J. Vicent Arcos
Machancoses
Oğdem Arıkan
James Ashton
Amit Assa
Renata Auricchio
Salvatore Auricchio
Naeem Ayub
Alastair Baker
Marcin Banasiuk
Hany Banoub
Andrew Barclay
Alkaterini Bargiota
Ulrich Baumann
Mark Beattie
Dominique Belli
Amir Ben-Tov
Marc Benninga
Beint Bentsen
Staffan Berglund
Hemant Bhavsar
Vishnu Biradar
Alexandra Bobarnac
Patrick Bontems
Vibhor Borkar
Osvaldo Borrelli
Sofia Bota
Samir Boukhir
Maria Victoria Bovo
Christian Braegger
Matteo Bramuzzo
Ronald Bremner
Ilse Broekaert
Efrat Brode
Jiri Bronsky
Pierre Broue
Elchanan Bruckheimer
Elaine Buchanan
Stephan Buderus
Yoram Bujanover
Martin Burdelski
Samy Cadranel
Jaoquim Calvo Lerma
Fiona Cameron
Angelo Campanozzi
Cristina Campoy
Katrine Carlsen
Isabel Casas Gallegos
Valeria Casotti
Gemma Castillejo
Carlo Catassi
Elena Cernat
Iain Chalmers
Atchariya Chanpong
Fabienne Charbit-Henrion
Christophe Chassard
Jeng Haw Cheng
Fang Kuan Chiu
Tracey Coelho
Maria Carmen Collado
Caeclie Crawley
Paula Crespo-Escobar
Nicholas Croft
Aron Cseh
Fugen Çullu Çokuğraş
Lorenzo D’Antiga
Gerard Damen
Giulia D’Arcangelo
Suzanne Davison
Ruth de Bruyne
Barbara de Koning
Lissy de Ridder
Thierry De Vreker
Dominique Debray
Rodrigo del Rio Castillo
David Devadason
Antal Dezsofi
Sarumathi Dhanapal
Teresa Di Chio
Angelo Di Giorgio
Tietie Dijkstra
Yulia Dmitrieva
Jernej Dolinšek
Magnus Domellöf
Natasa Dragutinovic
Joost Drent
Rémi Duclaux-Loras
Claire Dupont-Lucas
Ozlem Durmuş
Stine Dydensborg Sander
Marcin Dziekiewicz
Nils Ekvall
Yigal Ellenberg-Alter
Nicholas Embleton
Pablo Ercoli
Johanna Escher
Jessica Ezri
Jackie Falconer
Mary Fewtrell
Natasa Fidler Mis
Yigael Finkel
Bjorn Fischer
Diana Flynn
Maria Fotoulaki
Otilia-Elena Frasinariu
Michael Friedt
Raoul Furlano
Dolores García-Arenas
Victoria Garrick
Luca Garzoni
Marco Gasparetto
Edward Gaynor
Konstantinos Gerasimidis
Marta Germán Diaz
Marian Ghughunishvili
Edward Giles
Peter Gillett
Laurianne Giovannoni
Imeke Goldschmidt
Emmanuel Gonzales
Frédéric Gottrand
Enke Grabhorn
Tassos Grammatikopoulos
Melanie Greifer
Jenny Greig
Anne Griffiths
Alfredo Guarino
Girish Gupte
Figen Gurakan
Anat Guz Mark
Désirée Haafen-Visser
Richard Hansen
Steffen Hartleif
Jane Hartley
Corina Hartman
Almuthe Christina Hauer
Bruno Hauser
Paul Henderson
Denise Herzog
James Heubi
Klaas Heyland
Mel Heyman
Loreto Hierro
Johannes Hilberath
Susan Hill
Jonathan Hind
Andre Hoerning
Ilse Hoffman
Iva Hojsak
Bert Holvast
Matjaž Homan
Roderick Houwen
Lucy Howarth
Ondrej Hradsky
Tomas Hucl
Jessie Hulst
Steffen Husby
Seamus Hussey
Koen Huysentruyt
<table>
<thead>
<tr>
<th>Abstract Reviewers 2019</th>
<th>Abstract Reviewers 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warren Hyer</td>
<td>Sandhya Naik</td>
</tr>
<tr>
<td>Joanah Ikobah</td>
<td>Priya Narula</td>
</tr>
<tr>
<td>Giuseppe Indolfi</td>
<td>Antal Nemeth</td>
</tr>
<tr>
<td>Flavia Indrio</td>
<td>Jiri Nevoral</td>
</tr>
<tr>
<td>Tytti Jaakkola</td>
<td>Emanuele Nicastro</td>
</tr>
<tr>
<td>Jörg Jahnel</td>
<td>Tsunel Girma Nigatu</td>
</tr>
<tr>
<td>Christian Jakobsen</td>
<td>Komnilia Nikaki</td>
</tr>
<tr>
<td>Andreas Jenke</td>
<td>Lena Niseto</td>
</tr>
<tr>
<td>Binita Joshi</td>
<td>Andrea Florina Nita</td>
</tr>
<tr>
<td>Norman Junge</td>
<td>Valerio Nobili</td>
</tr>
<tr>
<td>Ahmed Kadir</td>
<td>Sara Nöbrega</td>
</tr>
<tr>
<td>Panayota Kafritsa</td>
<td>Lorenzo Norsa</td>
</tr>
<tr>
<td>Aikaterini Kakotrichi</td>
<td>Jan Nowak</td>
</tr>
<tr>
<td>Nicolas Kalach</td>
<td>Maree Yaa Nyarkon</td>
</tr>
<tr>
<td>Jochen Kammermeier</td>
<td>Andreas Nydegger</td>
</tr>
<tr>
<td>Ino Kanavaki</td>
<td>Giuseppina Oderda</td>
</tr>
<tr>
<td>Eva Karaskova</td>
<td>Salvatore Oliva</td>
</tr>
<tr>
<td>Savvas V Karkelis</td>
<td>Grzegorz Oracz</td>
</tr>
<tr>
<td>Stavroula Karyda</td>
<td>Rok Orel</td>
</tr>
<tr>
<td>Alemka Jaklin Kekez</td>
<td>Anders Paerregaard</td>
</tr>
<tr>
<td>Paul Kelly</td>
<td>Alexandra Papadopoulou</td>
</tr>
<tr>
<td>Zahra Khan</td>
<td>Raj Singh Parmar</td>
</tr>
<tr>
<td>Katayoun Khatami</td>
<td>Andrea Pärniczky</td>
</tr>
<tr>
<td>Seung Kim</td>
<td>Bernadeta Patro-Golab</td>
</tr>
<tr>
<td>Fevrosia Kiparissi</td>
<td>Joanna Pawlowska</td>
</tr>
<tr>
<td>Martina Klemenak</td>
<td>Licia Pensabene</td>
</tr>
<tr>
<td>Jutta Koegelmeier</td>
<td>Noel Peretti</td>
</tr>
<tr>
<td>Denizta Kofinova</td>
<td>Enrique Pérez-Cuadrado</td>
</tr>
<tr>
<td>Henrik Köhler</td>
<td>Robles</td>
</tr>
<tr>
<td>Sanja Kolaček</td>
<td>Laetitia-Marie Petit</td>
</tr>
<tr>
<td>Berthold Koletzko</td>
<td>Eva Pfister</td>
</tr>
<tr>
<td>Sibylle Koletzko</td>
<td>Alan Phillips</td>
</tr>
<tr>
<td>Anastasia Konidari</td>
<td>Judith Pichler</td>
</tr>
<tr>
<td>Bart Koot</td>
<td>Sara Mancell</td>
</tr>
<tr>
<td>Michal Kori</td>
<td>Roberta Mandile</td>
</tr>
<tr>
<td>Kallirroi Kotilea</td>
<td>Jake Mann</td>
</tr>
<tr>
<td>Daniel Kotlarz</td>
<td>Karl Mářil</td>
</tr>
<tr>
<td>Florence Lacaille</td>
<td>Luise Marino</td>
</tr>
<tr>
<td>Alain Lachaux</td>
<td>Javier Martin de Carpi</td>
</tr>
<tr>
<td>Christophe Laproix</td>
<td>Massimo Martinelli</td>
</tr>
<tr>
<td>Kelly Larmour</td>
<td>Johanna Martinez Osorio</td>
</tr>
<tr>
<td>Mauricio Larrarte King</td>
<td>Emmanuel Mas</td>
</tr>
<tr>
<td>Noémie Laverdure</td>
<td>Manar Matar</td>
</tr>
<tr>
<td>Dariusz Lebensztejn</td>
<td>Lorena Matarazzo</td>
</tr>
<tr>
<td>Emanuel Lubenthal</td>
<td>Patricia McClean</td>
</tr>
<tr>
<td>Huey Miin Lee</td>
<td>Patrick McKiernan</td>
</tr>
<tr>
<td>Hélène Lengliné</td>
<td>Valérie McLin</td>
</tr>
<tr>
<td>Michael Lentze</td>
<td>Luisa Meairin</td>
</tr>
<tr>
<td>Aaron Lerner</td>
<td>Jan Melek</td>
</tr>
<tr>
<td>Raffi Lev-Tzion</td>
<td>Victoria Merrick</td>
</tr>
<tr>
<td>Delphine Ley</td>
<td>Assylzhvan Messova</td>
</tr>
<tr>
<td>Daniela Liccardo</td>
<td>Dusanka Micetic-Turk</td>
</tr>
<tr>
<td>Rosa Maria Lima</td>
<td>Erasmo Miele</td>
</tr>
<tr>
<td>Torbjörn Lind</td>
<td>Walter A. Mihtsch</td>
</tr>
<tr>
<td>Elena Lionetti</td>
<td>Zrinka Mišak</td>
</tr>
<tr>
<td>Paolo Lionetti</td>
<td>Mar Miserachs</td>
</tr>
<tr>
<td>Carla Lloyd</td>
<td>Maria Mislou</td>
</tr>
<tr>
<td>Andrea Lo Vecchio</td>
<td>Sally Mitton</td>
</tr>
<tr>
<td>Ines Loverdos</td>
<td>Line Modin</td>
</tr>
<tr>
<td>Eberhard Lurz</td>
<td>Nicolette Moes</td>
</tr>
<tr>
<td>Thomas MacDonald</td>
<td>Nurul Husna Mohd Shukri</td>
</tr>
<tr>
<td>Sarah MacDonald</td>
<td>Christian Malgaard</td>
</tr>
<tr>
<td>Giuseppe Maggiore</td>
<td>Helena Moreira-Silva</td>
</tr>
<tr>
<td>János Major</td>
<td>Nezha Mouane</td>
</tr>
<tr>
<td></td>
<td>Yael Mozzer-Glassberg</td>
</tr>
<tr>
<td></td>
<td>Rafeeq Mohammed</td>
</tr>
<tr>
<td></td>
<td>Thomas Müller</td>
</tr>
<tr>
<td></td>
<td>Katalin Müller</td>
</tr>
<tr>
<td></td>
<td>Simon Murch</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**www.espghancongress.org 141**
ESPghan has a variety of educational activities, events and information that are available throughout the year.

**ESPghAN Education Partner Programme**

The ESPghan Education Partner Programme (EPP) was launched in 2015. Based on the adopted ESPghan Code of Conduct, the EPP has been developed and implemented to ensure the on-going development and implementation of an up-to-date, independent, high quality educational programme for health care professionals. The dedicated support and financial commitment from our founding partners helps to enhance support for ESPghan’s educational activities.

The EPP educational activities for 2019 can be viewed on our website in the Meetings and Events section: [www.espghan.org/meetings-and-events](http://www.espghan.org/meetings-and-events)

In addition to our established and very successful Summer Schools and the Young Investigator Forum that address primarily colleagues in subspecialty and research training, we are delighted to offer Master Classes that focus on a specific topic and are open to all ESPghan members with an active interest in the field.

**ESPghan’s EPP Partners in 2019 are:**

[Image of logos]

On behalf of ESPghan and its members, I wish to thank our EPP partners for their generous support and their commitment which is greatly appreciated indeed.

Raanan Shamir
ESPghan President

### Education Partner Programme

<table>
<thead>
<tr>
<th>Events</th>
<th>Date</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESPghan Mentorship Training</td>
<td>March 22–23, 2019</td>
<td>Porto, Portugal</td>
</tr>
<tr>
<td>ESPghan Monothematic Conference on the Gastrointestinal, Hepatologic and Nutritional Aspects of Cystic Fibrosis</td>
<td>April 04–05, 2019</td>
<td>Valencia, Spain</td>
</tr>
<tr>
<td>ESPghan Endoscopy Course</td>
<td>June 19–23, 2019</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>ESPghan GI Summer School</td>
<td>June 26–29, 2019</td>
<td>Montecatini, Italy</td>
</tr>
<tr>
<td>ESPghan Nutrition Summer School</td>
<td>July 01–05, 2019</td>
<td>Lago Maggiore, Italy</td>
</tr>
<tr>
<td>ESPghan AHP Summer School</td>
<td>September 12–15, 2019</td>
<td>Oxford or Cambridge, UK</td>
</tr>
<tr>
<td>ESPghan Young Investigator Forum</td>
<td>September 18–21, 2019</td>
<td>Bergen, the Netherlands</td>
</tr>
<tr>
<td>ESPghan Eastern European Summer School: A glance of paediatric gastroenterology, hepatology and nutrition in Eastern Europe</td>
<td>September 20–23, 2019</td>
<td>Varna, Bulgaria</td>
</tr>
<tr>
<td>ESPghan 5th IBD Masterclass</td>
<td>November 28–30, 2019</td>
<td>Malaga, Spain</td>
</tr>
<tr>
<td>ESPghan Monothematic Conference: Acute Liver Failure</td>
<td>Jan. 30 – Feb. 01, 2020</td>
<td>Athens, Greece</td>
</tr>
</tbody>
</table>

The ESPghan Education Partner Programme is based on educational grants and has been developed to ensure the on-going development and implementation of an up-to-date, independent, high quality educational programme for health care professionals.

More details on the ESPghan Educational Partner Programme and all ESPghan educational events can be found on our website: [www.espghan.org](http://www.espghan.org).
Congress Sponsors

The organiser would like to thank the following companies for their generous support of the ESPGHAN 52nd Annual Meeting.

Diamond

Abbott

Nestlé

Wyeth Nutrition

Platinum

Alexion

HiPP

Mead Johnson Nutrition

Nutricia

Silver

AbbVie

BioGaia

Jennessen

Novalac

Ymini

Bronze

Advanced Lipids

Arla Foods Ingredients

Ausnutria

AVANOS

CHR Hansen

Dairy Goat Co-operative

Finnland Componente Ingredients

Chrome

AMT

BASF

Baxter

Biocodex

Bühlmann

Dicofarm

Eurospital

Kendal Nutrition

CT RS

Novventure

Vaneeghen
Endoscopy Learning Zone Tutors 2019

<table>
<thead>
<tr>
<th>BEGINNERS</th>
<th>ELZ 1 Friday, 07 June 2019</th>
<th>ELZ 3 Saturday, 08 June 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper Endoscopy</td>
<td>Paul Henderson</td>
<td>Rok Orel</td>
</tr>
<tr>
<td>Upper Endoscopy</td>
<td>Luigi Dall’Oglio</td>
<td>Claudio Romano</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Gabor Veres</td>
<td>Andrew Barclay</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Simona Faraci</td>
<td>Rachel Tayler</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Matjaž Homan</td>
<td>Arun Urs</td>
</tr>
<tr>
<td>Gastrostomy placement</td>
<td>Erasmo Miele</td>
<td>Warren Hyer</td>
</tr>
<tr>
<td>Gastrostomy placement</td>
<td>Jérôme Viala</td>
<td>Alexandra Papadopoulou</td>
</tr>
<tr>
<td>The Endoscopist’s Toolbox</td>
<td>Ari Silbermintz</td>
<td>Samy Cadranel</td>
</tr>
<tr>
<td>Capsule Endoscopy</td>
<td>Ronald Bremner</td>
<td>Priya Narula</td>
</tr>
<tr>
<td>Foreign Bodies Removal</td>
<td>Claudio Romano</td>
<td>Jorge Amil-Dias</td>
</tr>
<tr>
<td>Endoscopy Simulator</td>
<td>Natalia Nedokopoulou</td>
<td>Shishu Sharma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADVANCED</th>
<th>ELZ 2 Friday, 07 June 2019</th>
<th>ELZ 4 Saturday, 08 June 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophageal / Varices banding</td>
<td>Simona Faraci</td>
<td>Patrick Bontems</td>
</tr>
<tr>
<td>Polypectomies +/- clips</td>
<td>Matjaž Homan</td>
<td>Warren Hyer</td>
</tr>
<tr>
<td>Gastric Varices bleeding</td>
<td>Ari Silbermintz</td>
<td>Douglas Fishman</td>
</tr>
<tr>
<td>Esophageal balloon dilatation</td>
<td>Frédéric Gottrand</td>
<td>Ronald Bremner</td>
</tr>
<tr>
<td>Foreign Bodies Removal</td>
<td>Rok Orel</td>
<td>Jorge Amil-Dias</td>
</tr>
<tr>
<td>Gastrostomy placement</td>
<td>Erasmo Miele</td>
<td>Gabor Veres</td>
</tr>
<tr>
<td>Gastrostomy placement</td>
<td>Jérôme Viala</td>
<td>Arun Urs</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Patrick Bontems</td>
<td>Andrew Barclay</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Muftah Eltumi</td>
<td>Rachel Tayler</td>
</tr>
<tr>
<td>Capsule Endoscopy</td>
<td>Priya Narula</td>
<td>Muftah Eltumi</td>
</tr>
<tr>
<td>Endoscopy Simulator</td>
<td>David Troendle</td>
<td>Salvatore Oliva</td>
</tr>
</tbody>
</table>

Endoscopy Learning Zone

The ESPGHAN 52nd Annual Meeting hosts this year again an Endoscopy Learning Zone. The ELZ is located in the exhibition hall.

Endoscopy Learning Zone

The Endoscopy Learning Zone will provide hands-on training in the following diagnostic and therapeutic endoscopy techniques:
- Capsule endoscopy
- Colonoscopy
- Endoscopy simulator
- Esophageal balloon dilatation
- Esophageal / varices banding
- Foreign body removal
- Gastrostomy placement
- Gastric varices bleeding
- Polypectomies
- Upper endoscopy
- The endoscopist’s toolbox

The training will be on biologic models and mannequins to achieve optimum simulation and interaction. The hands-on training will be supervised by some of the most experienced paediatric endoscopists in Europe.

The Endoscopy Learning Zone training sessions are restricted to a very limited number of places. If you have booked to attend one of the sessions please ensure that you show up on time.
The Endoscopy Learning Zone is generously supported by the following companies to which we are very grateful for their contribution:

**Aquilant**

Aquilant is proud to be the UK’s sole distributor of Fujifilm endoscopy products, enormous investment by Fujifilm Japan since the 1990s has seen Fujifilm products remain consistently at the cutting edge of endoscope technology. The latest 7000 series processor utilises innovative 4-LED multi light technology and the 700 series range of endoscopes feature CMOS chip, anti-blur and close focus technology.

Fujifilm leads the way in detection and characterisation with the advanced observation modes, Blue Light Imaging (BLI) and Linked Colour Imaging (LCI) which provide clinicians with unsurpassed endoscopic visualisation.

Membership of the Healthcare 21 Group provides the solid foundation required for us to continue investing in the long-term development of the business. Our vision is to be recognised as commercially innovative, patient focussed and ultimately, as your partner of choice.

**Avanos**

Avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter.

Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.

Avanos delivers recognised brands (MIC*, MIC-KEY®, CORFLO*, ENTRAL*) and reliable Digestive Health solutions that help improve patient outcomes and quality of life, particularly for patients in need of supplemental nutrition delivery through enteral feeding.

For more information, visit www.avanosmedicaldevices.com/digestive-health

**Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

In endoscopy, we develop technologies for diagnosing and treating diseases of the digestive system, airway and lungs, such as malignant and benign tumors, gastrointestinal diseases and cancers, abscesses as well as pulmonary diseases, including severe asthma.

For more information, visit www.bostonscientific.com

**Diagmed Healthcare Ltd**

Diagmed Healthcare Ltd is an independent, family owned distributor of numerous Gold Standard devices. By continuously striving to improve our service and offering for over 35 years we have remained relevant and competitive in an increasingly globalized market place. Our values of honesty, open communication, integrity and passion for our products and services allows us to meet and exceed customer expectations and ultimately benefit the patients.

For more information, visit http://diagmed.healthcare
The Endoscopy Learning Zone is generously supported by the following companies to which we are very grateful for their contribution:

**Erbe**

VIO3 from Erbe – “power your performance”

Erbe have shaped electrosurgery, developing it into today’s leading-edge technology, making Erbe an essential and reliable partner for many users worldwide.

VIO3 is yet another of our milestones in electro-surgical technology.

VIO3 has the right mode for all GI applications and with its logical and intuitive interface the VIO3 is designed to be optimally user-friendly.

The VIO3 combined with APC3 and the Erbe Jet 2 system provide the complete workstation for the most complex advanced endoscopic procedures.

---

**OKB Medical**

OKB Medical specialise in providing unique and innovative healthcare products in the UK for use in a range of medical disciplines and in the training of surgical skills.

3D Systems is the world’s leading producer of simulators for medical professionals and is at the cutting-edge of Virtual Reality Simulation Technology. Each simulator platform has been designed with medical specialists, encompassing all the necessary training elements from Basic Skills Practice through to complex Full Procedures.

The Simbionix GI MentorTM Express Endoscopy Simulator is available in the Endoscopy Learning Zone Area.

For more information, visit www.okbmedical.com

---

**PENTAX Medical**

PENTAX Medical is an established leading provider of flexible endoscopy products and accessories designed to meet a wide range of clinical and economic needs across a spectrum of clinical specialties including Gastroenterology, Pulmonology, Urology and ENT. Our mission is to improve the standard of patient care and quality of healthcare delivery with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY.

For more information, visit https://www.pentaxmedical.com

---

**Olympus**

Olympus delivers a wide range of specialist paediatric diagnostic and therapeutic technologies such as gastrointestinal endoscopes, surgical endoscopy systems, and other peripherals, covering early diagnosis to minimally invasive therapy to provide the best possible outcomes for patients and society. This year, Olympus celebrates 100 years of making people’s lives healthier, safer and more fulfilling around the world.

For more information, visit https://www.olympus.co.uk/medical/en/Home

---

**3D Systems**

3D Systems is the world’s leading producer of simulators for medical professionals and is at the cutting-edge of Virtual Reality Simulation Technology. Each simulator platform has been designed with medical specialists, encompassing all the necessary training elements from Basic Skills Practice through to complex Full Procedures.

The Simbionix GI MentorTM Express Endoscopy Simulator is available in the Endoscopy Learning Zone Area.

For more information, visit www.okbmedical.com
Breakfast Symposium

**Inspired by Human Milk Research**

**Time:** 07:15 – 08:15  
**Room:** Hall 3  
**Chair:** Bo Lönnerdal, USA

- **07:15** Protein: what did we learn from human milk  
  Sagar Thakkar, Singapore

- **07:45** The long term impact of early nutrition  
  Ferdinand Haschke, Austria

---

**Long Term Health Outcomes: The Role of Early Childhood Nutrition**

**Date:** Thursday, 6 June 2019  
**Location:** Glasgow, Scotland  
Scottish Event Campus (SEC) - Lomond Hall  
**Time:** 07:15 - 08:15

**The Role of Early Childhood Nutrition on Later Life**  
Rosan Meyer, RD, PhD Paediatric Dietitian  
Honorary Senior Lecturer, Imperial College, London, England

**How Intestinal Bacteria Modulate The Immune Response; Studies in “Humanized” Gnotobiotic Mice**  
Cathryn Nagler, PhD  
Professor of Pathology, Medicine, Pediatrics and the College Biological Sciences Division, The University of Chicago, USA

**Nutrition for Cognitive, Health and LT Performance. Benefits of Feeding a Milk Fat Globule Membrane (MFGM)**  
Javier Fontecha Alonso, PhD  
Researcher, Spanish National Research Council (CSIC) at Institute of Food Science Research (CIAL-UAM), Madrid, Spain

**Moderator:**  
Rosan Meyer  
Honorary Senior Lecturer, Imperial College, London, England

---

**Breakfast Symposium**

**Time:** 07:15 – 08:15  
**Room:** Lomond Hall  
**Chair:** Rosan Meyer, United Kingdom

- **07:15** The Role of Early Childhood Nutrition on Later Life  
  Rosan Meyer, United Kingdom

- **07:25** How Intestinal Bacteria Modulate The Immune Response; Studies in “Humanized” Gnotobiotic Mice  
  Cathryn Nagler, USA

- **07:45** Nutrition for Cognitive, Health and LT Performance. Benefits of Feeding a Milk Fat Globule Membrane (MFGM)  
  Javier Fontecha Alonso, Spain

- **08:05** Q&A  
  Rosan Meyer, United Kingdom
Satellite Symposia – Information

Breakfast Symposium

Thursday, 06 June 2019

Next Generation of infant formula – prebiotics, postbiotics and HMOs to support the immune system through the gut

<table>
<thead>
<tr>
<th>Time</th>
<th>07:15 – 08:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Hall 2</td>
</tr>
<tr>
<td>Chair</td>
<td>Hania Szajewska, Poland</td>
</tr>
</tbody>
</table>

07:15 Critical milestones in infant formula – how close we can get to breastmilk
Hania Szajewska, Poland

07:35 The next generation of infant formula – how composition meets functionality
Bernd Stahl, The Netherlands

07:55 The exciting potential of prebiotics, postbiotics and HMOs to support the immune system through the gut
Flavio Indrio, Italy

Lunch Symposium

Thursday, 06 June 2019

Human Milk Oligosaccharides and Their potential in Immune System Development

<table>
<thead>
<tr>
<th>Time</th>
<th>13:00 – 14:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Clyde Hall</td>
</tr>
<tr>
<td>Chair</td>
<td>Hania Szajewska, Poland</td>
</tr>
</tbody>
</table>

13:00 Human milk oligosaccharides as primers for the microbiome and immune system?
Lars Bode, USA

13:30 The Gut Microbiome and its Role in Early Immune Development and Allergies
Liam O’Mahony, Ireland

13:45 The Role of Human Milk Oligosaccharides in Allergy Management
Yvan Vandenplas, Belgium
Satellite Symposia – Information

Lunch Symposium  
Thursday, 06 June 2019

2’-Fucosyllactose: An Allergy Modulating Human Milk Oligosaccharide?

Time: 13:00 – 14:00  
Room: Hall 2  
Chair: Ardythe L. Morrow, USA

13:00 The Role of Human Milk Oligosaccharide (HMO) in Infant Nutrition  
Ardythe L. Morrow, USA

13:25 2’-Fucosyllactose: An Allergy Modulating Human Milk Oligosaccharide?  
Paul Forsythe, Canada

13:50 Q&A  
All Faculty

Lunch Symposium  
Thursday, 06 June 2019

When breast milk turns into a true challenge 2.0!

Time: 13:00 - 14:00  
Room: Lomond Hall  
Chair: Florence Lacaille, France

13:00 Welcome and Introduction  
Florence Lacaille, France

13:05 When the initial challenge of breast milk was mastered well!  
Florence Lacaille, France

13:25 Our Babies grow – so do their appetites and needs  
Suresh Vijay, United Kingdom

13:45 Q&A  
All Faculty
Satellite Symposia – Information

Evening Symposium

One Vision: Bringing Together Physicians and Patients to Achieve Their Goals

<table>
<thead>
<tr>
<th>Time</th>
<th>18:30 – 19:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Hall 2</td>
</tr>
<tr>
<td>Chair</td>
<td>Dan Turner, Israel</td>
</tr>
</tbody>
</table>

- **18:30** Disease Remission: I Want It All
  - Dan Turner, Israel
- **18:40** Under Pressure: Physicians’ Perspectives on Setting Goals
  - Amit Assa, Israel
- **18:57** I Want to Break Free: Supporting Patients to Achieve Their Goals
  - Nick Croft, United Kingdom
- **19:14** Don’t Stop Me Now: Understanding How Physicians’ and Patients’ Goals Can Align
  - All faculty
- **19:24** Q&A and Closing Remarks
  - All faculty

Evening Symposium

Why do we need dietary therapy in Crohn’s disease in an era of biologics?

<table>
<thead>
<tr>
<th>Time</th>
<th>18:30 – 19:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Hall 3</td>
</tr>
<tr>
<td>Chair</td>
<td>Frank Ruemmele, France</td>
</tr>
</tbody>
</table>

- **18:30** Why do we need nutrition therapy in an era of biologics?
  - David Wilson, United Kingdom
- **18:40** What are the targets for dietary therapy?
  - Rotem Sigall-Boneh, Israel
- **18:50** Present state of the art on Dietary management in Crohn’s Disease
  - Eytan Wine, Canada
- **19:10** The new kid on the block: The Crohn’s Disease Exclusion Diet for induction of remission
  - Arie Levine, Israel

Breakfast Symposium

Human Microbiota Shift; Consequences and Opportunities

<table>
<thead>
<tr>
<th>Time</th>
<th>07:15 – 08:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Hall 2</td>
</tr>
<tr>
<td>Chair</td>
<td>Paul Cotter, Ireland</td>
</tr>
</tbody>
</table>

- **07:15** Disorders Impacted By The Gut Microbiome, Opportunities For Microbiome Manipulation
  - Jon A. Vanderhoof, USA
- **07:35** Probiotic Solutions to Dysbiotic Drift: the need for integrative ecological approaches for the health of Person, Place and Planet
  - Susan Prescott, Australia
- **07:55** Q&A
  - All Faculty
## Satellite Symposia – Information

### Breakfast Symposium
Friday, 07 June 2019

**It’s All About the Mother: Maternal Factors Influencing Human Milk Composition**

**Time** 07:15 – 08:15  
**Room** Lomond Hall  
**Chair** Catherine Stanton, Ireland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15</td>
<td><strong>Milk Microbiome: Origin and Impact of Maternal Diet?</strong></td>
<td>Michelle McGuire, USA</td>
</tr>
<tr>
<td>07:45</td>
<td><strong>Current Insights into Maternal Genetic Contribution to Human Milk Composition</strong></td>
<td>Janet Williams, USA</td>
</tr>
</tbody>
</table>

### Breakfast Symposium
Friday, 07 June 2019

**L. reuteri DSM 17938 in Functional GI Disorders and beyond – The potential role in infection protection and fighting antibiotic resistance**

**Time** 07:15 – 08:15  
**Room** Hall 3  
**Chair** Ruggiero Francavilla, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15</td>
<td><strong>Evidence on L. reuteri DSM 17938 in functional GI disorders</strong></td>
<td>Hania Szajewska, Poland</td>
</tr>
<tr>
<td></td>
<td><strong>New perspectives of L. reuteri DSM 17938 in preventing GI and upper respiratory infections</strong></td>
<td>Diego Peroni, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>Disruption of the infant gut microbiota emergence: can we prevent the clinical consequences?</strong></td>
<td>Alexis Mosca, France</td>
</tr>
</tbody>
</table>
**Sponsors & Exhibitors List**

<table>
<thead>
<tr>
<th>Company</th>
<th>Country</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-BIOTICS</td>
<td>Spain</td>
<td>34</td>
</tr>
<tr>
<td>ABBOTT</td>
<td>USA</td>
<td>12</td>
</tr>
<tr>
<td>AbbVie</td>
<td>USA</td>
<td>–</td>
</tr>
<tr>
<td>Advanced Lipids</td>
<td>Israel</td>
<td>5</td>
</tr>
<tr>
<td>Alexion Pharma GmbH</td>
<td>Switzerland</td>
<td>14</td>
</tr>
<tr>
<td>Applied Medical Technology, Inc.</td>
<td>USA</td>
<td>19</td>
</tr>
<tr>
<td>Arla Foods Ingredients</td>
<td>Denmark</td>
<td>6</td>
</tr>
<tr>
<td>Association of European Coeliac Societies (AOECS)</td>
<td>Belgium</td>
<td>40</td>
</tr>
<tr>
<td>Ausnutria B.V.</td>
<td>The Netherlands</td>
<td>29</td>
</tr>
<tr>
<td>Avanos</td>
<td>Belgium</td>
<td>20</td>
</tr>
<tr>
<td>BASF</td>
<td>Germany</td>
<td>28</td>
</tr>
<tr>
<td>Baxter</td>
<td>Switzerland</td>
<td>26</td>
</tr>
<tr>
<td>Betapol – Bunge Loders Croklaan</td>
<td>The Netherlands</td>
<td>30</td>
</tr>
<tr>
<td>BINC – Geneva</td>
<td>Switzerland</td>
<td>16</td>
</tr>
<tr>
<td>BIOCODEX</td>
<td>France</td>
<td>17</td>
</tr>
<tr>
<td>BioGaia</td>
<td>Sweden</td>
<td>7</td>
</tr>
<tr>
<td>BÜHLMANN Laboratories AG</td>
<td>Switzerland</td>
<td>18</td>
</tr>
<tr>
<td>Children's Liver Disease Foundation (CLDF)</td>
<td>United Kingdom</td>
<td>38</td>
</tr>
<tr>
<td>Chr. Hansen A/S</td>
<td>Denmark</td>
<td>9</td>
</tr>
<tr>
<td>Dairy Goat Co-operative (N.Z.) Ltd.</td>
<td>New Zealand</td>
<td>8</td>
</tr>
<tr>
<td>DEKAvitamins.com/Callon Pharma</td>
<td>The Netherlands &amp; USA</td>
<td>43</td>
</tr>
<tr>
<td>DICOFARM</td>
<td>Italy</td>
<td>27</td>
</tr>
<tr>
<td>European Federation for the Care of Newborn Infants (EFCNI)</td>
<td>Germany</td>
<td>39</td>
</tr>
<tr>
<td>European Foundation for the Care of Newborn Infants (EFCNI)</td>
<td>Germany</td>
<td>41</td>
</tr>
<tr>
<td>Eurospital S.p.A.</td>
<td>Italy</td>
<td>31</td>
</tr>
<tr>
<td>FrieslandCampina</td>
<td>The Netherlands</td>
<td>10</td>
</tr>
<tr>
<td>FrieslandCampina Ingredients</td>
<td>The Netherlands</td>
<td>4</td>
</tr>
<tr>
<td>HiPP</td>
<td>Germany</td>
<td>15</td>
</tr>
<tr>
<td>IMMUNDIAGNOSTIK AG</td>
<td>Germany</td>
<td>32</td>
</tr>
<tr>
<td>Inbiose NV</td>
<td>Belgium</td>
<td>46</td>
</tr>
<tr>
<td>Jennewein Biotechnologie GmbH</td>
<td>Germany</td>
<td>1</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>Switzerland</td>
<td>33</td>
</tr>
<tr>
<td>Kendal Nutricare Ltd.</td>
<td>United Kingdom</td>
<td>22</td>
</tr>
<tr>
<td>Laboratoires CTRS</td>
<td>France</td>
<td>24</td>
</tr>
<tr>
<td>MDPI</td>
<td>Switzerland</td>
<td>45</td>
</tr>
<tr>
<td>Mead Johnson Nutrition</td>
<td>USA</td>
<td>11</td>
</tr>
<tr>
<td>Miris AB</td>
<td>Sweden</td>
<td>23</td>
</tr>
<tr>
<td>Nestlé</td>
<td>Switzerland</td>
<td>13</td>
</tr>
<tr>
<td>NOVALAC</td>
<td>France</td>
<td>2</td>
</tr>
<tr>
<td>Noventure</td>
<td>Spain</td>
<td>25</td>
</tr>
<tr>
<td>Nutricia</td>
<td>The Netherlands</td>
<td>3</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Company Limited</td>
<td>Japan</td>
<td>36</td>
</tr>
<tr>
<td>vaneeghen</td>
<td>The Netherlands</td>
<td>47</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>United Kingdom</td>
<td>42</td>
</tr>
<tr>
<td>Wyeth Nutrition</td>
<td>Switzerland</td>
<td>21</td>
</tr>
<tr>
<td>Yili Maternal and Infant Nutrition Institute (YMINI)</td>
<td>China</td>
<td>–</td>
</tr>
</tbody>
</table>

**as of 26 April 2019**
2'-FUCOSYLLACTOSE: AN ALLERGY MODULATING HUMAN MILK OLIGOSACCHARIDE?

Thursday, 6 June, 13:00–14:00, Hall 2

TOPIC:
2'-FL HMO & Allergy
Learn about the emerging role of 2'-fucosyllactose (2'-FL) human milk oligosaccharide (HMO) in allergy modulation as well as its role in shaping the human gut microbiome, immunity and more.

SPEAKERS:
Professor Ardythe Morrow, PHD
Cincinnati Children’s Hospital, USA

Associate Professor Paul Forsythe, PHD
McMaster University, Canada

LIVE Q&A SESSION WITH SPEAKERS AT THE ABBOTT BOOTH
Thursday, 6 June, 16:30–17:00, Booth 12
Join us at BOOTH #12 for a Q&A session with our speakers, Dr. Ardythe Morrow and Dr. Paul Forsythe, where you’ll have an opportunity to ask questions about the evidence presented at the symposium.
At Abbott, we’re all about helping you live the best life you can through good health. We keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health. Every day and around the world, we’re discovering new ways to make life better.

AB-Biotics is a global biotechnology company focused on well-documented probiotics and precision medicine. Pharmaceutical, dietary supplement and functional food industries under B2B premises are our main partners. Our probiotics for children, AB-KOLICARE and AB-KOLICARE DIGEST are marketed worldwide under different brand names.

At ANHI, our mission is to connect and empower people through science-based nutrition resources to optimize health worldwide. Our goal is to make it easier for you to help your patients be well-nourished.

EDUCATION • CONFERENCES • RESOURCES

LEARN MORE ABOUT ANHI OR TAKE A COURSE TODAY BY VISITING ANHI.ORG

VISIT US AT BOOTH #12
CONFIDENCE IS MIC-KEY* SF
Empower families to feel confident with tube feeding.

Come and see our latest innovation at booth number 20

We are a global, research-based biopharmaceutical company dedicated to developing and delivering a consistent stream of innovative medicines. We are driven by cutting-edge science and passionate people on a relentless pursuit to discover new and better outcomes, which go beyond care, to transform the lives of patients living with inflammatory bowel disease and other autoimmune diseases. For more information about AbbVie, please visit us at www.abbvie.co.uk

Advanced Lipids is a joint venture between Frutarom, a global leader in the fields of taste and health, and AAK, a global provider of value-adding vegetable oils and fats to the infant formula industry and many other industries. Combining Frutarom’s clinical and chemical expertise in lipid technologies with AAK’s international strength in food safety, production and logistics, Advanced Lipids offers a unique package of clinical research, development, flexible blending, quality and logistics.
<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Country</th>
<th>More information</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Switzerland</td>
<td><a href="http://www.alexion.com">www.alexion.com</a></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>USA</td>
<td><a href="http://www.appliedmedical.net">www.appliedmedical.net</a></td>
<td></td>
</tr>
</tbody>
</table>

**Alexion**

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies – Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP). Alexion also developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (gMG). Alexion focuses its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

**Applied Medical Technology, Inc. (AMT)**

AMT is a global leader and manufacturer of enteral feeding devices and accessories, providing the best medical device products to increase patient comfort and improve patient outcomes. Our products include the MiniONE® low-profile Balloon, Non-Balloon & Capsule Non-Balloon Buttons, G-JET™ low-profile Gastric-Jejunal Enteral Tube, Capsule Monarch® G-Tube, AMT Bridle™ Nasal Tube Retaining System, MiniACE™ low-profile Antegrade Continence Enema Button and the CINCH™ Tube Securement Device. All AMT products are proudly made in the USA!

**Could it be LAL-D?**

Lysosomal acid lipase deficiency (LAL-D): a life-threatening, underdiagnosed disease that can be ruled out with an ENZYMATIC BLOOD TEST*

*Reference:
### Lacprodan® MFGM-10

Supporting early life cognitive development

---

### Booth Directory Listing

<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Country</th>
<th>More Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Denmark</td>
<td><a href="http://www.arlafoodsingredients.com">www.arlafoodsingredients.com</a></td>
</tr>
<tr>
<td>40</td>
<td>Belgium</td>
<td><a href="http://www.aoecs.org">www.aoecs.org</a></td>
</tr>
</tbody>
</table>

**Arla Foods Ingredients**

**Discovering the wonders of whey**

Ingredients for the next generation: Our overriding goal is continuously developing a range of scientifically documented ingredients that resemble key functionalities in human milk. Used in infant formula they contribute to healthy growth and development of formula fed infants. Our dedicated infant nutrition and product development teams draw expertise from a broad base of specialists from academic key opinion leaders. As well as offering extensive support, our specialists work towards a common goal: to help you meet the current and future needs of both your business and your customers.

**AEOCS**

Founded in 1988, the Association of European Coeliac Societies (AEOCS) is an independent, non-profit organisation. It is the umbrella organisation of European national coeliac societies with currently 39 enrolled Member societies across Europe and internationally. AEOCS represents people who are affected by coeliac disease or dermatitis herpetiformis (DH) and seeks to collaborate with international coeliac organisations worldwide. The Association is actively involved in several international initiatives to raise awareness of coeliac disease, to promote research into the diagnosis and management of this illness.
Avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.

Avanos delivers recognised brands (MIC*, MIC-KEY*, CORFLO*, ENTRAL*) and reliable Digestive Health solutions that help improve patient outcomes and quality of life, particularly for patients in need of supplemental nutrition delivery through enteral feeding.

Kabrita infant formula is based on 100% Dutch goat milk. Goat milk has a number of natural characteristics, including the easy digestibility of goat milk protein. Maathuis et al. conclude that "the kinetics of protein digestion of the goat milk infant formula is more comparable to that of human milk than that of the cow’s milk infant formula" (JPGN 2017;65(6):661-6).
BASF, a leading player in the human nutrition industry, is a global supplier of high quality ingredients for a wide range of applications in early life nutrition, dietary supplements, pharmaceuticals as well as functional and medical nutrition. With our longstanding expertise offering a comprehensive product and service portfolio, BASF is well-positioned to offer nutritional solutions such as Human Milk Oligosaccharide 2'-Fucosyllactose (HMO 2'-FL), omega-3 and omega-6 fatty acids, lutein, vitamins to support future innovations for the early life nutrition market.

Baxter International Inc. provides a broad portfolio of essential hospital and renal products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Bunge Loders Croklaan is a trusted global producer and supplier of sustainable high-quality oils and fats. Its products are used in a wide range of applications, ranging from bakery and confectionery to culinary and infant nutrition. Over 30 years ago in the Netherlands, Loders Croklaan invented the process to accurately rearrange fatty acids on triglycerides without using chemicals. This process led to the development of Betapol® which mimics the unique Sn-2 fat structure found in breast milk. With it, we created the OPO category of infant milk formula and revolutionized the IMF market.

BINC GENEVA: A scientific platform for infant and maternal health
Biostime Institute for nutrition and care is a non-for profit foundation committed to advancing scientific cooperation and fostering research on maternal and infant health. We aim to stimulate science and research in Europe and to empower parents with information on the crucial early years of their child’s life.

BINC focuses on 5 research areas of expertise:
- Microbiota, allergies, infant brain development, nutrition and child obesity, maternal health
- BINC Geneva and BINC China is part of health and Happiness Group: a world global premium nutrition and lifetime wellness provider.
BioGaia is an innovative Swedish healthcare company and a world leader in probiotics with 28 years experience of developing, marketing and selling probiotic products. Over the years we have created networks of leading, independent researchers and specialists, manufacturing experts and local distribution partners worldwide. Our products are recommended by pediatricians and other healthcare professionals in more than 100 countries.

BioGaia’s products contain Lactobacillus reuteri, a probiotic bacteria that helps good microorganisms restore a natural balance in the gut. To date L. reuteri has been tested in more than 200 clinical trials (February 2019) and proven effective and safe in children and adults.

Calprotectin is the best marker for IBD/IBS diagnosis and IBD therapy follow up. With the new and easy to use IBDoc® calprotectin home test, invasive procedures can be avoided and the child and its parents are empowered for their disease management. BÜHLMANN has developed into THE CALPROTECTIN COMPANY with highest quality standards and its determination to increase the knowledge and application of calprotectin in pediatrics. BÜHLMANN’s new Quantum Blue® Infliximab and Adalimumab trough level rapid assays, are the first point of care tests that allow determination of biologics levels within 15 minutes.

Children's Liver Disease Foundation (CLDF) is a charity based in the UK. We take action against the effects of childhood liver disease, providing information, emotional support, family and young people’s services and projects, research funds and a voice for all affected. At least two children are diagnosed with a liver disease every day in the UK. CLDF is the only UK charity dedicated to fighting all forms of childhood liver disease.
Dairy Goat Co-operative (DGC) is the world's market leader for nutritional products for infants and children based on goat milk. DGC pioneered the world's first commercialised infant formula from goat milk, and continues to provide high quality branded goat milk nutritional powders to more than 30 countries around the world and continues to drive the category into the 21st century. DGC uses the most recent nutritional science (including two randomised double-blind clinical trials) combined with state of the art processing using whole goats' milk to deliver the natural benefits of goat milk to infants and young children.

Chr. Hansen is a global bioscience company aiming at improving food and health. Probiotics are a key focus area for us. We have been working with clinically documented probiotics for more than 25 years and offer a premium range of probiotic strains under the Probio-Tec® brand – including the two best documented probiotic strains in the world named LGG® and BB-12®. Together with our partners we bring documented probiotics to market in convenient formats for infants and children, e.g. drops. At Chr. Hansen we engage in scientific partnerships with universities and research institutions and are represented in several international scientific associations.

New clinical results for BB-12™ within infant colic
Visit us at booth #9
- and get the exciting results of a new clinical study on Bifidobacterium, BB-12™
DEKAsvitamins.com develops and commercializes DEKAs. DEKAs fat-soluble vitamins are based on a clinically tested delivery technology that enhances their absorption. DEKAs Essential and DEKAs Aqua-E are for patients with Cholestatic Liver Disease. DEKAs Bariatric is given after Bariatric Surgery. DEKAs Plus are all-in-one multivitamin and mineral supplements for patients with Cystic Fibrosis. DEKAs is made in the USA by Callion Pharma (www.callionpharma.com). DEKAs is widely available in the Americas and Europe. DEKAs is a Food for Special Medical Purposes and must be taken under medical supervision. Contact us via info@dekasvitamins.com.

Dicofarm is a nutraceutical and pharmaceutical group based in Italy. The group was founded in 1977 and since then has established a strong experience in developing of high quality products. Our daily obligation is to realize products and solutions capable of improving people’s quality of life. Our portfolio embodies our profound commitment to innovation and include OTX medications, Food Supplements and Medical Devices in key therapeutic areas that cover many Pediatric fields such as Neonatology and Gastroenterology.

The European Foundation for the Care of Newborn Infants (EFCNI) is the first pan-European organisation and network to represent the interests of preterm and newborn infants and their families. It brings together parents, healthcare experts from different disciplines, and scientists with the common goal of improving long-term health of preterm and newborn children. EFCNI’s vision is to ensure the best start in life for every baby.  For more information: www.efcni.org

The European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA) is an umbrella organisation representing 36 national Crohn’s and Ulcerative Colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations. We are an organisation of people united in our commitment to improve the life of the over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility.
Royal FrieslandCampina provides millions of consumers all over the world with dairy products containing valuable nutrients from milk. We supply consumer products such as dairy-based beverages, infant nutrition, cheese and desserts in more than 100 countries, while we also produce ingredients and semi-finished products for infant nutrition, the food industry and the pharmaceutical sector for manufacturers around the world. The company is fully owned by Zuivelcoöperatie FrieslandCampina B.V., with 18,645 member farmers in the Netherlands, Germany and Belgium and is one of the world’s largest dairy cooperatives. FrieslandCampina has branch offices in 33 countries. The Company’s central office is based in Amersfoort, the Netherlands.

Eurospital, an Italian IVD Company with 70 years of history, focuses its activities in specific sectors such as in vitro diagnosis of Coeliac Disease, IBD, detection of genetic predisposition to Coeliac, Type 1 Diabetes and Lactose Intolerance.

Actively present worldwide, Eurospital’s aim is to provide Paediatricians, Gastroenterologists and Laboratory Immunologists with highly innovative diagnostic tests such as Calprest family products for calprotectin determination, Eu-tTG and α-Endomysium for the identification of the coeliac patient, as well as XeliGen, DiabeGen and LactoGen for the determination of genetic predisposition to CD, T1D and lactose intolerance.


www.frieslandcampinaingredients.com
FrieslandCampina Ingredients is a leading producer of essential ingredients and base powders for the global infant formula market. We are the experts in infant nutrition solutions and strongly focus on optimising microbiome in four areas: brain, growth, immunity and digestion. With over 75 years of experience, our deep understanding of ingredients and applications enables us to develop next generation infant nutrition ingredients such as HMO’s and optimised proteins.

HiPP GmbH & Co. Vertrieb KG is Germany's leading manufacturer of baby food with a strong focus on organic premium quality. It offers infant, follow-on and growing-up formula, a huge range of complementary feeding, a product range for pregnant and breastfeeding women and also provides baby care cosmetics. The company is a family-run business which was founded in 1932 and is based in Pfaffenhofen, Bavaria, Germany. HiPP products are exported in 60 countries all over the world.

Immundiagnostik AG, founded in 1986 by Dr. F. P. Armbruster (CEO), is specialised on the development, production, and world-wide distribution of innovative parameters and detection methods for laboratory diagnostics and medical research. Focused on the development of immunological tools, of HPLC and molecular biology methods, and of new applications for mass spectrometry (LC-MS/MS), IDK concentrates on the development and production of laboratory diagnostics (from screening to monitoring). IDK holds a strong portfolio in markers of cardio-reno-vascular system, skeletal system, oxidative stress/anti-aging, gastroenterology and nutrition. The company owns more than 35 patents worldwide.

Inbiose has made its mark as a leader in the development of human milk oligosaccharides, which are of paramount importance for the health of newborns and developing infants. Inbiose develops and produces specialty carbohydrate ingredients that are addressing needs in markets including human nutrition, dietary supplements, medical nutrition and beyond. The company develops cost-effective processes for the production of specialty carbohydrates using its proprietary GlycoActives® high-productivity platform. The company develops partnerships with global industry segment leaders to develop and commercialize new specialty carbohydrate ingredients. More information can be found at www.inbiose.com.
Jennewein Biotechnologie GmbH

Jennewein Biotechnologie GmbH is a leading company specializing in the production of rare functional monosaccharides and oligosaccharides for nutritional, pharmaceutical, cosmetic and medical applications. The company produces rare monosaccharides such as L-Fucose and Sialic Acid. It also manufactures an extensive portfolio of HMO’s such as 2’-Fucosyllactose, 3’-Fucosyllactose, Lacto-N-tetraose, Lacto-N-neotetraose and acidic HMO’s like 3’-Sialyllactose and 6’-Sialyllactose. Jennewein’s human milk oligosaccharides are produced using the latest fermentation technology. This process is based on research and ensures a high quality and safety of the product. These HMO’s are approved for kosher and halal. 2’-Fucosyllactose is also approved for the US and EU market.

Karger Publishers – Connecting the World of Biomedical Science

Karger Publishers is a globally active medical and scientific publishing company. Independent, Swiss-based and family-run in the fourth generation, the company is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science.

The Karger publishing program comprises some 50 new book releases every year as well as 105 peer-reviewed journals. In line with the company’s commitment to the global transfer of knowledge, Karger content is published predominantly in English, with a strong focus on basic and clinical research.

Kendal Nutricare Ltd specialises in the production of formulated full-cream infant formulas and infant cereals marketed under the brand “Kendamil”, and adult nutrition products marketed under the brand “Kendalife”.

We are the only British manufacturer of infant formulas in the UK and use British whole milk, sourced from the Lake District UNESCO World Heritage Site.

Since 1962 we have been manufacturing in Kendal, in a BRC grade AA certified factory where we employ 135 experienced staff including engineers, operative technicians, laboratory microbiologists and research scientists.

Kendal Nutricare have recently won the ‘Federation of Small Businesses, International Business of the Year Award 2019’ and the ‘Northern Powerhouse, High Growth Markets Exporter of the Year Award 2019’.

Laboratoires CTRS was founded in 2002 to develop, register and market innovative therapies targeted at orphan diseases. The company commercialises a therapy for two ultra-rare bile acid synthesis defects and a product for the treatment of multiple myeloma. CTRS is fully committed to bring new treatments and satisfy unmet medical needs for extremely small patient population with a special focus on liver disorders. It partners with the healthcare community to provide services aimed at improving patients’ standard of care. CTRS has been awarded the prestigious 2014 Prix Galien France and 2016 Prix Galien International for its product Orphacol® (cholic acid).
**Exhibitor Directory Listing**

**Booth No. 45**
- **Country:** Switzerland
- **More information:** www.mdpi.com

A pioneer in scholarly open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines. Our 202 diverse, peer-reviewed, open access journals are supported by over 35,500 academic editors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).

**Booth No. 11**
- **Country:** USA
- **More information:** www.meadjohnson.com

For over 110 years, Mead Johnson has been a global leader in pediatric nutrition. We develop, manufacture, market and distribute more than 70 products in over 50 countries. Our mission is to nourish the world’s children for the best start in life. The Mead Johnson Pediatric Nutrition Institute (MJPNI) pioneers new discoveries that improve the health and well-being of children. Our team of experts focus on advancing scientific understanding, engaging with global experts and enabling innovation to inform the development of nutrition solutions. Since June of 2017, MJN has been part of RB (Reckitt Benckiser), a global health and hygiene company seeking to become the global leader in consumer healthcare. Mead Johnson’s science, innovation, product portfolio and mission are vital, foundational elements of the new company’s largest global business unit – RB Health.

**DO MORE THAN JUST MANAGE COW’S MILK ALLERGY: HELP GIVE HER THE ABILITY TO PROTECT HERSELF FROM FUTURE ALLERGIC MANIFESTATIONS††**

**ONLY NUTRAMIGEN WITH LGG® CAN**

TRANSFORMING THE LIVES OF BABIES WITH COW’S MILK ALLERGY

Visit us at booth 11

†Versus Nutramigen without LGG®.


Nutramigen with LGG® is a food for special medical purposes for the dietary management of cow’s milk allergy and must be used under medical supervision.

Nutramigen with LGG® is not recommended for premature and immunocompromised infants unless directed and supervised by a healthcare professional.

**IMPORTANT NOTICE:** Breastfeeding is best for babies. The decision to discontinue breastfeeding may be difficult to reverse and the introduction of partial bottle-feeding may reduce breast milk supply. The financial benefits of breastfeeding should be considered before bottle-feeding is initiated. Failure to follow preparation instructions carefully may be harmful to your baby’s health. Parents should always be advised by an independent healthcare professional regarding infant feeding. Products of Mead Johnson must be used under medical supervision. *Trademark of Mead Johnson & Company, LLC. © 2018 Mead Johnson & Company, LLC. All rights reserved. LGG® is a registered trademark of Chr. Hansen A/S. **
Miris AB is the manufacturer of the Miris Human Milk Analyzer. Miris Human Milk Analyzer provides a fast and simple way to measure the macronutrients in human milk enabling targeted fortification in your NICU. Miris has over 12 years of experience in human milk analysis in clinical care and the Miris Human Milk Analyzer is approved as a medical device in Europe and FDA approved for clinical use in US.

Nestlé helps the next generation of children to develop their full potential and live healthier lives by providing high quality, innovative, science-proven nutrition solutions and education for mothers and infants in the crucial first 1000 Days' of life.

Nestlé Health Science is a science-driven nutritional health business focusing on medical nutrition and consumer health products to change the course of health for consumers, patients and its partners in healthcare.

The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals worldwide. NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at www.nestlenutrition-institute.org

ModuLife offers medical education as well as a virtual patient support platform designed to support healthcare professionals and patients throughout the dietary therapy journey.

Healthcare professionals can learn more about the CDED therapy and become ModuLife experts thanks to dedicated e-learning modules. Patients can locate ModuLife experts in their area, access a large selection of CDED-friendly recipes & meal plans, track their food intake, diet adherence and well-being.

CDED combines a whole food diet with partial enteral nutrition (Modulen® IBD). It is designed to reduce the exposure to dietary components hypothesized to negatively affect the microbiome, intestinal barrier and innate immunity without sacrificing the possibility of enjoying whole foods, which makes it highly acceptable for patients. Recent data from a randomised controlled trial demonstrate the benefits of the CDED therapy on remission rates, gut microbiota and tolerance, paralleled to the exclusive enteral nutrition (EEN), a proven dietary intervention and standard treatment for CD*.1-4

Visit www.mymodulife.com to get more information and register for our free online medical training.

1. Van Limbergen J et al. OP05, presented at the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark.
2. Sigall Boneh R et al. DOP42, presented at the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark.
3. Dunn KA et al. P832, presented at the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark.
4. Wine E et al. P346, presented at the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark.
<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Country</th>
<th>More information</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>France</td>
<td><a href="http://www.novalac.com">www.novalac.com</a></td>
</tr>
<tr>
<td>25</td>
<td>Spain</td>
<td><a href="http://www.noventure.com">www.noventure.com</a></td>
</tr>
</tbody>
</table>

**Novalac**

The majority of infants experience at least one dietary problem in the first months of life. Pioneer in pediatric gastro-enterology and allergology, Novalac developed a comprehensive range of adapted infant formulas. Each specialty formula, whether it manages GI troubles, allergies, or other problems, is backed by at least one clinical trial, coordinated by internationally renowned experts. Present in more than 60 countries worldwide, Novalac (or Novamil) is almost exclusively distributed through pharmacies.

**Noventure**

Noventure is an innovation-based enterprise, headquartered in Barcelona, specialized in licensing medical devices to partner companies. Noventure’s products are natural polymers based on a proprietary barrier technology that reinforces the epithelia, thereby restoring its functionality. In Gastroenterology, our newest product is Gelsectan®, a medical device intended to restore the intestinal function in those patients suffering from alterations due to Irritable Bowel Syndrome (IBS), and to relief and prevent symptoms such as chronic or relapsing diarrhoea, abdominal tension, pain, bloating and flatulence.

**Exhibitor Directory Listing**

**Booth No. 36**

**Country:** Japan

**More information:** www.takeda.com

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven bio-pharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

---

**Booth No. 3**

**Country:** The Netherlands

**More information:** www.nutricia.com

Nutricia pioneers nutritional solutions that help people live longer, more joyful and healthier lives. Building on more than a century of nutritional research and innovation, Nutricia continues to transform lives through the power of nutrition.

Nutricia’s science-based products and services support healthy growth and development during the first 1000 days. Nutricia also helps to address some of the world’s biggest health challenges including conditions in early life such as pre-term birth, faltering growth, food allergy and rare metabolic diseases, as well as age-related conditions and chronic disease, such as frailty, cancer, stroke and early Alzheimer’s disease.

As part of Danone, Nutricia fully embraces the company’s “One Planet. One Health” vision reflecting that the health of people and the health of the planet are interconnected and therefore seeks to protect and nourish both.

Visit the Nutricia booth and get a chance to win a special prize

*Product availability and/or design varies by country. To find out more, speak to one of our Nutricia representatives at booth no. 3*
REVESTIVE®

REVESTIVE® (teduglutide) 1.25mg and 5mg powder and solvent for solution for injection

REVESTIVE® is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be followed periodically after initiating efficacy and safety in patients with long-standing GI diseases, including SBS. Clinical improvement in patients with SBS may be observed in the first 2-3 months of treatment, and increased absorptive capacity may be observed in patients with long-standing SBS. The clinical benefit is maintained for at least 2 years of treatment. Patients who still have presence of colon-in-continuity or distal/terminal ileum; if no...
For 100 years, Wyeth Nutrition has pioneered nutrition science with premium-quality products that meet the needs of infants, young children, and adults, including mothers to be and lactating mothers.

Parents and doctors can be confident that we use and will continue to use extensive clinical rigor, scientific research, world-class manufacturing, and product safety standards to provide optimal nutritional support for healthy outcomes.

This relentless commitment to excellence will drive us to create the most advanced nutrition that will help ensure a bright and healthy future.

Come and visit Wyeth Nutrition at Booth #21
Disclosure of Sponsorships

Please find below the contribution from members of the Pharmaceutical Codes of Practice in accordance with the respective rules and transparency regulations.

<table>
<thead>
<tr>
<th>N/N COMPANY</th>
<th>AMOUNT</th>
<th>ITEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Avanos</td>
<td>13.840 €</td>
<td>Sponsorship Package Bronze</td>
</tr>
<tr>
<td>2 DICOFARM</td>
<td>7.560 €</td>
<td>Sponsorship Package Chrome</td>
</tr>
<tr>
<td>3 Noventure</td>
<td>9.450 €</td>
<td>Sponsorship Package Chrome</td>
</tr>
</tbody>
</table>
Congress Venue
Scottish Event Campus (SEC)
Glasgow, G3 8YW
Scotland – United Kingdom

Congress Language
The complete scientific programme including all courses will be held in English. A simultaneous translation will not be available.

Congress Office
The congress office and registration desk are located in Hall 5 of SEC.
Phone: +44 (0)141 576 34 56

Congress Opening Hours
Industry Exhibition
Wednesday, 05 June 2019 18:30 – 20:30
Thursday, 06 June 2019 08:00 – 18:00
Friday, 07 June 2019 08:00 – 18:00
Saturday, 08 June 2019 08:00 – 14:15

Abstracts
All abstracts accepted for presentation (oral or poster) will be published in the Journal of Paediatric Gastroenterology and Nutrition (JPGN). The abstracts will also be published in digital format in the Congress App as well as on Congress Talks & Speakers.

ESPghan Abstracts on USB Key
Kindly sponsored by Nestlé
Abstracts presented at the ESPghan 52nd Annual Meeting are also available on a USB Key and are being distributed from the Nestlé stand no. 13 during exhibit opening hours.
Please visit the booth to meet with a Nestlé representative and present the voucher found in your congress bag in exchange for your USB Key.

Certificate of Attendance
Delegates are able to print their Certificate of Attendance (not the CME-CPD Certificate) at the Self-Print-Counters located in Hall 5 of the SEC by scanning the barcode printed on their name badge.

Coffee & Lunch Breaks
Snacks and refreshments during the official break times are included in the registration fee. The catering areas are located in the Industry Exhibition (Hall 4). The Clydebuilt Bar & Kitchen on the concourse level serves as a cash bar.
Kindly note that gluten- and lactose-free coffee and lunch breaks will also be served at the catering area in the Industry Exhibition (Hall 4).

ESPghan AGM
Annual General Meeting
Assembly of ESPghan members on Friday, 07 June 2019 from 17:30 – 19:45 (Lomond Hall).

Internet Corner
The Internet Corner is located in the Industry Exhibition (Hall 4). Printing facilities are available.

Mobile Phones
Delegates are kindly requested to keep their mobile phones on silent mode in all rooms where scientific and educational sessions are being held, as well as in and around the poster and exhibition area.

Name Badge
Upon registration onsite, all participants will receive a name badge, which must be worn visibly for the entire duration of the congress. The name badge acts as entrance ticket for the congress. Name badges will not be reprinted. For lost badges, a fee of 25% of the original registration fee applies.

Public Transport & Bike Rental
All delegates receive a ScotRail Conference Rover ticket onsite. The ticket is valid from 05 – 08 June 2019. You can also use the free bike service ‘Nextbike’ to discover the city. Free unlimited rentals for all delegates! Register on www.nextbike.co.uk, enter your personal details and enter the code 569856 under my account/vouchers.

Silence Room
A place of tranquility in the midst of a lively conference area. The silence room is available to members of all religions and all world views. It is accessible during the congress hours and is located at room Etive on the ground level. Please follow the signs onsite.
The following measures have been taken to make the Annual Meeting more sustainable:

- Name badges made of FSC paper (‘FSC’ stands for Forest Stewardship Council, an organization that works to promote the practice of sustainable forestry worldwide)
- Conference pencils made of biodegradable plastic
- Notebooks made of recycled paper
- Conference bags made from high quality, environmentally-friendly cotton in the fair trade program “Made in Africa” supporting women empowerment in communities in Ethiopia
- Refillable water bottles made of glass for every delegate
- Usage of local products for catering to the most possible extent
- Free public transportation tickets for all delegates during the conference dates within the ‘Conference Zone’

Welcome Reception
The Welcome Reception will take place at the SEC in the Industry Exhibition (Hall 4) on Wednesday, 05 June 2019 starting 18:30 (free of charge for congress participants). Please note that your badge serves as your entrance ticket.

Programme Changes
Should last minute changes due to functional, private or organisational needs be necessary, they will be announced – when possible – on the congress website and the Congress App. The event organiser accepts no liability for any additional costs caused by a change of programme.

Disclaimer
Neither ESPGHAN nor EUROKONGRESS GmbH shall be liable for accidents, bodily injury, and theft as well as for additional costs due to the change of event date, location, and programme or similar. Liability for additional costs due to delays, changes or cancellations of flights, trains or other means of transport as well as due to strike action, illness, weather or environmental disasters is also excluded. It is the responsibility of each participant to arrange appropriate theft-, accident-, health- as well as travel-cancellation insurance. Participants take part at their own responsibility and risk.

HiPP ORGANIC COMBIOTIC®
Important building blocks provide for a good start

Breast milk is the best nutrition for a baby, as it supplies important building blocks for baby’s healthy development. If breastfeeding is not possible, the baby should be given a milk formula, which is based on the natural model and whose composition is based on current scientific findings.

HiPP 1 ORGANIC COMBIOTIC® fulfils these criteria, is well tolerated and contains functional building blocks with proven benefits:

- Low protein content: for healthy weight gain
- Prebiotics and probiotics: significant reduction in gastrointestinal infections
- LCP (DHA/ARA): promote cognitive development

In addition, in reliable HiPP organic quality, controlled according to the highest standards.

Important note: Breast milk is the best nutrition for an infant. Infant formula should only be used following advice from a paediatrician, midwife or other independent experts.

References:
1 Tiedemann M et al. Clin Nutr 2014; 33:588-596
The congress registration fees include:

- a name badge
- access to all sessions
- access to the poster and exhibition area
- all personal congress documents
- the coffee breaks and lunches
- a ScotRail Conference Rover ticket
- invitation to the Welcome Reception (subject of availability)

Congress Cancellation Policy

cancellations had to be submitted in writing. Cancellations received up until Sunday, 31 March 2019 incurred a cancellation fee of 50 € for the Annual Meeting and of 25 € for the courses. From this date onwards or in case of a no-show, registration fee reimbursements were no longer possible unless the organisers were provided with a named replacement who took on the registration.

The Members Evening registration fee is non-refundable.

CME-CPD Credits (EACCME)

The congress has been approved for CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). The number of CME credits granted, and how to claim them, are available on the congress website and in the congress app.

In accordance with EACCME rules & regulations, CME-CPD Credits may only be granted once attendance onsite has been confirmed and the online evaluation form completed after the conference has ended. Hostesses will be available by each session hall entrance to scan attendance. It is the responsibility of participants to ensure their attendance is scanned on all conference days to accrue the maximum possible credits. Only participants who have had their attendance scanned will be emailed the evaluation form.
See you in Copenhagen 2020!

6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

03–06 June 2020
Copenhagen · Denmark

www.fispghan.org
www.espghancongress.org
Barcelona, Spain
October 19–23, 2019
Venue: Fira Gran Via

We bring together
the best in
gastroenterology.
Join us!
DISCOVER THE BEST FROM NATURE AND SCIENCE!

Check out the latest insights on the benefits of Friso’s LockNutri technology at FrieslandCampina booth nr. 10.